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ABSTRACT 
Alzheimer‟s disease (AD) is a progressive neurodegenerative disorder which is 
characterised by impairment of memory and learning. The impairment is caused by 
neuronal death which originates in the parts of the brain that execute memory 
functions:  the entorhinal cortex and hippocampus. The neuronal death is believed to be 
caused by the amyloid-  (A ) peptide which is prone to oligomerisation and 
aggregation into insoluble amyloid plaques (AP). The levels of soluble A  and the 
number of AP:s are increased in the AD brain which is attributed to increased 
production and impaired clearance of A . 
Another hallmark of AD, after neuronal death and the increased presence of A , is 
inflammation in the form of activated microglia and increased levels of inflammatory 
proteins in the brain. Inflammation in the CNS has been shown to increase the 
production of A  and to impair, and even kill, neurons. On the other hand, 
inflammation has been shown to increase the removal of pathogens, such as A , from 
the brain by increasing the phagocytic acticity of microglia. Inflammation is also 
associated with an increased secretion of neurotrophic factors that can protect neurons. 
Somehow this clearance of A  is impaired in AD and the levels of neurotrophic factors 
are decreased. 
The work on this thesis has been focused on the inflammatory component of AD and 
how it can be modulated into performing activities that are beneficial for neurons 
without evoking the harmful activities of inflammation. For this purpose a human 
microglial cell line, CHME3, was characterized with regard to interaction with A  and 
inflammatory responses. The CHME3 microglial cell line was used as a model of 
inflammation in the human brain. In this model, we tested the ability of the 
neuropeptide -MSH to inhibit inflammation induced by A 1-40 and cytokines, and 
found that -MSH, on the contrary, increased secretion of the inflammatory cytokine 
interleukin (IL)-6. -MSH was also found to protect human neuronal cells against 
necrotic stress. The possibility of stimulating microglia into phagocytosis of A 1-42 and 
the concurrent responses was also investigated. We found that the omega-3 fatty acid 
DHA and the adjuvant protollin had a stimulatory effect on phagocytosis of A 1-42. 
DHA also had an inhibitory effect on the secretion of several cytokines. Microglia that 
were phagocytic of A 1-42 displayed increased expression of several inflammatory 
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markers compared to non-phagocytic cells. Thus, inducible nitric oxide synthase 
(iNOS) was expressed to a larger extent on phagocytic cells. Treament with DHA 
abolished this imbalance in iNOS expression, indicating a less harmful phenotype of 
phagocytic cells upon treatment with DHA. Furthermore, inflammation in the form of 
IFN  stimulated phagocytosis of A 1-42 while decreasing the secretion of the 
neurotrophin brain-derived neurotrophic factor and inducing microglial cell death. A 1-
42 was also found to decrease the secretion of BDNF. The effect of omega-3 
supplement on the levels of A 1-42, tau and inflammatory markers in the cerebrospinal 
fluid and plasma of AD-patients was investigated in an intervention study. There were 
no detectable differences in any of the markers after 6 months of treatment with omega-
3 compared with placebo control. However, at base line, a significant positive 
correlation between the soluble interleukin (IL)-1 receptor type II was observed. 
The major finding in this thesis is the reduction in BDNF induced by A 1-42, and the 
AD-related cytokine IFN , suggesting a new pathogenic mechanism in AD. Other 
important findings are the beneficial effect of DHA on microglial activities, which 
support the use of omega-3 supplements for treatment of AD. However, the results 
from the intervention study did not provide additional support for the use of omega-3, 
but suggest the importance of early intervention. -MSH was found to promote 
neuronal survival suggesting a potential role for this peptide and its receptors for the 
treatment of neurodegenerative disorders. 
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1 INTRODUCTION 
 
1.1 ALZHEIMER’S DISEASE 
The connection between progressive cognitive decline and the presence in the brain of 
aggregates of the amyloid-  (A )-peptide, and tangles of the protein tau, was first described by 
the German psychiatrist and neuropathologist Alois Alzheimer in a speech 1906. The syndrome 
was recognized as a distinct disorder which was given the name Alzheimer‟s disease (AD). The 
main pathological hallmark of AD is neurodegeneration, that is, the impairment and death of 
neurons. 
  
Neurodegeneration in the central nervous system (CNS) is part of normal aging. In some cases 
this degeneration is accelerated as a manifestation of a pathological condition. This can be acute 
as in the case of head trauma or stroke. However, it can also be a slow progressive process as in 
the case of Parkinson‟s disease and the dementia-type diseases. The most common cause for 
dementia is AD which accounts for 50-70% of all cases [1]. With the increased life span 
associated with the modern world the prevalence of dementia is on the rise. In 2001 there were 
24 million people in the world that were suffering from dementia and this number will double 
every year according to the prognosis [2]. The other major pathological hallmarks of AD beside 
neuronal loss are amyloid plaques (AP) and neurofibrillary tangles (NFT:s) [3; 4]. Although a 
great deal of controversy exists about the relative importance of AP:s contra NFT:s in AD, 
there is an overwhelming body of evidence showing that AP:s and the peptides they are 
composed of are culprits in the neurodegenerative processes in AD and based on this 
knowledge the “amyloid cascade hypothesis” has been formulated [5]. NFT:s are intracellular 
deposits of aggregated microtubule-associated proteins (MAP:s), and result from 
hyperphosphorylation of the MAP tau [6]. AP:s are composed of A , which is secreted by 
neurons and other cells through cleavage of the larger, membrane-bound, amyloid-precursor 
protein (APP) [7; 8]. APP can be metabolised by two enzymatic pathways. One pathway is 
amyloidogenic, i.e. it results in the production of the aggregation-prone and neurotoxic A . The 
other pathway is non-amyloidogenic and results in the production of a non-pathological peptide 
(P3) [9]. APP is metabolised by three enzymes: -, - and -secretase [10; 11]. Cleavage by - 
and -secretase yields P3 while cleavage by - and -secretase yields A . In the metabolism of 
APP there is also production of an intracellular COOH-terminal fragment, -amyloid precursor 
protein intracellular domain (AICD), which is believed to interact with the transcription of 
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genes [12]. Released together with A  or P3 are also the NH2-terminal fragments, soluble 
APP  and  (sAPP  and sAPP ). APP can be metabolized into A  peptides of different 
lengths. The 40 and 42 amino acid (aa) forms are believed to be the most produced variants, 
with the 42 aa form (A 1-42) being the most abundant in plaques [13].  
 
The A  peptides are prone to self-aggregation and deposition into insoluble plaques, but they 
also exist in the form of soluble monomers and oligomers, which are increased in the AD brain . 
Species of A  peptides and NFT:s have been shown to contribute to neuronal impairment and 
death in a number of studies, but the current view appears to emphasise the interaction between 
A and NFT:s in the progression of the disease [14; 15; 16; 17; 18]. A  peptides have been 
shown to impair and kill neurons in a plethora of studies [19; 20; 21; 22; 23; 24; 25]. In the 
brain of a person suffering from AD there are higher levels of soluble A -species and AP:s than 
in the non-AD brain [5]. This over-abundance has been attributed to increased production of 
APP, increased processing of APP by -secretase and impaired clearance of A . 
Somehow, the balance between production and clearance/degradation of A  is disturbed in AD.  
The fact that an inflammatory component exists in AD is well established. Increased levels of 
pro-inflammatory cytokines, such as interleukin (IL)-1 and IL-6, have been found in the brains 
of AD-patients [28; 29; 30], and there is an increase in the number of activated microglia and 
astrocytes in the areas of neurodegeneration and AP:s  [31; 32]. Furthermore, elevated levels of 
inflammatory cytokines have been measured in serum and cerebrospinal fluid (CSF) from 
patients with AD [33; 34].  
 
The clinical progression of AD is such that the cognitive disturbances are first observed as a 
decline in memory. Difficulties in storing and retrieving new information are the first symptoms 
to surface [35]. As the disease progresses there is a more general impairment in cognition and 
psychiatric symptoms such as apathy and depression may appear [36]. Finally, the cognitive 
decline is such that daily activities become impossible and at this stage the disease is associated 
with aggression, delusion and hallucinations. The clinical picture is mirrored by the pathological 
progression of the disease. Increased levels of AP:s and NFT:s, together with neuronal loss, are 
first seen in the entorhinal cortex and later progress to the hippocampus [37]. These areas are 
fundamental for the formation and retrieval of new memories [38]. Later in the disease there is a 
progression of the pathology to the rest of the cerebral cortex, which explains the general 
cognitive decline in the final stages of the disease [35; 39]. Parallel to the cortical degeneration 
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there is impairment and death of neurons in the basal forebrain [40; 41]. These neurons are 
cholinergic and project to the cortex and hippocampus in particular [42; 43]. The cholinergic 
input to the hippocampus is believed to synchronize and control the activity of the hippocampal 
neurons, thus making storage and retrieval of memory possible [44]. It is not known if 
disturbances in one area may worsen, or even cause, the problems in other areas but detrimental 
network effects are very likely. 
 
1.2 THE IMMUNE SYSTEM AND INFLAMMATION 
When the tissue of an organism is damaged by infection or trauma, its ability to cope with the 
challenges of the world, and to fulfill the demands of biological drives and instincts are reduced 
to a certain degree. In other words, homeostasis of the organism is lost. It is not hard to imagine 
that the evolutionary drive to develop toward restoration of homeostasis must have been very 
strong, and thus the immune system developed. The ability of single-cell organisms to engulf, 
phagocytose, threatening objects or organisms can perhaps be described as the first, archaic, 
form of immune defence. There is an appealing and immediate logic in the removal and 
destruction of the pathogenic entity. However, different forms of pathogens induced 
differentiation of the immune system so that other forms of immune responses evolved, 
producing an arsenal including free radicals, membrane-perforating molecules, apoptosis-
inducing signalling, and antibodies. However, these responses may destroy an invading 
pathogen, but would do little for the restoration of tissue homeostasis and could in fact increase 
the level of tissue damage. To restore homeostasis the immune response must reach an endpoint 
where it is down-regulated, resolved, and rebuilding and healing of the tissue takes place [45]. 
The immune system promotes rebuilding and healing by inducing the secretion of growth 
factors that increase the survival of cells, stimulate them to regain their lost or impaired 
functions and increase their proliferation to fill the empty space [46; 47; 48]. 
 
The immune system has traditionally been divided into an innate and adaptive, or humoral, part. 
The innate system, which controls the response of inflammation, is the oldest part and is created 
with a kind of “general” understanding of what a foreign pathogen or debris is. The innate 
immune response is thus quite crude and can be harsh for the surrounding tissue. It is, however, 
on constant alert with cells placed in the tissues for the detection of disturbances, and can mount 
a quick response.  
The adaptive part of the immune system is based on the production of antibodies, which 
recognise pathogens as something that does not belong to the organism. The antibodies are 
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secreted from B-cells which produce one type of antibody. By the interaction of B-cells with 
pathogens (or vaccines) the antibodies become more specialised, and the cells that produce the 
antibody in question become more numerous and responsive, in short the system adapts to the 
new situation. The marking of a pathogen with antibodies generally does not produce any effect 
on the pathogen, but guides immune cells to phagocytose the object, or produce lysis of the 
pathogen by the binding of complement proteins. The time frame of the adaptive immune 
response depends on if the immune system has encountered the pathogen before or is naïve. It 
is, however, regarded as much slower than the innate system, since it depends on the interaction 
with the innate system and if naïve, migration of cells in the circulation and lymphatic system. 
 
The innate immune response can be divided into the complement system and the inflammatory 
response. The complement system, which is considered the oldest part of the immune system of 
multicellular organisms, is based on the assembly of proteins in a cascade forming a pore 
complex that produces lysis of the pathogen onto which it binds. The binding can be guided by 
interaction with the adaptive immune system through binding of antibodies, or by the 
recognition of pathogens by a protein in the complement cascade. Inflammation is induced by 
the recognition of a pathogen or foreign object by resident immunocompetent cells. Through a 
cascade of inflammatory signals there is recruitment of blood-borne immune cells into the tissue 
through the blood vessel wall, which is made permeable to cells by the inflammatory signals.  
 
The immune response following a pathogenic or traumatic challenge can be illustrated as 
follows: A disturbance is induced in the tissue due to damage, or a cellular or molecular 
pathogen. The disturbance is detected by the innate immune system in the form of: 
 
 debris from dead cells and destroyed tissue 
 extracellular microorganisms in the form of associated molecular patterns 
 intracellular microorganisms in the form of the presentation of abnormal proteins 
 other immunomodulatory molecular entities that the immune system reacts to in general, 
and specifically, mediators produced from other cells for the coordination of the 
immune response 
 
The first cells to encounter and respond to a disturbance in the tissue are resident macrophages 
and dendritic cells, both of which are derived from monocyte precursor cells [49; 50]. 
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Monocytes can differentiate into different forms of macrophages depending on the 
microenvironment in the tissue that they enter, exemplified by the microglia in the brain or the 
Kupffer cells in the liver [51]. Macrophage-like cells such as microglia express a wide array of 
receptors with which the cells surveil the environment for disturbances [52; 53; 54; 55; 56].  
The profile of receptors that macrophage-like cells express differs according to the activation 
phenotype, which in turn is determined by the signals that the cell receives [57; 58; 59; 60; 61]. 
If an object is recognized by one of these receptors, it will result in activation of the 
macrophage-like cell. Activation of the cell will result in changes in the behaviour of the cell. 
The pattern of secretion is changed, with increased secretion of immunomodulatory and effector 
molecules, such as free radicals. The consequence is that macrophage-like cells can be more or 
less responsive, or qualitatively different in their response to a specific disturbance as a result of 
the concurrent immunomodulatory signals that the cell receives. 
 
Some of the immunomodulatory molecules that are secreted attract and activates blood-borne 
immune cells as well as resident cells, such as the endothelium so that adhesion molecules are 
expressed on the lumen side. This enables the blood-borne immune cells to attach to the vessel 
wall at the site of infection or trauma due to reciprocal expression of adhesion factors on cells 
and endothelium. Furthermore, the vessel wall becomes leaky upon activation of endothel, 
which permits tissue entry, or extravasation, of the activated cells adherent to the vessel wall. 
Another consequence of this is the flow of fluid into the tissue, which creates an oedema. The 
first cells to extravasate and execute their functions are the neutrophilic granulocytes , together 
with, or followed by, monocytes. As mentioned above, macrophages and microglia recognise 
pathogens by means of receptors, which are activated by molecular patterns associated with 
pathogens. This type of receptors are known as pathogen-associated molecular pattern (PAMP)-
receptors, the most well-known being the Toll-like receptors (TLR:s), which recognize bacterial 
capsule components, among others. When a pathogen is recognized by a PAMP-receptor it 
activates the cell, with subsequent production of immunomodulatory molecules that coordinate 
the response of the immune system by endo-, para- and autocrine signalling. Activation of a 
PAMP-receptor may also induce a phagocytic response whereupon the macrophage will attempt 
to engulf the antigenic object. Phagcytosed antigenic material is normally degraded and 
presented on major histocompability complex type II (MHCII) proteins. 
 
Neutrophils are actively phagocytic in the early phases of the immune response, while 
macrophages become more phagocytic in the later phases. Activated neutrophils also release 
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antimicrobial and immune signalling molecules, as well as secrete enzymes that degrade the 
extracellular matrix. The neutrophils die by apoptosis after performing their activities and are a 
major part of the pus that is formed at a site of lesion. After the neutrophils die, the 
macrophages clear the site of the apoptotic neutrophils, and the debris and pus that is the result 
of the rather harsh effort of the neutrophils. In the process of phagocytosis of the neutrophils the 
macrophages receives down-regulating signals that inactivate the inflammatory responses of the 
macrophages, which promotes the resolution of the inflammation, i.e. the phase where tissue 
rebuilding and healing can take place [62]. Recent research has also implicated soluble 
mediators in the induction of resolution [63; 64; 65; 66; 67]. In situations of chronic 
inflammation the resolution phase is not reached because of continuous inflammatory 
stimulation or lack of pro-resolving stimulation. 
 
However, there is a parallel series of events that takes place at the same time and that 
determines the nature of the following responses. Shortly after the neutrophils enter the site, T-
cells extravasate and are introduced to the pathogen by the interaction of MHC type I and II 
(MHCI and MHCII) and the corresponding T-cell receptor (TCR). CD8-positive T-cells are 
known as killer T-cells (TK-cell) because of their cytotoxic activities, while CD4-positive cells 
are known as helper T-cells (TH-cell) due to their function as coordinators of the immune 
response. The peptides presented on MHCI are derived from the metabolism of the presenting 
cell itself, and the purpose is to detect cells that have disturbances in their metabolism, that can 
be caused by intracellular pathogens or transformation. MHCI binds to CD8+ TCR:s and if the 
peptide is recognized as foreign the CD8+ T-cell will be activated and become a full-fledged 
TK-cell that releases cytotoxic molecules to destroy the cell it is interacting with. The peptides 
presented on MHCII are derived from pathogens that were phagocytosed by macrophage-like 
cells or dendritic cells, and interact with TCR:s on CD4+ T-cells. If recognized by the naïve T-
cell as foreign it will become an activated TH-cell. ATH-cell can then differentiate into subtypes 
of helper cells that secrete different molecules, thus directing the immune response into 
different response patterns. The choice of subtype is determined by the types of co-stimulation 
that the TH-cell receives when its TCR is stimulated by the antigenic peptide. It is believed that 
the co-stimulation reflects the type of pathogen and that the TH-cell differentiation is directed 
toward a subtype that can direct the immune response to the most effective response. There are 
four generally accepted subtypes of TH-cells: TH1-, TH2, Treg and TH17-cells. TH1- and TH2-cells 
are considered the most important, since their role in making the decision of the immune 
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response to be dominated by an innate, cell-mediated (TH1) or an adaptive, antibody-mediated 
(TH2) profile. 
 
 
1.2.1 Molecular mediators of the immune response 
To activate cells of the immune system and guide them to the site of insult a system of 
communication is needed. This is accomplished by the secretion of molecules from cells 
activated by their detection of a tissue insult, and the expression of receptors for the same 
molecules on cells of the immune system. Receptors for the molecular mediators are not only 
expressed on immune cells, but also commonly on bystander cells. In many cases, the mediators 
have other effects apart from regulation of the immune system, such as the induction of 
apoptosis. Prolonged immune activation can therefore become pathological and have 
detrimental effects on the tissue. Mediators can be membrane-bound, thus requiring cell-cell 
contact, but the majority of immune mediators are secreted molecules. 
 
1.2.1.1 Cytokines 
The group of immune mediators that perhaps is most well-known is the cytokines. Cytokines 
are peptides or proteins that are produced not only by cells of the immune system, but also by 
other cell types. Cytokines have roles and functions beyond the regulation of the immune 
response, for example the pro-inflammatory cytokine interleukin (IL)-1  has an important role 
in the regulation of memory [68].  
The distinction of cytokines into two major classes is based on the TH1/TH2 categories of 
immune responses. Cytokines that promote a TH1 immune response are called pro-
inflammatory, since inflammation is the cornerstone of the TH1 response. The most well-known 
TH1 cytokines are IL-1 , interferon (IFN) , tumour necrosis factor (TNF)  and IL-12. TH2-
inducing cytokines are called anti-inflammatory, since they inhibit inflammatory functions as 
well as promoting a humoral, adaptive immune response. The most well-known TH2 cytokines 
are IL-4, IL-10 and IL-13. Cytokines are synthesized and secreted “on-demand”. The receptors 
for cytokines are expressed at low levels in the resting state, but the levels can increase 
drastically upon activation. Furthermore, there are several examples of decoy cytokine receptors 
and soluble cytokine receptors, which may or may not have signal transducing properties. 
Cytokines are very potent even at low concentrations, and can activate cells with a very low 
number of receptors. Stimulation with cytokines usually results in the secretion of even more 
cytokines and increased expression of cytokine receptors in a cascade. The effects of cytokines 
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are highly redundant and animals deficient in the gene for a particular cytokine can appear 
normal and healthy. 
 
1.2.1.2 Chemokines 
Chemokines, or chemotactic cytokines, are also peptide or protein mediators, and they are also 
synthesized and secreted on-demand upon activation. Chemokines act as a homing signal, 
chemoattractant, for immune cells and are important for assembling the immune cells at the site 
of insult, and they have been implicated in the pathology in AD [69]. Thus, cells at the site of 
insult become activated and secrete chemokines. A chemokine concentration gradient appears 
in the space around the secreting cells, and cells that express the receptor for the chemokine 
respond by moving in the direction of the gradient.  
 
1.2.1.3 Arachidonic acid derivatives 
Another type of immune-regulating messenger is the fatty acid derivatives, eicosanoids, that are 
produced from the phospholipids in the cell membrane. Phospholipase A2 cleaves arachidonic 
acid (AA) from the membrane and AA can then take part in several biosynthetic pathways that 
can result in the formation pro- and anti-inflammatory lipid mediators, although production of 
anti-inflammatory lipids downstream of PLA2 has been reported [70]. Metabolism of AA by 
cyclooxygenase (COX) creates prostaglandins, prostacyclins and thromboxanes, depending on 
which enzyme that comes downstream of COX [71], while metabolism of AA by lipoxygenase 
creates the members of the leukotriene family of eicosanoids . 
 
1.2.1.4 Cell-cell contact 
An important type of signalling involved in the regulation of the immune response is the 
ligation of two membrane-bound molecules on different cells. This type of signalling is 
dependent on the close proximity of the transmitting and responding cell. The interaction 
between an antigen-presenting cell and a TH-cell via MHCII and TCR is an example of this kind 
of signalling. Another important example is the signalling between macrophage/microglia-
bound CD40 and T-cell/astrocyte-bound CD40L, resulting in an inflammatory activation [72; 
73]. 
 
1.2.2 Intracellular signalling and gene activation in inflammation 
For the soluble and membrane-bound mediators to exert their effects after binding to their 
receptors, a system of intracellular signalling transmits the message to the effector molecules 
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and genes. The most important among these is the nuclear factor (NF)- B pathway, which has 
become almost synonymous with inflammation. NF- B is a complex of two proteins: a 
transcription factor, which is the active NF- B, and an inhibitor called I B. Inflammatory 
stimulation, such as IL-1  and TNF activates I B kinase (IKK), which phosphorylates I B, 
causing its release, resulting in a now active NF- B, which translocates to the nucleus where it 
activates inflammatory genes [73; 74; 75; 76; 77]. Another pathway that is activated by 
cytokines is the janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway, which is induced by, among others, the pro-inflammatory cytokines IFN  and IL-6, 
and which mediates inflammation by activation of genes displaying a STAT-motif [78; 79]. 
Many studies have shown that the NF- B and JAK/STAT pathways interact to produce the 
inflammatory response [80; 81; 82]. There is also an increased activation of the mitogen-
activated protein kinases (MAPK) in activated cells, which contributes to the activation by 
enhancing secretion, proliferation and morphological changes. In particular, the p38 and c-jun 
N-terminal kinases (JNK) have been implicated in inflammation. JNK is also an activator of the 
transcription factor activator protein (AP)-1 which regulates several important inflammatory 
genes. Signalling mediated by increased levels of cAMP has been shown to inhibit 
inflammation, but it may be stimulatory under some circumstances. Signalling through the 
phosphatidylinositol-3-kinase (PI3K) pathway is another pathway shown to activate NF- B. A 
pathway that appears to have both pro- and anti-inflammatory forks is the peroxisome-
proliferator associated receptor (PPAR) pathway. PPAR proteins bind fatty acids, such as 
eicosanoids, and thereafter regulates a number of target genes by binding to and activating the 
retinoid-X-receptor (RXR) [83; 84; 85]. 
 
1.3 INFLAMMATION IN THE CENTRAL NERVOUS SYSTEM 
The CNS is different from other tissues in the body. It is shielded from the rest of the organism 
by the blood brain barrier (BBB), which controls the flux of cells and molecules into (and from) 
the CNS. Under normal conditions the BBB should be closed for circulating cells of the 
immune system, and if they are present in the CNS, it is a sign of a traumatic or pathological 
event. An exception is the influx of monocytes that is believed to replenish the population of 
resident microglia under normal conditions. The demanding and complex type of work 
performed by neurons is sensitive to disturbances. If immune cells, with their potentially 
harmful activities, had unlimited access to the brain the consequences could be dire. It is clear 
that the brain, being at the top of the hierarchy of the body, is presented with unique challenges 
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when it comes to maintaining homeostasis. In the normal CNS, the immune system is 
represented by the microglia. However, astrocytes can perform many functions associated with 
the immune system, such as cytokine production. 
 
1.3.1 Damage and impairment of neurons caused by inflammation 
1.3.1.1 Oxidative stress 
Free radicals generated during inflammatory activation can cause damage to neurons by 
destroying macromolecules. Neurons are highly dependent on the integrity and fluidity of their 
cell membrane to execute their functions effectively. Lipids in the cell membrane are highly 
susceptible to lipid peroxidation by free radicals. The lipid peroxidation also produces 
aldehydes that can bind to, and destroy, macromolecules vital to the cell [86]. 
 
1.3.1.2 Pro-apoptotic stimulation 
The pro-inflammatory cytokine TNF  has been shown to induce apoptosis in neurons [87]. The 
receptor for TNF  has a moiety in its intracellular signalling domain called a death domain 
(DD). DD:s exist on other members of the TNFR-family, on receptors for other cytokines such 
as the IL-1 receptor type I (IL-1RI), and on PAMP-receptors, although the evidence for a pro-
apoptotic effect is less extensive than for TNF . The mere existence of a DD does not imply 
that ligand-binding results in apoptosis. The decision of dying, or not, is taken with regard to the 
total pro- and anti-apoptotic signals that are being transduced into a cell at any given time.  
 
1.3.1.3 Negative effects on neuronal plasticity 
The pro-inflammatory cytokines TNF  and IL-1  has been shown to raise the threshold for the 
induction of long-term potentiation (LTP), which is a major mechanism for the formation of 
memories. Inflammation can thus directly impair learning and cognition [88; 89; 90]. 
 
1.3.1.4 Excitotoxicity 
Inflammation has been shown to decrease the expression of glutamate transporters on 
astrocytes. These transporters remove glutamate from the synaptic cleft, secreted during 
neuronal signalling. If glutamate remains in the synapse in high concentration the post-synaptic 
cell may be overstimulated. The net result of overstimulation of glutamate receptors is an 
increase in the intracellular levels of Ca
2+
, which creates a type of toxicity called excitotoxicity 
[91; 92]. Calcium ions are important intracellular messengers that regulate enzymes that, if left 
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active and without control, can induce apoptosis or make the cell go into necrosis directly. It has 
also been shown that quinolinic acid, which is a glutamate receptor agonist, is released from 
activated microglia and may contribute to excitotoxicity [93; 94; 95]. 
 
1.3.2 Cellular mediators of inflammation in the CNS 
1.3.2.1 Resident cells – microglia, astrocytes and neurons 
In the CNS, several cell types can contribute to the inflammatory response. Microglial cells 
have long been considered the main inflammatory cells in the CNS. In the healthy CNS, 
microglia are in a resting state with ramified processes that are surveilling the environment for 
disturbances. When activated, the microglia proliferate and change morphology into a round 
amoeboid shape that is similar to that of activated macrophages. Activation also increases the 
secretion of inflammatory mediators and the expression of their receptors. Another type of 
cells that can induce and modulate inflammation in the CNS is the astrocyte. Astrocytes are 
derived from neural precursor cells, not from bone-marrow derived mesenchymal stem cell as 
proper immune cells (and microglia). Astrocytes have some similarities to TH-cells, such as 
production of IFN  and expression of CD40L. They can produce reactive oxygen and nitrogen 
species and perform phagocytosis [96; 97]. The main task of astrocytes, however, appears to 
be the maintenance of neurons and their functions. An important task of astrocytes is the 
clearance of neurotransmitters from the synaptic cleft which prevents neuronal 
overstimulation as described above. Astrocytes are also constituents of the BBB. Confronted 
with an insult, astrocytes and microglia interact to produce an inflammatory response. This 
response can differ in secretory products and other activities according to the type of 
stimulation induced by the insult. It is also known that neurons and microglia interact to 
modulate the inflammatory response. For example, neuronal activity induces the release of 
fractalkine from the neuron, and this has an inhibitory effect on harmful microglial activities 
[98; 99]. Another example is the secretion of the neurotrophin brain-derived neurotrophic 
factor (BDNF) from active neurons, which has been shown to modulate microglial activation 
[100; 101]. 
 
Cells migrating from the periphery  
Monocytes have been shown to cross the BBB with subsequent release of inflammatory 
factors. The distinction between monocytes and microglia is blurred, since it is believed that 
microglia are monocytes that have entered the CNS and differentiated into microglia due to 
the microenvironment of the brain parenchyme. The contribution of microglia vs monocytes 
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to the harmful and beneficial responses associated with inflammation in the CNS is unclear, 
mainly due to the difficulties in distinguishing the two cell types from each other. While 
resting microglia have a morphology that is different from unactivated monocytes, the 
morphology of activated microglia is similar to that of activated monocytes, macrophages, 
and they also have a similar expression of cellular markers. The notion that microglia are 
derived from monocytes, together with the large overlap in responses and characteristics in 
activated microglia and monocytes, raises the question if the distinction is meaningful. 
 
1.4 MICROGLIAL ACTIVITIES IN INFLAMMATION 
1.4.1 Secretory products 
1.4.1.1 Cytokines 
Just like other macrophage-like cells, microglia are capable of synthesizing and secreting a wide 
range of pro- and anti-inflammatory cytokines. The cytokines that have been most studied with 
regard to microglial secretion are IL-1 , TNF  and IL-6. 
 
1.4.1.2 Growth factors 
Microglia can also secrete growth factors that can stimulate healing and regrowth of the tissue. 
Of great importance for AD is the secretion of BDNF. Many studies, published during the last 
30 years demonstrate the importance of BDNF in memory formation and neuroprotection [102; 
103; 104; 105; 106; 107; 108; 109]. Nerve growth factor (NGF) is another neuroprotective 
growth factor that microglia can produce [110]. The growth factors secreted by microglia can 
also act in an auto- or paracrine manner. As was discussed above, BDNF is secreted from 
microglia and has been shown to modulate activation of microglia. 
 
1.4.1.3 Oxidative stress 
Microglia can be a source of oxidative stress through the induction of inducible nitric oxide 
synthase (iNOS). Free radicals are also produced by cyclooxygenase (COX) enzymes during 
the production of eicosanoids. Another source of oxidative stress is the lysosomal enzymes, 
which are active in lysosomal degradation of phagocytosed debris or pathogens. 
 
1.4.2 Phagocytosis and degradation of debris and pathogens 
For the body to be cleared of debris from tissue turnover, pathogens and foreign objects, a 
system for removal, clearance and degradation must be in place. Removal of objects from the 
tissue is carried out by the process of phagocytosis. Phagocytosis is mainly performed by cells 
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of the immune system. Particularly, macrophage-like cells, dendritic cells and neutrophils are 
proficient at phagocytosis.  
 
1.4.2.1 The mechanism of phagocytosis 
For phagocytosis to take place, the cell must recognize an object as being “worthy” of 
phagocytosis. As described above, an array of surface receptors fulfill this role by acting as 
sensors on objects encountered in the tissue. If the object is recognized as antigenic, a signal is 
transduced into the cell and a rearrangement of the cytoskeleton takes place to engulf the object. 
When completely engulfed, the object is in an intracellular vesicle called phagosome. The 
recognition of the object by the receptor can have other consequences than engulfment. Many 
phagocytic receptors can also mediate an inflammatory activation of the cell. An exception is 
the CD18 molecule that recognizes the phoshatidylserine moieties on the outer leaflet of the 
membrane of apoptotic cells without activation. Apoptotic cells are ubiquitous in most tissues 
due to normal cell turnover. It would cause unnecessary damage and stress if an inflammation 
was induced everytime a cell dies. As mentioned above, the PAMP-receptors can mediate 
phagocytosis. Another type of receptor that can mediate phagocytosis is the scavenger 
receptors. The scavenger receptors recognize, for example, oxidized peptides and stimulate their 
uptake. Fc-receptors can mediate phagocytosis of objects that have been opsonized with 
antibodies. Complement fragment 5a binds to bacterial surfaces and stimulates their 
phagocytosis when binding to complement receptors on microglia or macrophages. 
 
1.4.2.2 The mechanisms of degradation 
The invagination produced by the phagocytic process will close and become the phagosome, an 
intracellular vesicle that contains the phagocytosed material. The phagosome later docks and 
fuses with a lysosome, forming a phagolysosome. It is in the phagolysosome that degradation of 
the phagocytosed material takes place. The milieu in a phagolysosome is acidic, which 
promotes denaturation. Oxygen-independent degradation occurs by proteases, lipases, amylases 
and nucleases in the phagolysosome, digesting the phagocytosed material. Oxygen-dependent 
degradation is performed by activation of a respiratory burst. The respiratory burst is the 
production of oxidative stress by NADPH oxidase and myeloperoxidase, which are meant to 
destroy bacteria in the phagolysosome. This oxidative stress can have detrimental consequences 
for the surrounding tissue. 
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1.4.3 Inflammation and AD 
The connection between AD and inflammation may be stronger than just activation of microglia 
or other cells induced by the neuronal cell death in the AD-brain. A  has been shown to have 
pro-inflammatory effects on microglia, as well as astrocytes, in several studies [111; 112; 113; 
114]. Inflammation has been shown to increase the production of APP, and to increase 
amyloidogenic metabolism of APP [115; 116; 117]. Theoretically, this is suggestive of a vicious 
circle which starts with an increase in either the levels of A  or inflammatory mediators, and 
which later becomes self-sustaining. Another question that is raised is why the activated 
microglia and astrocytes are unable to remove the excessive levels of A  from the brain by 
phagocytosis. Inflammation increases phagocytosis, but with regard to the AD brain, it appears 
that phagocytosis is either insufficient or inhibited. Some of the ways in which inflammation 
can contribute to the pathology in AD are summarized in Fig. 1. 
Glutamate uptake
-> excitotoxicity
MHCII
CD40 – CD40L
Cytokines
Oxidative stress
apoptosis +
A
apoptosis
necrosis
necrosis
apoptosis
-
A oligomers
plaque
A
Synaptic 
dysfunctionBDNF -
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Fig. 1. Pathological interplay between A  and inflammation in AD. The major neurotoxic 
pathways of A  according to the author are presented in this figure: (a) Oligomeric A  can induce 
toxicity directly on neurons. (b) A  induces synaptic dysfunction with potential disturbances in 
neuronal BDNF secretion. (c) Activation of microglia and astrocytes by A  increases oxidative 
stress and secretion of inflammatory cytokines. (d) Binding of CD40 – CD40L, which are increased 
by A , further activates the microglia and inhibits phagocytosis of A . (e) impaired glial uptake of 
glutamate may cause excitotoxicity. 
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1.5 MODULATION OF THE INFLAMMATORY RESPONSE INTO A THERAPY 
FOR AD 
The immune system is capable of a wide range of responses that can be destructive or protective 
for neurons. The main strategy would be to invoke an immune response that stimulates 
beneficial activities, but at the same time inhibits activities that can be detrimental. To remove a 
disease-causing pathogen is in most cases probably the most effective way of treating a disease. 
In the case of AD, the main pathogen is A . To stimulate cellular uptake, phagocytosis, of A  is 
a promising strategy for treatment for AD. In some animal studies, stimulation of phagocytosis 
by immunization have been shown to be effective in removing plaques and to promote 
cognitive performance [118]. Human clinical trials with passive immunization have been 
started, but were aborted due to serious side effects in a few participants, highlighting the 
danger of manipulation of immune responses: stimulation into phagocytosis can activate the 
cells into performing unwanted and damaging activities. The activities that should be inhibited 
are those associated with a full-blown inflammation such as secretion of pro-inflammatory 
molecules and production of oxidative stress. Growth factors secreted by microglia and 
astrocytes can protect and enhance the activities of neurons. Secretion of growth factors is a 
valuable therapeutic target in itself. Stimulation of glial or neuronal production of growth 
factors would be beneficial for many disorders in the CNS. When evaluating therapies for AD, 
the effects on microglial and astrocyte growth factor should be taken into account. The 
reciprocal stimulatory relation between inflammation and A  has been discussed in this thesis. 
It is conceivable that just decreasing the level of inflammation in the AD brain can help to break 
the vicious circle. 
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2 THESIS AIMS 
The primary aim of this thesis is to develop a strategy for using inflammatory responses in the 
treatment of neurodegenerative conditions particularly with regard to AD, i.e. to investigate if 
the mechanisms of inflammation can be controlled in a way that harmful responses are down-
regulatedm while beneficial responses are enhanced. Most studies on the influence of 
inflammation on neurodegenerative conditions that have been performed in the past, have 
focused on the global repression of inflammatory responses, i.e. positive outcomes of the 
experiments have been defined as the absence of activity of the immune cells studied. However, 
it may be that when repressing the inflammatory response, the beneficial activities that are 
associated with inflammation are also repressed. Inflammation is a process with an ending, 
resolution, which previously has been viewed as a more or less passive down-regulation of the 
inflammatory response due to the absence of activating stimuli. In recent studies, resolution has 
been suggested to be an active process that is mediated and controlled by signalling molecules 
and their receptors. 
 
2.1 SPECIFIC AIMS 
To realize the primary aim of this thesis the following three specific aims were formulated: 
 to characterize human CHME3 microglia with regard to interactions with A  and 
inflammation, with special emphasis on phagocytosis of A  
 to investigate if immunomodulatory substances can stimulate phagocytosis of Ab and 
increase neuronal survival and function through direct effects on neuronal cells or 
indirect effects on microglia 
 to investigate the effects of omega-3 on inflammatory factors in CSF and plasma from 
AD patients 
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3 METHODOLOGY 
3.1 GENERAL OVERVIEW 
A number of methods and techniques were utilized to perform the experiments and producing 
the data presented in the studies of this thesis. In this section we will describe the methods and 
techniques, discuss their benefits and drawbacks, and compare them to alternative methods used 
to analyze the same type of material. 
 
3.1 CELLULAR MODELS – PAPERS I, II, IV AND PRELIMINARY RESULTS 
3.1.1 A model of human microglia: The human CHME3 microglial cell line 
The most appropriate in vitro model of human microglia would be to use human primary 
microglia from aged controls and AD-patients. However, the availability of human primary 
microglia is extremely limited for obvious reasons. Microglia derived from aged humans are 
only available from post mortem material or excess material from brain surgery. In addition, the 
methodologies of culturing adult human microglia, and the ethical and administrative issues, are 
non-trivial. An alternative source of human primary microglia is to isolate microglia from 
aborted human fetuses which is less demanding than work on adult microglia. However, there is 
still a problem with insufficient number of cells for the purpose of the experiment. Added is 
also the issue of extrapolating the responses of embryonic cells to aged cells. Transformed, 
immortalized, cell lines are commonly used in models of pathology to mimic their primary cell 
counterparts. The CHME3 microglia cell line used in this thesis was created by transfection 
with SV40 large T antigen [119]. Transformation caused by SV40 large T antigen immortalizes 
the cell by the expression of the gene product which binds to the p53 and retinoblastoma tumour 
suppressor protein [120]. The abolished anti-tumour defense results in transformation of the 
cells through spontaneous mutations that remain in continuous generations by removal of the 
function of proteins that detect genomic abnormalities and control cell-cycle progression. This 
allows for the continouos and fast proliferation of cells that normally would proliferate slowly 
and finally go into senescence. The drawback of using cell lines is that by removing parts of the 
system that controls the genomic integrity of the cell, it is possible that the cell line will change 
with time due to accumulated mutations, thus changing the original phenotype of the cell line. 
Another disadvantage is that the inhibition of the cellular control machinery may affect 
signalling pathways that are relevant for experimental results. There are no commercially 
available human microglial cell lines and to the author‟s knowledge, only two human cell lines 
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exist, with the CHME3 line being one of them. Fig. 2 shows the CHME3 microglial cells in 
culture  
 
 
3.1.2 A model for neurodegeneration on human neuronal cells 
The human neuroblastoma SK-N-SH SY5Y (SY5Y) is one of the most commonly used models 
of human neurons. SY5Y cells express several neuronal proteins and activities, but they are 
highly mitotic and are morphologically different from primary neurons. A common method for 
neuronal differentiation of SY5Y cells is the treatment with retinoic acid [121]. This treatment 
increases the expression of neuronal proteins and induces changes in morphology toward a 
neuronal phenotype, i.e. neurite extension, although the cells are still mitotic. One neuronal 
protein that is upregulated by retinoic acid is TrkB, which is the receptor for BDNF [122]. If the 
SY5Y cells are first treated with retinoic acid, then treated with BDNF in serum-free medium 
for an extended period of time, neuronal morphology and biochemical profile is further 
enhanced, the cells become post-mitotic and projects an extensive neurite network. 
 
3.1.3 Immunochemistry 
Immunochemistry, or the use of antibodies to analyse different types of samples, is a versatile 
technique that is involved in several of the methods used in the papers of this thesis. 
Immunocytochemistry (ICC) is the use of antibodies to “stain” cells, which can then be 
analysed with microscopy or flow-cytometry. ELISA (enzyme-linked immunosorbent assay) is 
a similar method based on antibodies, and used to quantify molecules in solution. MesoScale 
multiplex analysis is based on the same principle as ELISA, but the detection system is different 
and the method allows simultaneous analysis of several molecules. The methodology used in 
the studies in this thesis is based on indirect immunofluorescence, i.e. secondary antibodies that 
Fig. 2. This 
microphotograph, taken 
in an inverted 
microscope, shows 
human CHME3 
microglia in culture. 
Note the morphological 
heterogeneity of the 
cells with both 
elongated, process-
bearing cells and 
amoeboid cells. 
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are reactive to the species producing the primary antibody are added after incubation with the 
primary antibody. The secondary antibodies are labelled with different types of markers for 
detection of the immunoreaction, and in our work we have used secondary antibodies labelled 
with fluorescent markers, hence immunofluorescence. The use of indirect immunofluorescence 
will produce an amplification of the signal from the molecule investigated, since several 
secondary antibodies can react with one primary antibody. The direct immunofluorescence from 
a primary antibody directly labelled with a fluorophore is usually too weak to be detected in the 
microscope. Directly labeled primary antibodies are commonly used in flow-cytometry but have 
the disadvantage of being expensive.  
 
3.1.3.1 Visualization in the microscope 
Inspection in the microscope was used for qualitative assessment of samples. Both regular 
fluorescent and confocal microscopy were utilized. Confocal microscopy uses laser to render a 
slice of immunofluorescene from a sample at a particular z-value. If a series of consecutive 
slices is rendered, a 3-dimensional image is created. By immunochemical staining for relevant 
markers, it is thus possible to assess the subcellular location of, for example, a phagocytosed 
object. Quantitative assessment in the microscope is possible, but time-consuming, and subject 
to bias. 
 
3.1.3.2 Quantification of phagocytosis and immunoreactivity of cells with flow-cytometry 
Cytometry is the technique of measuring characteristics of cells. In flow-cytometry the cells are 
measured as they flow past a detector, one by one, so that the characteristics of each individual 
cell are emitted as a signal. The signal is produced by projecting laser light on the cells, and the 
light that is reflected, or emitted, from the cells is detected by photo-detectors. A common 
application of flow-cytometry is to produce specific information about the presence of a certain 
molecule, condition or process in the cells. To accomplish this, the cells are incubated with 
fluorescent antibodies or dyes for the detection of a certain molecule, physical condition or 
process. Data from flow-cytometry are commonly presented as scatter plots in an analysis 
program. In these plots it is possible to establish borders that determine if a signal is positive or 
not, thus yielding binary quantitative data. The borders are established by analyzing the 
negative controls, which set the limit for the cellular presence of the molecule analysed.  
To effectively produce unbiased, quantitative data of the cellular presence of markers or 
phagocytosed material, we developed a technique for analysing adherent cells with flow-
cytometry. This technique was used to quantify phagocytosis, cellular markers and the data on 
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apoptosis as assessed with the TUNEL-assay presented in the Preliminary results. This method 
is used extensively for the analysis of blood-borne cells, which are non-adherent on cell plastic. 
In this thesis we analysed microglia, cells that are strongly adherent, which makes analysis 
complicated. Adherent cells must be detached mildly, not to affect the characteristics that are to 
be quantified. In addition, enzymatic detachment which is the most common method for 
detaching cells brings the risk of degrading epitopes of interest. To avoid this, the cells were 
detached with a commercial buffer containing salts and chelators that promote a mild form of 
detachment. 
 
3.1.3.3 Outline of the experiments 
Human CHME3 microglia and neuroblastoma SY5Y cells were routinely cultured and sub-
cultured under sterile conditions. In all experiments the cells were seeded in standard multi-well 
plates or dishes. Before the treatments, the wells or dishes were washed with serum-free 
medium and left with this for 1 h, after which the treatments were added to the cultures. All 
treatments were prepared in serum-free medium. The importance of avoiding serum when 
performing experiments on immuno-competent cells is highlighted by the presence of 
immunoactive substances in serum that can influence the experiments. Cell proliferation and 
cell death assays were performed immediately at the end of the experiment. Cells destined for 
ICC and analysis in the microscope were dried on to their coverslip and fixed with 4% 
paraformaldehyde (PFA). Cells destined for analysis of phagocytosis and immunoreactivity 
were detached and the resulting cell suspension was fixed with 1% PFA. The lower 
concentration of PFA used for fixation of the cell suspension is motivated by the background 
fluorescence of PFA that can create problems in the analysis. However, we have found that PFA 
also promotes attachment of the cells to the coverslip and hence the higher concentration was 
used for microscopical analysis. 
 
3.1.3.4 Analysis of phagocytosis 
The intracellular presence of a labelled object can easily be detected and quantified with flow-
cytometry or manual microscopical inspection (see above). However, evidence is needed to 
show that the object is phagocytosed and not attached to the cell in an unspecific manner. To 
confirm intracellular localisation and phagocytosis, ICC for lysosome-associated membrane 
protein-2 (lamp-2) was performed and analysed by confocal microscopy for the co-localization 
of A 1-42 with lamp-2.  
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Flow-cytometry was used to quantify the phagocytosis of A 1-42 or latex beads by the CHME3 
microglia. First, control samples incubated without the fluorophore-labelled A 1-42 or latex 
beads were analysed, generating a base line signal in the wavelength channel of the fluorophore. 
In subsequent analyses, all cells that emitted a signal that was higher than this base line were 
considered phagocytic, and phagocytic activity in a culture was expressed as the percentage of 
phagocytic cells. 
 
3.1.3.5 Analysis of cellular phenotype 
The phenotype of CHME3 microglia was analysed with flow-cytometry by quantification of 
cells being immunoreactive to the cellular markers investigated. A base line separating positive 
and negative cells was generated in analogy to the methodology on phagocytosis, and the 
immunoreactivity to the marker was expressed as a percentage of the total number of cells.  
To determine the phenotype of phagocytic and non-phagocytic microglia, the differential 
expression of the cellular markers in the phagocytic and non-phagocytic populations were 
assessed. Immunoreactivity was expressed as the percentage of cells being positive for a marker 
in the phagocytic, or non-phagocytic, population. A difference in the percentage indicates a 
difference in phenotype. 
 
3.1.3.6 Analysis of secretory products 
The secreted levels of relevant molecules were analysed in all papers included in this thesis. 
With regard to this, it is important to note that the level of a secreted product is subject to 
several factors that influence the appreciated level of a molecule. Spontaneous or enzymatic 
degradation can influence the levels, as well as sticking of the molecules to cell membranes or 
culture dishes. 
 
3.1.3.6.1 ELISA (enzyme-linked immunosorbent assay) and MesoScale multiplex analysis 
ELISA is the most common method to analyse secretory products from cell cultures or bodily 
fluids, such as CSF or serum. It is a well-established and uncomplicated assay that can be 
optimized by the end user for special applications. The drawback is that there is a relatively 
high variability in this method, which is a consequence of the immunohemistry utilized, and the 
detection system, usually based on absorbance. The secondary (or detection) antibody is 
commonly conjugated with an enzyme that after addition of a substrate yields a product, the 
detected level of which is proportional to the concentration of the molecule investigated. In 
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some ELISA:s, fluorescence or luminescence replaces absorbance as a detection system, thus 
increasing sensitivity and reliability.  
Another drawback of ELISA is the large amount of sample that is consumed, especially if 
several molecules are to be analysed in each sample. To overcome these limitations multiplexed 
analyses have been developed. In paper IV, the MesoScale multiplex technique was used for 
the measurement of a set of TH1 and TH2 cytokines. This technique does not only allow analysis 
of several antigens in a small sample volume, but is also a lot more sensitive than an absorbance 
based ELISA, since it is based on luminescence. Furthermore, with the MesoScale technique, 
the luminescence is activated by electricity which reduces the background problem. 
 
3.1.3.7 Analysis of cell proliferation and cell death 
Monitoring of the well-being of the cells is a routine task to help interprete other data, such as 
secretion. In studies on neurodegeneration, the data from proliferation and cell death assays are 
commonly the primary outcome of the experiment, as in the case of the Preliminary results 
included in this thesis. 
 
3.1.3.7.1 The MTT-assay 
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is an old 
„workhorse‟ in the studies on cellular proliferation and death. It is well-established, and 
relatively uncomplicated and therefore still commonly used despite the surfacing of related, 
more sensitive, but more expensive assays. The assay relies on the activity of mitochondrial 
reductases, which are active in healthy, living cells. The MTT salt is a substrate to these 
enzymes and if added to living cells they will produce a coloured product, the absorbance of 
which is measured and proportional to the amount of living cells in the culture. Data from the 
MTT-assay are usually normalized to the control treatment data (= 100%). 
 
3.1.3.7.2 The LDH-assay 
The LDH (lactate dehydrogenase)-assay is also an old workhorse in studies on cellular toxicity 
for the study on necrosis. Necrotic cells cannot maintain their membrane integrity, resulting in 
leakage of cytosolic molecules, such as LDH, into the culture medium. Measurement of the 
LDH-activity in the culture medium gives information about the degree of necrosis in the 
culture. The LDH-activity is assessed by adding a substrate to a volume of conditioned medium 
and then measuring the absorbance of the product, that is proportional to the amount of necrosis 
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in the culture. The data from the LDH-assay is normalised to a positive control, i.e. cells lysed 
with a detergent, thus creating 100% cell death. 
 
3.1.3.7.3 The TUNEL-assay 
To analyse apoptosis, yet another established assay was used. The TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labelling)-assay is performed on fixed cells in 
suspension or cells attached to a coverslip. In apoptosis there is a characteristic fragmentation of 
DNA, creating  a large number of free endings that are recognised by the enzyme terminal 
deoxynucleotidyl transferase (Tdt), adding nucleotides to these endings. In the TUNEL-assay, 
the reaction is performed in the presence of fluorophore-conjugated nucleotides resulting in 
fluorescent labelling of apoptotic nuclei. The number of apoptotic nuclei is expressed as a 
percentage of the total number of nuclei. The quantification of apoptosis can be performed 
manually by counting positive nuclei in the microscope. However, the quantification is faster 
and more reliable by analysing a cell suspension in a flow-cytometer. The data on neuronal 
apoptosis in the Preliminary results were generated in this way. 
 
3.2 EFFECTS OF INTERVENTION WITH EPAX ON INFLAMMATORY 
MARKERS IN AD-PATIENTS – A CLINICAL RANDOMIZED TRIAL 
Paper III in this thesis is part of the OmegAD-study, which is aimed at investigating the 
potential of omega-3 fatty acids for the treatment of AD. In the OmegAD-study a global 
approach has been applied with regard to outcome variables. Cognitive function, and nutritional 
status were assessed, as well as the levels of inflammatory markers, which is the focus of paper 
III in this thesis. 
 
3.2.1 The study population 
In the original OmegAD-study, 361 patients were recruited from the specialist memory clinics 
at Karolinska University Hospital, Huddinge, and from Danderyd Hospital and St. Göran 
Hospital in Stockholm. The patients were included on the basis of the diagnosis of mild to 
moderate AD according to DSM-IV classification. All patients were medicated with 
acetylcholine esterase-inhibitors for at least 3 months before the start of the study and this 
treatment continued during the study. The population studied in paper III is a subgroup of 40 
patients that were the 40 first participants included in the OmegAD study. Patients under 
medication with non-steroidal anti-inflammatory drugs (NSAIDS) were not included. 
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3.2.2 Study design 
The participants were randomly assigned to EPAX (see 3.3.5) or placebo groups. At baseline 
the participants were subject to cognitive and neuropsychiatric evaluation as well as 
anthropometric assessment. Blood was sampled from all participants and CSF was sampled 
through lumbar puncture in a subset of the participants. Treatment with EPAX/placebo 
continued for 6 months, after which new evaluation and collection of blood and CSF was 
performed. After this all participants were given EPAX for another 6 months after which the 
last evaluations were performed. 
The plasma and CSF were analysed with commercial ELISA for the levels of IL-6, TNF  and 
sIL-1RII. High sensitivity ELISA was used to analyse the levels of IL-6 and TNF  in CSF. 
CSF samples were sent to Clinical Neurochemistry Laboratory, Mölndals Lasarett, Gothenberg, 
Sweden, for analysis of t-tau, p-tau and A 1-42. The plasma levels of high sensitive C-reactive 
peptide (hsCRP) was analysed at Dept. of clinical chemistry, Karolinska University Hospital, 
Stockholm, Sweden. 
 
3.3 INTRODUCTION TO THE IMMUNOMODULATORY SUBSTANCES USED 
To test the possibility of influencing the inflammatory response, a number of substances with 
immunomodulatory properties were tested in the human microglial model. Furthermore, to 
investigate the effect of an intervention with omega-3 fatty acids, AD patients were treated with 
EPAX (see 3.3.5), a mixture of omega-3 fatty acids. In the Preliminary results we present data 
from studies on the potential of -MSH to protect human neuronal cells from necrosis and 
apoptosis. 
 
3.3.1 Protollin 
Protollin is an adjuvant made of hydrophobic outer membrane proteins from N. meningitides 
which are non-covalently complexed with LPS from Shigella flexneri 2a. Protollin has been 
shown to stimulate removal of A  from transgenic AD-mice [123], an effect that the authors 
attributed to microglial activation, through activation of TLR type 2 and 4. This substance 
cannot pass the BBB through normal routes, but nasal administration can be used for transport 
into the CNS. 
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 IL-1
Interleukin-1 is one of the two archetypical pro-inflammatory cytokines. It is produced by a 
number of cell types, although the secretion from cells of the monocyte lineage is the most 
studied. IL-1  is secreted, while its sibling IL-1  is mostly encountered in a membrane-bound 
form. They both activate the same receptor, IL-1R type I, which is membrane-bound. There is 
also a secreted form of this receptor, sIL-1R type I, which can act as a decoy receptor, but can 
also initiate signal transduction if its complex with IL-1 is inserted into the membrane of a 
responsive cell. An inactive decoy receptor also exists in a membrane and soluble form, IL-
1RII, and is considered anti-inflammatory by acting as a sink for IL-1 . In the introduction to 
inflammation above, the several pathways that are activated when by the IL-1R were discussed. 
The broad spectrum of IL-1R activation is mirrored in the literature where this cytokine has 
been implicated in various functions and pathological conditions. The stimulation of neurons in 
the hypothalamus by IL-1  induces some of the physiological and behavioural changes 
associated with inflammation, the sickness syndrome, which is associated with decreased 
energy and appetite as well as increased body temperature and hyperalgesia [124]. The 
importance of IL-1  for the regulation of neuronal plasticity has been mentioned. IL-1  also has 
functions as a growth factor in the development of the nervous system [125].  
 
 
 IFN
Interferon-  is the second archetypical pro-inflammatory cytokine. It is mainly produced by 
activated TH1-cells and is considered the prime activator of cells of the monocyte lineage, 
stimulating them to attain a pro-inflammatory TH1 phenotype. There are two types of receptors 
for IFN  (IFNGR1 and IFNGR2) which upon binding of the ligand first homodimerize, after 
which two IFNGR1 and IFNGR2 homodimers associate, thus forming a heterodimer formed by 
association of two different homodimers. The assembly of this complex makes signal 
transduction through Jak1/2 – STAT1 possible, resulting in the transcription of a number of 
genes, among them one of the subunits of the B complex, which is expressed in low levels in 
basal conditions. The effects of IFN  on the activation of iNOS and expression of MHC)I and II 
has been discussed in the introduction of this thesis. 
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3.3.4 DHA and EPA 
Docosahexanoic acid (DHA) is an omega-3 fatty acid that has received lot of attention in recent 
times for its proposed beneficial effects on several conditions related to inflammation, in the 
periphery as well as in the CNS. Of special interest are the metabolites that result from 
biotransformation of DHA. Neuroprotectin D1 is a fatty acid derived from DHA that has been 
shown to protect neurons and have anti-inflammatory properties [67; 126]. Another derivative 
of DHA is maresin, which also has been shown to be anti-inflammatory and to stimulate 
phagocytosis [127]. Neuroprotectin D1 and maresin are believed to mediate the resolution stage 
of inflammation. Eicosapentaenoic acid (EPA) is also an omega-3 fatty acid with anti-
inflammatory properties [126].  Resolvins are derivatives of EPA and believed to mediate the 
effects of EPA [67]. As the name implies, resolvins favour the resolution of inflammation and 
as such can be neuroprotective by limiting inflammation in the CNS. It should also be noted that 
there are pathways between the metabolism of DHA and EPA, permitting the conversion of 
metabolites from each pathway to metabolites of the other. 
Effects of DHA and EPA can also be mediated by influence on membrane dynamics and 
fluidity. DHA is abundant in the brain gray matter, while EPA is not. However, the conversion 
potential between the two fatty acids, and the results from studies showing that EPA has 
beneficial effects on disorders in the CNS, suggest an important role of EPA in the CNS. 
Both EPA and DHA can activate the PPAR family of proteins, which can contribute to their 
anti-inflammatory effects [128].  
 
3.3.5 EPAX and placebo 
EPAX 1050TG™ is a product of Pronova Biocare A/S Lysaker, Norway. It is a capsule which 
contains 430 mg DHA and 150 mg EPA. The placebo capsules contained 1 g corn oil which 
includes 0.6 mg of linoleic acid.  
 
3.3.6 -Melanocyte stimulating hormone ( -MSH) 
-MSH is a thirteen amino acid neuropeptide that has been shown to have potent anti-
inflammatory properties. Neuroprotection by -MSH has been reported in a number of studies 
on animals, but data from experiments on human tissues are scarce [68; 129].  The effects of -
MSH on human tissues have not been studied extensively. -MSH binds to melanocortin 
receptors of which there are five subtypes (MCR1R, MCR2R, etc) [130]. All subtypes have 
been found in the brain, except MCR2R, which is a receptor for adrenocorticotrophic hormone 
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(ACTH), exclusively. MCR2R is expressed in the adrenal cortex where its activation stimulates 
the secretion of cortisol. Signal transduction through melanocortin receptors is mediated by 
stimulatory G-proteins, which activates adenylyl cyclase (AC), followed by production of 
cAMP. cAMP activates protein kinase A (PKA) which in turn activates the cAMP-response 
element binding (CREB)-protein. The activated CREB-protein then activates genes with anti-
apoptotic functions, and functions positively regulating neuronal plasticity. The anti-
inflammatory effect of -MSH is proposed to be mediated by the inhibition of NF- B and the 
induction of anti-inflammatory cytokines [131; 132; 133]. 
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4 RESULTS AND DISCUSSION 
In paper I the human CHME3 microglia cell line was characterized with regard to 
inflammatory responses after incubation with A 1-40. The effects of IFN  and -MSH by 
themselves, and together with A 1-40, were also studied. The presence of MCR:s was also 
investigated. The inflammatory response was measured by the secretion of IL-6 and cell 
proliferation. 
In paper II we widened the scope to include inflammatory responses that can be beneficial. As 
in paper I, the inflammatory response was measured by the secretion of IL-6. The phagocytosis 
of A 1-42 and the secretion of BDNF were introduced as positive outcomes of microglial 
activation. ICC was also performed to elucidate the phenotype of microglia that phagocytose 
A 1-42. 
Paper III is part of the OmegAD-study which is an intervention study aimed at investigating 
the potential of omega-3 fatty acids for the treatment of AD. The participants in the OmegAD-
study were patients diagnosed as suffering from mild to moderate AD based on DSM-IV 
classification. Plasma and CSF were analysed for the levels of markers related to inflammation 
and AD at base line, and after 6 months of treatment with the omega-3 preparation or placebo. 
To further study the effects of omega-3 fatty acids on inflammation in the CNS we performed 
an in vitro study that resulted in paper IV. The methodology in paper II was used to study the 
effects of the omega-3 fatty acid DHA on phagocytosis of A 1-42, secretion of IL-6 and BDNF, 
and the inflammatory phenotype of the CHME3 microglia. The effects of DHA on phagocytosis 
of inert latex beads and other parameters were also studied. In the studies on latex beads, the 
secretion of a set of TH1 and TH2 cytokines was also studied. 
In the Preliminary results we describe the results obtained when investigating the 
neuroprotective and plasticity-promoting effects of -MSH on differentiated human neuronal 
cells. Cell proliferation and cell death, as well as the degree of apoptosis were measured. The 
effects on plasticity were analysed with ICC and Western blotting. 
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4.1 CHARACTERIZATION OF HUMAN CHME3 MICROGLIA WITH REGARD 
TO INTERACTIONS WITH A 1-42 AND INFLAMMATION 
In paper I and II, the human CHME3 microglia were analysed with regard to their reactions to 
incubation with A 1-42 and a set of immunomodulatory substances. The responses in terms of 
secretion of the pro-inflammatory cytokine IL-6 and the neurotrophin BDNF, cell proliferation 
and cell death, as well as phagocytosis of A 1-42 will be discussed. 
 
4.1.1 Secretion of IL-6 from human CHME3 microglial cells 
As a cytokine that appears in the later part of the acute phase and that is the effector of 
inflammation on several tissues, IL-6 can be used as an indicator of inflammatory responses. 
  
4.1.1.1 Secretion of IL-6 upon incubation with pro-inflammatory cytokines (Paper I, II, IV) 
Pro-inflammatory stimulation in the form of IL-1  and IFN  increased IL-6 secretion, as 
expected. The most vigorous secretion was induced by IL-1  (50 ng/ml) which after 48 h of 
incubation increased the levels of IL-6 in the medium around 20-30 times over the levels 
observed under basal conditions.  
 
4.1.1.2 Secretion of IL-6 upon incubation with A 1-40 or A 1-42 (Paper I, II, IV) 
A 1-40 at 5 M induced a significant increase in IL-6 secretion of 40% over vehicle (paper I). 
There was no significant effect on IL-6 secretion from the cells upon incubation at 2 M (5 
g/ml fluorophore-labelled A 1-42 (paper II). Although the difference in concentration of the 
A  in the two papers, we believe that the major cause is a difference in the activating properties 
of A 1-40 and A 1-42, which has been suggested in previous studies [134]. The preparation 
procedure and the solvent used are also factors that may influence the outcome of experiments 
on A . A key event appears to be the oligomerisation of A  which creates neurotoxic forms of 
A , while fibrillisation creates forms that are less toxic [135]. Aside from neurotoxicity, the 
immune-activating properties of A  have also been shown to be dependent on the aggregational 
form of A  in studies in rat microglia [134]. An explanation to the differences in effects may lie 
in the appearance of structures resulting from differential aggregation of A  dissolved or 
prepared in different conditions. The appearance of structures that act as Ca
2+
-ionophores, or 
ligands to receptors that mediate activation is possible.  
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IL-6 has been shown to be increased in the brains of AD patients, rendering IL-6 a prime 
suspect of being involved in the pathology of this disease [136]. There are, however, beneficial 
effects of IL-6 on neurons. Studies in vitro have shown that IL-6 can promote neurite outgrowth 
and neuronal survival [137; 138; 139; 140]. However, in a study by Qiu et al it was shown that 
rat cortical neurons were more severely affected by incubation with N-methyl-D-aspartate 
(NMDA) and A 1-42 when IL-6 was present [141]. In addition, IL-6 has been shown to inhibit 
neurogenesis, and promote astrocyte differentiation from neuronal precursor cells [104; 142; 
143]. Furthermore, as one of the “final” cytokines in the pro-inflammatory cytokine cascade, 
IL-6 is an effector of many of the harmful responses of inflammation [144]. It is most probable 
that inhibition of the increased secretion of IL-6 observed in the AD brain would be beneficial. 
To conclude, CHME3 microglia respond to IL-1  and IFN  stimulation with increased IL-6 
secretion, thus showing a normal macrophage-like response to this type of stimulation. The cells 
respond to A 1-40 with an increase in their secretion of IL-6 in a dose-dependent manner, while 
A 1-42 was without effect at the concentrations tested.  
 
4.1.2 Secretion of BDNF from human CHME3 microglial cells 
The secretion of BDNF was analysed in paper II and IV. An increased secretion of BDNF is a 
positive outcome of inflammation that has been reported in several studies. The focus has been 
on the secretion of BDNF from neuronal cells, while microglial secretion has been receiving 
relatively little attention. Neuronal secretion of BDNF is most likely more important than glial 
secretion for the functioning of neurons due to the temporal and spatial qualities required for 
consolidation of memory. However, one should not discard the possibility that glial secretion 
can play a beneficial role in neurodegenerative conditions by increasing the interstitial 
concentration of BDNF. 
 
4.1.2.1 Secretion of BDNF upon incubation with pro-inflammatory cytokines (Paper I, II, 
IV) 
A presumably detrimental reduction in the secretion of BDNF was seen when the microglia 
were incubated with IFN  (50 ng/ml) (paper II). As discussed above, this is in discord with 
other reports showing an increase in growth factor secretion in inflammation. However, in the 
experiments presented in this thesis the microglia were stimulated with quite high 
concentrations of IL-1  and/or IFN  which are only two of the components of the 
inflammatory cascade, and it may be that the situation in the brain is different. Nevertheless, it 
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suggests a pathological effect of IFN  that is relevant for AD and that may play a role in the 
pathology and pathogenesis of this disease. The effects of IL-1  on the secretion of BDNF were 
small and co-incubation with IFN  produced results similar to those obtained with IFN  alone. 
In paper IV a small, yet significant stimulatory effect on BDNF secretion could be observed 
upon incubation with IL-1  and latex beads. In view of the lack of effect upon stimulation with 
A 1-42 and IL-1 , and when stimulating the cells with IL-1  alone, it can be speculated that 
phagocytosis of the latex beads modulated the response to IL-1  into increased secretion of 
BDNF. 
 
4.1.2.2 Secretion of BDNF upon incubation with A 1-42 (paper II, IV) 
In paper II, a negative effect on the secretion of BDNF was observed upon incubation with 
A 1-42. At the concentration of 1 g/ml the results were inconsistent, i.e. in the Protollin series 
of experiments a significantly lower level of BDNF was observed, while in the cytokine series 
of experiments the effect was not statistically significant. In Fig. 3 the data from all experiments 
with 1 g/ml A 1-42 are combined, showing a significant reduction in the secretion of BDNF 
from CHME3 microglia. At the concentration of 5 g/ml, A 1-42 significantly decreased 
microglial secretion of BDNF to 50% that of control. No additive effect was observed when the 
microglia were incubated with A 1-42 and IFN . What is the mechanism by which A 1-42 lowers 
the secretion of BDNF from microglia? Tong et al found that A 1-42, in approximately the same 
sublethal range of concentrations used in this thesis, impaired the phosphorylation of CREB, 
thereby reducing activation of genes with a CRE motif [145; 146]. Furthermore, they found that 
this effect was separate from the acute neurotoxicity, and related to the impairment of neuronal 
plasticity. However, impairment of neuronal plasticity, can certainly contribute to the 
neurodegeneration in the AD brain by depriving neurons of trophic stimulation. It is the 
author‟s opinion that the extremely high concentrations used to kill neurons in vitro are 
irrelevant for AD, since neurons would never or rarely encounter A  at those concentrations in 
vivo. The notion that incubation with a high concentration of A  for a short time can equal 
exposure to low concentrations for years is far-fetched and unrealistic in the author‟s opinion. In 
fact, the “secondary” effects of A , such as inflammation and negative regulation of plasticity 
and growth factors, may be pivotal in the pathogenesis of AD. 
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4.1.3 Cell proliferation and cell death 
A simple assay for activation of hematopoietic cells is to assess their proliferation which in 
most cases is increased upon activation. It is unclear if this is applicable for primary cultures of 
microglia, which represent a very differentiated cell and as such have a limited proliferation 
capacity. The CHME3 cell line, on the other hand, is very proliferative as a consequence of 
transformation. 
 
4.1.3.1 Microglial proliferation and cell death upon incubation with pro-inflammatory 
cytokines (paper I, II) 
Long-term (96 h) incubation with IFN  decreased cell proliferation drastically and 
microscopical inspection of the cultures at this stage showed cells in severe stress. IFN  is 
known to increase oxidative stress by the activation of iNOS and lysosomal oxidases which 
may explain this finding. Notably, IFN  produced no detectable detrimental effects on 
microglial viability at the earlier time points, suggesting an accumulation of toxicity that fits 
well with a hypothetical increase in oxidative stress. 
 
4.1.3.2 Microglial proliferation and cell death upon incubation with A 1-40 or A 1-42 (paper 
I, II) 
A 1-40 was found to decrease microglial viability at the lowest concentration tested (5 M) 
when incubated for 24 h. There were no effects of A 1-42 on cell viability or cell death at the 
concentrations tested. 
 
Fig. 3. Combined data from the 
cytokine and Protollin 
experiments showing a reduction 
of microglial BDNF secretion 
upon incubation with 1 g/ml 
A 1-42. The data are expressed as 
% of control vehicle set at 100%, 
and shown as median ± 
percentiles (25% - 75% and 10% 
- 90%). Statistical difference 
from control is indicated by * (p 
< 0.001) and ** (p < 
0.0000001). 
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4.1.4 Phagocytosis 
Removal of debris and pathogens from the tissue to restore homeostasis is an important activity 
of cells of the monocyte lineage. To analyse the phagocytic capacity of CHME3 microglia the 
cells were incubated with fluorophore-conjugated A 1-42 or latex beads and analysed with flow-
cytometry. ICC using antibodies against lamp-2 were performed to establish phagocytosis of 
A 1-42 by showing the lysosomal location of intracellular A 1-42 using confocal microscopy, 
thus indicating that the phagocytosed A 1-42 was destined for degradation (see paper II). 
  
 
4.1.4.1 Phagocytosis of latex beads (paper IV) 
Latex beads are considered to be relatively inert from the perspective of activation. At 48 h of 
incubation, an average of 13.1% (+/- 5.5% SD) of the cells displayed phagocytosis of latex 
beads, representing the basal level. 
 
4.1.4.2 Phagocytosis of A 1-42 (paper II, IV) 
The first visible sign, as analysed in inverted fluorescence microscope, of cellular uptake of 
A 1-42 was observed at about 4 h after incubation. The phagocytosed A 1-42  first appeared as 
small, vague clouds of fluorescence. Later, small and round dots of strong fluorescence started 
to appear. When inspecting the cells in microscope, it was clear that only a subset of CHME3 
microglia were actively phagocytic with regard to A 1-42. This was confirmed when the cells 
were analyzed with flow-cytometry revealing that an average of 3.6% (+/- 1.1% SD) of the 
CHME3 microglia contained the fluorophore-conjugated A 1-42 in the DHA series of 
experiments (paper II). Hence, the number of cells showing uptake of latex beads is higher 
than the number of cells showing uptake of A 1-42 in comparable conditions, indicating a 
Fig. 4. This 
microphotograph, taken 
in a confocal microscope, 
shows fixed human 
CHME3 microglia that 
have been incubated with 
biotinylated A 1-42. After 
fixation the cells were 
stained with antibodies 
against IL-1  A 1-42 was 
visualized by incubation 
with streptavidin-AMCA 
(blue). 
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difference in the mechanism of phagocytosis of the two objects. Fig. 4 shows IL-1 -positive 
CHME3 microglia with uptake of A 1-42. 
 
4.1.4.3 Effect of pro-inflammatory cytokines on phagocytosis (paper II, IV) 
Pre-incubation with IFN  significantly stimulated the phagocytosis of A 1-42. This may be 
mediated STAT proteins, since activation of these transcription factors has been associated with 
increased phagocytic activity [147]. However, since the effect became apparent at a late time 
point, it is reasonable to suggest that mediators secondary to IFN  may be important. A 
stimulatory effect on phagocytosis by IFN  is also in accord with other cellular effects 
associated with activation with IFN : upregulation of antigen-presentation, increase in 
lysosomal activity and activation of iNOS [147; 148; 149; 150; 151; 152]. IL-1  did not 
increase the phagocytosis of A 1-42 or latex beads, and the combination of IFN  and IL-1  
produced effects similar to those seen upon incubation with IFN  alone. 
 
4.1.5 Microglial phenotype and relation to phagocytosis 
The phenotype of CHME3 microglia was analysed in paper II and IV. In paper II, Protollin 
was found to increase the number of IL-1  positive phagocytic cells. In paper II, we 
interpreted a cellular signal of a secreted inflammatory protein with the assumption that an 
increase over basal levels is a sign of activation. Thus we concluded that Protollin activated the 
cells, which is in line with Protollin being a TLR2 agonist. However, in paper IV, where both 
the secretion of IL-6 and cellular IL-6 were analyzed, it was found that cultures with a high 
secretion of IL-6 displayed a low number of cells with a cellular expression of IL-6. It may be 
that cells with a high secretory activity are being emptied of the secretory product, thus showing 
a low signal. More experiments are needed to elucidate the relationship between the cellular and 
secreted levels of secretory proteins but for now, no conclusion can be drawn about the 
activation status of the CHME3 microglia based on the cellular presence of IL-1 . 
 
4.1.5.1 Differential phenotype of phagocytic and non-phagocytic microglia (paper II and IV) 
Among cells showing phagocytosis of A 1-42 the proportion of iNOS-positive cells was larger 
than among non-phagocytic cells. Furthermore, a similar pattern was observed with regard to 
the expression of IL-1RI. This leads us to believe that microglia with an inflammatory 
phenotype are more prone to phagocytose A 1-42. Interestingly, there were differences in the 
phenotype of microglia showing phagocytosis of A 1-42 vs microglia that phagocytose latex 
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beads. Among cells showing phagocytosis of A 1-42, there was a significantly higher proportion 
of cells being positive for iNOS and IL-1RI. In the case of latex beads, the pattern was 
completely reversed. Latex beads are relatively inert from an activation perspective and are 
many times larger than the aggregates/deposits of A 1-42 observed in the cultures as judged by 
microscopical inspection. Hence, it is not unreasonable to assume that the molecular 
mechanisms of recognition and phagocytosis are different, depending on the objects. 
 
4.2 IMMUNOMODULATION OF RESPONSES RELATED TO 
NEUROPROTECTION AND NEURODEGENERATION 
In our human cellular models of phagocytosis and neurodegeneration we tested a set of 
substances for their ability to stimulate beneficial activities and to inhibit harmful responses. 
The effects of an intervention with omega-3 fatty acids on inflammatory factors in AD-patients 
were also studied. 
 
4.2.1 Modulation of phagocytic activity by Protollin and DHA 
In paper II, the ability of Protollin to stimulate phagocytosis of A 1-42 by CHME3 microglia 
was tested. The microglia were pre-stimulated with 0.001 – 1 g/ml protollin for 24 h after 
which fluorophore-labelled A 1-42 was added to the cultures and phagocytosis of A 1-42 was 
analysed at 24 – 96 h after addition of A 1-42. In paper IV, the effects of the omega-3 fatty acid 
DHA on phagocytosis of A 1-42 and latex beads were investigated. The cells were incubated 
with 0.01 – 2.5 M DHA together with fluorophore-conjugated A 1-42. Alternatively, 0.05 M 
DHA, alone or together with IL-1 , was added to the microglial cultures together with latex 
beads. 
In preliminary studies on mouse microglia it was found that 24 h of pre-incubation with 
Protollin was most effective for stimulation of phagocytosis of A 1-42. The interpretation of this 
result was that the effects on phagocytosis by Protollin were mediated by the secretion of 
secondary products, which affect phagocytosis by auto- and paracrine stimulation. The effect of 
Protollin on phagocytosis of A 1-42 by the human CHME3 microglia was limited. A small but 
significant increase was obsered in the late phase of the experiment upon treatment with the 
lowest concentration of protollin (0.001 g/ml). Several studies have found that TLR2 ligands 
can stimulate phagocytosis [153; 154]. However, in these studies, the phagocytosis of bacteria 
or tissue debris was the focus and there may be different pathways or mechanisms involved in 
the phagocytosis of A . Recently, it has been suggested that TLR2 activation is, in fact, vital for 
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activating microglia into performing the functions of inflammation, such as phagocytosis [155]. 
It has also been found that TLR2 is vital for microglia activation by A . In the present 
studies, the number of phagocytic microglia was quite low in basal conditions compared to 
other studies on the phagocytosis of A 1-42 [157; 158]. However, those studies were performed 
on non-human microglia and the number of phagocytic cells was in some cases quantified with 
other methods, which can explain the difference. However, in a study on aged human primary 
microglia, Familian et al found a comparable level of phagocytosis, as analysed with flow-
cytometry [159],  
DHA was found to have a stimulatory effect on phagocytosis of A 1-42 at 6 h. This effect 
seemed to linger at 24 h, although the result was not significant. The short time of action of 
DHA may be due to oxidation of DHA or its downstream products. In addition, the poor 
solubility of DHA or its downstream products in cell-culture medium, may make them stick to 
the culture dish, thus reducing their effective time of action. The phagocytosis of latex beads 
was only analyzed at 48 h. At this time point, there was no effect on phagocytosis by the 
treatment with DHA, IL-1  or the combination of the two. In agreement with this result, there 
was no effect of DHA at any concentration on the phagocytosis of A 1-42 at this time point. 
 
4.2.2 Effects on microglial activation by -MSH 
The effects of -MSH on CHME3 microglia activated by A 1-40 or IFN  were analysed with 
regard to the secretion of IL-6 and cell proliferation. There was no anti-inflammatory effect of 
-MSH with regard to the secretion of IL-6. On the contrary, we found a dose-dependent 
stimulatory effect on IL-6 secretion by -MSH by itself. The absence of inhibition on IL-6 
secretion may be explained by the absence of a B binding site on the IL-6 gene, and the 
stimulation may be explained by the presence of a CRE motif. CRE is activated by the CREB 
protein, which in turn is activated by PKA, which is the primary signaling pathway that is 
activated by -MSH. PKA is activated by cAMP, which has been implicated in the inhibition of 
NF- B, thus mediating the anti-inflammatory effect of -MSH [160; 161]. In accord with this 
result, Jun et al found that activation of type 2 and 5 MCR:s stimulated the secretion of IL-6. 
We demonstrate that human CHME3 microglia express the MCR type 1, 3, 4 and 5. 
Melanocortin receptor has also been shown to activate PKC and the PI3K pathway in addition 
to activation of AC [162; 163; 164; 165]. The involvement of PKC in the regulation of 
inflammation is well-known and NF- B activation was shown to occur downstream of PI3K 
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[166]. It seems clear therefore that -MSH may act in a pro-inflammatory manner under the 
some circumstances. 
 
4.2.3 Effects on microglial phenotype by Protollin and DHA 
To determine the effect on the phenotype of human CHME3 microglia upon treatment with 
Protollin or DHA, the cellular immunoreactivity to a set of markers of the whole microglial 
population was analysed, as well as the differential immunoreactivity of phagocytic and non-
phagocytic cells. 
 
4.2.3.1 IL-1  (paper II, IV) 
Pretreatment with Protollin was found to increase the number of IL-1 -positive phagocytic cells 
compared to cultures treated with A 1-42 alone at the 24 and 48 h time points. Cultures treated 
with A 1-42 alone, the phagocytic microglial population displayed a higher expression of IL-1  
compared to non-phagocytic cells. This difference was seen at 6 h but disappeared at 24 h, in 
accord with the results in paper II. In contrast, at this time point cultures treated with DHA 
together with A 1-42 displayed a significantly larger number of IL-1 -positive microglia that 
were phagocytic of A 1-42 (see Fig. 4).Treatment with DHA alone increased the total number of 
IL-1 -positive cells at 24 h. Regarding the effect of DHA on the differential immunoreactivity, 
of phagocytic and non-phagocytic cells, it was found that at 48 h there were a significantly 
higher number of phagocytic microglia expressing IL-1  in all the treatments. There was no 
effect on the total number of IL-1 -positive cells in the experiments on latex beads upon any of 
the treatments, nor were there any differences between phagocytic and non-phagocytic cells. 
Interestingly, the cultures treated with 50 ng/ml IL-1  for 48 h did not display any difference in 
the number of cells showing immunoreactivtiy to IL-1  compared to the other treatments. 
 
4.2.3.2 iNOS (paper II, IV) 
A rather consistent result upon incubation of the microglia with A 1-42 was the significantly 
higher number of iNOS-positive cells in the phagocytic population compared with the non-
phagocytic. In paper II, this pattern of differential expression of iNOS was seen during the 
whole experiment, including the latest time point (96 h). The pattern of differential expression 
disappears with time upon incubation with Protollin, with equal distribution of iNOS between 
the phagocytic and non-phagocytic microglia at the latest time point at 96 h. In paper IV, there 
were more iNOS-positive cells in the phagocytic population in cultures treated with A 1-42 
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alone at 48 h, in accord with the results seen in paper II. Similarly, treatment with DHA 
abolished the difference in expression between phagocytic and non-phagocytic microglia. 
Interestingly, in experiments with latex beads, the expression of iNOS was more abundant in 
the non-phagocytic population, in contrast to the result upon incubation with A 1-42. 
 
4.2.3.3 IL-1RI (paper II, IV) 
With regard to phagocytosis of A 1-42, there were significantly more IL-1RI-positive cells in the 
phagocytic population in all treatments and time points. At the latest time point at 96 h, the 
difference between the populations appeared to abate. 
 
4.2.3.4 TNF  (paper IV) 
The cellular expression of TNF  was analysed in the experiments on latex beads. The total 
immunoreactivity of the microglia was not altered upon any of the treatments. However, there 
was higher expression of TNF  in non-phagocytic cells than in phagocytic cells upon treatment 
with 0.05 M DHA for 48 h.  
 
4.2.3.5 IL-4R (paper IV) 
The cellular expression of IL-4R in the experiments on latex beads was not altered upon any of 
the treatments, nor did any of the treatments affect the differential immunoreactivity to IL-4R of 
the phagocytic and non-phagocytic cells. 
 
4.2.3.6 IL-6 (paper IV) 
Analysis of the cellular expression of IL-6 in the experiments on latex beads showed a 
significantly higher expression in phagocytic cells in the cultures treated with DHA and IL-1  
for 48 h. Microglia treated with IL-1  alone were also suggestive of this imbalance, but the 
difference was void of statistical significance. 
 
4.2.4 Preliminary results 
Studies on our model of neuronal cell death in differentiated human neuronal SY5Y cells 
showed a protective effect of -MSH on necrosis induced by ionomycin. Furthermore, we have 
preliminary data that indicate a positive effect of -MSH on apoptosis induced by 
staurosporine.  
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4.2.4.1 Effects of -MSH on cell death induced by ionomycin 
To evaluate the protective properties of -MSH on necrotic cell death differentiated SY5Y cells 
were incubated with 1 M ionomycin, alone or together with 0.01 – 1 M -MSH for 48 h.  
Microscopical inspection of the cultures at this timepoint showed that 1 M ionomycin caused 
extensive cellular stress indicated by retracted neurites, rounded-up cells, and cellular 
deattachment. In all cultures where treated with -MSH, in all concentrations examined, there 
was visibly less extensive cellular stress. These observations were mirrored in the results from 
the LDH-assay which confirmed extensive necrotic cell death by 1 M ionomycin (40.5% of 
positive control for ionomycin compared to 25% of positive control for vehicle, p < 0.05) (Fig. 
4). The LDH-assay also confirmed protection by -MSH in the concentration 0.1 M with a 
LDH-activity comparable to vehicle (23% of positive control, p < 0.05 when comparing with 
ionomycin alone). 
 
4.2.4.2 Effects of -MSH on apoptosis and cell death induced by staurosporine 
Protective effects of -MSH on cellular stress induced by staurosporine were investigated by 
incubating differentiated SY5Y cells with 250 and 500 nM staurosporine, alone or together with 
0.001 – 1 M -MSH for 48 h. For analysis of apoptosis with the TUNEL-assay, differentiated 
SH SY5Y cells were incubated for 48 h with 500 nM staurosporine, alone or together with 0. 1 
or 1 M -MSH. 
 
4.2.4.2.1 Cell viability 
Preliminary data from the MTT-assay indicate a substantial negative effect of 250 and 500 nM 
staurosporine on differentiated SY5Y cells. Cell viability was decreased to 10% of vehicle 
control by 250 and 500 nM staurosporine. -MSH increased cell viability to 38% when the cells 
were incubated with a concentration of 1 M together with 250 nM staurosporine and to 31% 
when 1 M -MSH and 500 nM staurosporine were added to the cells. 
 
4.2.4.2.2 Cell death 
Preliminary data from the LDH-assay indicate necrosis (or late apoptosis) in the cultures treated 
with 250 and 500 nM staurosporine. Both concentrations increased LDH activity in the medium 
to around 40% of positive control compared to 24% of positive control in the vehicle group. 
The preliminary results indicate a slightly protective effect of -MSH in the highest 
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concentration: when 1 mM -MSH was incubated with 500 nM staurosporine, the LDH-
activity decreased from 44 to 34%. 
 
4.2.4.2.3 Apoptosis 
The number of apoptotic cells in the cultures was determined with the TUNEL-assay. A cell 
suspension from each treatment was subjected to the TUNEL-method. The number of TUNEL-
positive cells was then quantified with flow-cytometry. Preliminary data indicate a protective 
effect of -MSH to staurosporine-induced apoptosis. In the culture treated with 500 nM 
staurosporine alone, 69% of the cells were identified as TUNEL-positive compared with 46% in 
the vehicle group. Treatment with 500 nM staurosporine together with 0.1 M -MSH reduced 
the number of TUNEL-positive cells to 61% and 1 M -MSH reduced the percentage even 
further to 51%. 
 
4.2.4.3 Effects of -MSH on reduction in cell viability induced by A 25-35 
To investigate protective effects of -MSH on A -mediated toxicity differentiated SY5Y cells 
were incubated with 5, 25 and 50 M A 25-35 alone or together with 1 M -MSH for 24 h. 
 
4.2.4.3.1 Cell viability 
Preliminary data from the MTT-assay suggest a decrease in cell viability by 5 M A 25-35 to 
71% of vehicle and a slight protective effect by 1 M -MSH. Incubation of the cells with 5 
M A 25-35 and 1 M -MSH increased cell viability to 83% of vehicle. Similarly, incubation 
with 25 M A 25-35 and 1 M -MSH resulted in increased cell viability to 82% from the 69% 
of vehicle that was induced by incubation with 25 M A 25-35 alone. Incubation with 50 M 
A 25-35 alone decreased cell viability to 64% of vehicle and this was increased to 69% by 1 M 
-MSH. 
 
The protective effect of a substance on apoptosis and necrosis, respectively, may be attributed to 
different mechanisms. -MSH can protect cells from apoptosis by the increased production of 
cAMP which is mediated by all MCR:s. cAMP activates PKA and ERK [131; 163], which are 
known to be protective when activated. Downstream of PKA is the activation of CRE-
containing genes, among which are several anti-apoptotic members of the bcl-2 family and 
BDNF. The mechanism for protection against necrosis is more unclear. Necrosis is not a 
controlled process but rather the breakdown of vital processes due to extreme stress in the form 
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of altered pH, osmotic pressure, physical damage and ionic imbalance. Of course, apoptosis can 
lead to necrosis if the stress is too severe, and it is not unreasonable to assume that the two 
processes interact. For example, an anti-apoptotic substance may to some degree rescue cells 
that are exposed to a type of stress dominated by necrosis by relieving the cells from the 
additional stress caused by the apoptotic process that most probably is working in parallel, 
consuming valuable ATP in the process. It can also be speculated that the activation of ERK, or 
other kinases implicated in the activity of cells, increases survival by increasing the activity of 
signalling pathways that support the integrity of a cell (actin remodelling, membrane 
maintenance, etc). 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Protection by -MSH from neuronal cell death induced by ionomycin. 
Differentiated SY5Y cells were incubated with 1 M ionomycin, alone or together with 
0.01- 1 M -MSH and analysed with LDH-assay. The data are expressed as % of positive 
control (vehicle-treated cells lysed with 2% Triton-X100) and shown as median ± 
percentiles (25% - 75% and 10% - 90%). * indicates statistically significant difference 
from vehicle (p < 0.05). # indicates statistically significant difference from 1 M 
ionomycin (p < 0.05). 
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4.3 EFFECTS ON MARKERS RELATED TO INFLAMMATION AND AD IN AD-
PATIENTS AFTER SUPPLEMENTATION WITH OMEGA-3 OR PLACEBO 
In paper III the effects of the intervention on AD-patients with omega-3 fatty acids on the 
levels of markers related to inflammation and AD in CSF and plasma were analysed. There was 
no significant effect on the levels of any of the markers analysed after 6 months of treatment 
with EPAX or placebo. At baseline, a positive correlation was found between the levels of the 
soluble IL-1 receptor (sIL-1RII) and A 1-42. However, after 6 months of treatment with EPAX 
or placebo, this correlation was lost. sIL-1RII is a secreted receptor which is lacking the 
intracellular signalling domain of the functional IL-1RI and is therefore called a decoy receptor 
[167]. sIL-1RII can therefore be considered an anti-inflammatory, or even a pro-resolving 
factor. Secretion of sIL-1RII from monocytic cells is induced by anti-inflammatory cytokines 
such as IL-4 and IL-13 which also induce the secretion of the endogenous IL-1R antagonist (IL-
1Ra) [168].  sIL-1RII can thus be viewed as part of the TH2 polarisation mechanism by 
sequestering IL-1  and blocking IL-1 . Since human blood contains high concentrations of 
sIL-1RII under basal conditions it can also exert a dampening effect when the immune system is 
under pathogenic challenge, thus preventing sepsis or other extreme and dangerous conditions. 
The interpretation of this result discussed in paper III is that an increase in the levels of A 1-42 
in the CSF drives an inflammatory response in the brain and sIL-1RII is secreted in higher 
levels as a protective response. Indeed, the levels of sIL-1RII were higher in a population of 
patients with mild to moderate AD [169]. However, an increase in the levels of A 1-42 in CSF 
has been linked to an improvement in the condition. An impaired transport of A 1-42 into the 
CSF has in fact been proposed as a pathogenic mechanism in AD. An alternative explanation, 
that appears more plausible in the light of data from recent studies, is that high levels of A 1-42 
in the CSF is related to a low degree of inflammation in the CNS, which is expressed in the 
result from paper III as an increase in the anti-inflammatory sIL-1RII due to lack of TH1 
suppression by TH2 mediators. The lack of effect on the markers analysed in this study can be 
explained by the timing of intervention. Several of the studies on intervention on established 
AD has been yielded negative results. It may be that it is too late for intervention with omega-3 
when the disease has progressed to a symptomatic stage. At this stage it is believed that the loss 
of neurons has been going on for some time and treatment with omega-3 may be ineffective. 
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5 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
The primary aim of this thesis was to investigate the possibility of modulating inflammation in a 
way that increases beneficial activities while downregulating the harmful ones for the treatment 
of neurodegenerative conditions, particularly with regard to AD. For this purpose a human 
microglial cell line, CHME3, was characterized for the use as a model of AD-related 
inflammation in the CNS. This resulted in the establishment of a model of phagocytosis of A 1-
42 by human microglia. In this model a number of immunomodulatory compounds were tested 
for their capacity of stimulating phagocytosis of A 1-42. Furthermore, other responses related to 
neurodegeneration and inflammation were studied upon different treatments.  
 
To summarise all the studies presented in this thesis, the author would like to present what he 
believes are the major findings: 
 
 A 1-42 may play a new pathological role by reducing the secretion of BDNF from 
human microglia 
 Only a subset of human CHME3 microglia are phagocytic of A 1-42 
 Microglia that phagocytose either A 1-42 or latex beads are of different phenotype, or 
alternatively, attain a different phenotype upon phagocytosis 
 Human CHME3 microglia exhibited several differences in responses compared to 
animal models of microglia 
 Inflammation related to AD in the form of IFN  induces an activation of microglia that 
is associated with increased phagocytosis, increased secretion of IL-6, impaired 
neuroprotective activities in the form of reduced secretion of BDNF, and microglial cell 
death 
 Omega-3 fatty acid supplementation in the form of EPAX may be ineffective for the 
treatment of established AD treated with acetylcholine esterase inhibitors, based on the 
lack of detectable changes in the levels of  A 1-42, t-tau and p-tau in the CSF, and in the 
levels of inflammatory markers in CSF and plasma   
 The omega-3 fatty acid DHA may be useful for the prevention, or treatment, of AD by 
stimulating microglial phagocytosis of A 1-42 and decreasing the levels of inflammatory 
cytokines 
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 Treatment with -MSH may be beneficial for the outcome of neurodegenerative 
conditions in humans, although the unexpected pro-inflammatory effect on human 
microglia should be viewed with caution. 
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When studying inflammation in general and inflammation in the CNS in particular, it is 
apparent that much work remains for the characterization of the different activation phenotypes 
of macrophage-like cells such as microglia. Considering the detrimental involvement of 
microglia in neurodegenerative disorders and the potential of microglia to promote neuronal 
health, an effort to elucidate the response profiles of different activation phenotypes is highly 
motivated. The author hope that the work presented in this thesis is a contribution to this effort, 
and he would like to point out a few areas that are associated with AD and which deserves to be 
investigated: 
 
 The contribution of different surface proteins on human microglia to the recognition 
and phagocytosis of A  
Fig. 5. An updated version 
of Fig. 1 based on the 
results presented in this 
thesis. A 1-42 decreases 
microglial secretion of 
BDNF in concentrations 
that do not induce 
inflammatory activation. 
IFN  stimulates the 
phagocytosis of A 1-42 
while at the same time 
decreasing microglial 
secretion of BDNF. DHA 
stimulates phagocytosis 
and have an inhibitory 
effect on the secretion of 
cytokines of both TH1 and 
TH2 type. 
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 Beneficial and detrimental microglial responses, aside from phagocytosis, that are 
consequences of A  binding to the surface proteins 
 Elucidate the control of the expression of the surface proteins regulating phagocytosis - 
can they be induced pharmacologically? 
 
A concept that has been touched upon several times in this thesis, and which has just recently 
been receiving the attention it justly deserves, is the concept of resolution. It may be that 
resolution has been clouded in obscurity and thus has been regarded as “the thing that happens 
when inflammation stops and everything is OK again. New research in this field has suggested 
that resolution is not only the end of inflammation, but an active process that is mediated by 
molecules that bind to receptors, similar to when inflammation is induced. In fact, it may be 
futile and contra-productive to even separate the two from each other since resolution is the 
end-stage of a healthy inflammatory response. To focus exclusively on inhibiting inflammation 
in therapy may hypothetically leave the tissue in an “unresolved” state, which perhaps is not the 
most optimal outcome. In fact, an anti-inflammatory role of NF- B, and the involvement of NF-
B in the resolution of inflammation has been suggested by Lawrence et al [170]. 
 
Considering the involvement of inflammation in neurodegenerative disorders, the recent update 
of the concept of resolution opens up a new area of potential therapeutic targets. In this 
research, the author believes that some areas should be prioritised: 
 
 Elucidation of the pharmacology of resolution. The receptors that receive pro-resolving 
signals must be characterised for effective treatments to be developed. 
 The link between inflammation and resolution. Is there a transition point which is under 
the control of factors other than pro-resolving signals?   
 Pro-resolving factors in normal conditions. Can they be beneficial for the prevention of 
neurodegenerative disorders without compromising host immune defence?  
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Senile plaques in the Alzheimer's disease (AD) are 
formed by aggregation of β-amyloid (Aβ) peptide. 
Aβ peptide has been shown to activate microglia 
and stimulate their production of inflammatory 
factors, such as cytokines. In the AD brain, the 
continued presence of amyloid plaques may keep 
microglia persistently activated, leading to chronic 
inflammation in the CNS. It is well established that 
α-melanocyte-stimulating hormone (α-MSH) gives 
rise to anti-inflammatory and anti-pyretic effects. 
The biological activities of α-MSH are mediated by 
one or more of the melanocortin receptor (MCR) 
subtypes, i.e., MCR1 - MCR5. The aim of the pres-
ent study was to determine the effect of α-MSH alone 
and on Aβ-activated microglial cells with regard to 
the secretion of inflammatory cytokines, such as 
interleukin-6 (IL-6), and to determine which recep-
tor subtype mediates the effects of α-MSH. The 
human microglial cell line, CHME3, was incubated 
for 24 h with freshly dissolved Aβ1-40, interferon-γ 
(IFN-γ) and/or α-MSH. Freshly dissolved Aβ1-40 
(5-60 µM) resulted in a dose-dependent decrease in 
cell viability, along with a dose-dependent increase 
in IL-6 release. Neither IFN-γ nor α-MSH affected 
the Aβ-induced secretion of IL-6, but resulted in 
a dose-dependent increase in basal IL-6 release. 
Agouti, the endogenous antagonist of MCR1 and 
4, further increased the α-MSH-induced secretion 
of IL-6. RT-PCR showed the expression of MCR1, 
MCR3, MCR4 and MCR5 mRNA. The combined 
data suggest that the effect of α-MSH in increasing 
IL-6 release from the human microglial cell line is 
mediated by MCR3 or MCR5.
Keywords: Alzheimer's disease; Cell viability; Interferon; 
Interleukin; Melanocortin receptors
INTRODUCTION
Alzheimer's disease (AD) is a progressive neurode-
generative disorder and the most common form of 
dementia in the elderly. The senile plaques in AD are 
formed by aggregation of β-amyloid (Aβ) peptide, 
a 39-42 amino acid cleavage product of β-amyloid 
precursor protein (APP). Senile plaques in the AD 
brain are surrounded by activated astrocytes and 
microglia, the source of inflammatory and cytotoxic 
factors. The reactive glial cells produce cytokines 
such as interleukin-1 (IL-1β), interleukin-6 (IL-6) 
and tumour necrosis factor-α (TNF-α) (Griffin et al., 
1989; Bauer et al., 1991; Dickson et al., 1993), as well 
as chemokines, complement factors and acute phase 
reactants (Vandenabeele and Fiers, 1991; Eikelenboom 
et al., 1994; Neuroinflammation working group, 2000; 
Galimberti et al., 2003; McGeer and McGeer, 2003). 
Furthermore, elevated levels of IL-1β (Cacabelos et al., 
1991; Blum-Degen et al., 1995), TNF-α (Tarkowski et 
al., 1999) and chemokines (Galimberti et al., 2003), 
have been observed in serum and cerebrospinal fluid 
(CSF) from AD-patients, whereas the levels of IL-6 
have been shown to be either increased or unaltered 
as compared to healthy, age-matched controls (Blum-
Degen et al., 1995; Hampel et al., 1997; Martinez et 
al., 2000; Neuroinflammation working group, 2000). 
Significant activation of microglia appears to occur at 
an early stage of the disease, i.e., before severe cogni-
tive decline has occurred (Vehmas et al., 2003).
   There is ample evidence that Aβ peptide stimulates 
the activation of microglia, leading to increased synthe-
sis and release of pro-inflammatory cytokines (Araujo 
and Cotman, 1992; Del Bo et al., 1995; Lindberg et al., 
2005), as well as cytotoxic factors such as proteolytic 
enzymes, nitric oxide (NO), quinolinic acid, glutamate, 
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and reactive oxygen species (ROS) (see Benveniste et 
al., 2001). Some of these microglial products may be 
responsible for the indirect neurotoxic effects of Aβ 
(Selkoe, 1994; Giulian et al., 1996). 
   It is well established that α-melanocyte-stimulating 
hormone (α-MSH) gives rise to anti-inflammatory 
(see Catania and Lipton, 1998) and anti-pyretic effects 
(Glyn and Lipton, 1981). For example, α-MSH has 
been shown to inhibit hyperalgesia induced by the pro-
inflammatory cytokine IL-1β in rats (Oka et al., 1996). 
The biological activities of α-MSH are mediated by 
one or more of the melanocortin receptor (MCR) sub-
types, i.e., MCR 1 - MCR 5 (see Tatro, 1996; Adan and 
Gispen, 1997; Wikberg, 1999; Cone, 2005). The most 
abundant subtypes in the brain are MCR3 and MCR 4, 
whereas the expression of MCR5 is lower. MCR1 is 
mainly expressed in monocytes (Rajora et al., 1996), 
and MCR2 mainly in the adrenal cortex (Mountjoy et 
al., 1992; Cammas et al., 1995).
   The aims of this study were to investigate the effects 
of Aβ1-40 on a human microglial cell line with regard to 
the secretion of cytokines and cell viability. The pos-
sibility to modulate the microglial responses to Aβ1-40 
with α-MSH was analysed, as well as the effects of 
α-MSH on microglia under basal conditions.
METHODS
Materials
Human Aβ1-40, in a lyophilised trifluoroacetate (TFA) 
salt, was purchased from rPeptide (Athens, GA, USA). 
α-MSH was obtained from Melacure AB (Uppsala, 
Sweden) or Bachem Holding AG (Germany), and agou-
ti from Phoenix Pharmaceuticals, Inc (Belmont, USA). 
Interferon-γ (IFN-γ), 3-(4,5-dimethylthiazol-2-yl)-2-5-
diphenyl tetrazolium bromide (MTT), H89, dimethyl 
sulfoxide (DMSO), and GeneEluteTM Mammalian Total 
RNA Miniprep Kit, were obtained from Sigma-Aldrich, 
Inc. (Stockholm, Sweden). IL-6 Quantikine Duoset, 
TNF-α and IL-1β high sensitivity (HS) kits, and IL-1α 
and caspase-1 ELISA kits were obtained from R&D 
Systems Europe, Ltd (Oxon, UK). Dulbecco's modi-
fied Eagle medium (DMEM) with high glucose, foetal 
bovine serum (FBS), gentamicin, L-glutamine, TryPLE 
and Taq-platinum were purchased from Invitrogen, 
Life technologies (Stockholm, Sweden). RQ1 RNase-
free DNase, AMV Reverse Transcription System 
and Nuclease-free dH2O were purchased from SDS 
Biosciences (Falkenberg, Sweden). All other organic 
reagents were purchased from VWR International AB 
(Stockholm, Sweden).
Cell Cultures
The CHME-3 microglial cell line was a kind gift from 
Professor M. Tardieu (Université Paris Sud, France). 
Human primary microglia from 8 - 10 week embryos 
were immortalised by transfection with the SV40 large 
T antigen (Janabi et al., 1995). The cells were grown in 
DMEM-containing high glucose (4.5 g/l), L-glutamine, 
10% foetal calf serum and gentamicin, and maintained 
at 37°C in a humidified atmosphere with 5% CO2. The 
CHME-3 cells were tested for and free of mycoplasmic 
infection.
Cell Stimulation
CHME-3 cells were seeded into 24-well plates at a 
concentration of 2.5 x 104 cells per well and cultured 
in serum-containing medium for 24 h. In order to treat 
the microglia, the culture medium was removed and 
replaced by fresh medium without serum and antibiot-
ics. A dose-response curve with 5-60 µM freshly dis-
solved Aβ1-40 was performed. The concentrations of 20 
and 40 µM Aβ1-40 were used for a time-response curve 
between 5 and 48 h. Dose-response curves of 1 - 100 
µM IFN-γ, 0.001 - 20 µM α-MSH and 0.1- 20 µM 
agouti and combination treatments were performed for 
24 h. The Aβ1-40 peptide was dissolved in distilled H2O 
and then diluted in medium immediately prior to use. 
The IFN-γ, agouti and H89 were dissolved in serum-
free medium, and α-MSH was dissolved in saline, prior 
to incubation with the microglial cells. Co-stimulation 
with Aβ and IFN-γ were performed in the presence or 
absence of α-MSH. The stimulation with α-MSH was 
also performed in the presence of agouti or the protein 
kinase A (PKA) inhibitor H89. Each condition was 
carried out in 4 wells (3 for treatment with agouti) and 
each type of treatment was performed in 3 independent 
experiments (4 for IFN-γ).
Measurements of Cytokine Secretion
The culture medium was collected after 24 h of incuba-
tion, or at the time points 5, 8, 24, 30 and 48h for the 
time-response curve, snap frozen in liquid nitrogen and 
stored at -70°C until use. All samples were centrifuged 
before analysis. Secretion of IL-6, TNF-α, IL-1α, IL-1β 
and caspase-1 to the culture medium was assessed by 
commercially available ELISA-kits, according to the 
manufacturer's protocols. For each set of experiments, 
standard curves were run. The secretion of IL-6 after 
treatment with the different substances was normalised 
against the basal secretion, i.e., after vehicle treatment.
Cell Viability
The cell viability was analysed using the colometric 
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MTT assay. MTT was dissolved in serum-free culture 
medium to a final concentration of 0.3 mg/ml and then 
added to the cells for 1 h at 37°C. The medium was 
then aspirated and the insoluble product remaining in 
the culture well was dissolved in DMSO. The resulting 
solutions were analysed in duplicates in a spectropho-
tometer at 592 nm, the absorbance maximum for the 
coloured product of reduced MTT, formed by the activ-
ity of mitochondrial dehydrogenases in viable cells. 
The OD values of the treated cells were normalised 
against the controls.
Reverse Transcription-Polymerase Chain Reaction 
(RT-PCR)
RT-PCR was used to analyse the expression of MCR 
subtypes in the CHME-3 cells. Cells from six dif-
ferent passages in six independent experiments were 
detached with TryPLE, centrifuged for 5 min at 1000g 
in a Wifug centrifuge and the pellets were then washed 
with phosphate-buffered saline (PBS). The pellets were 
dissolved with the lysis solution supplied with the 
GeneEluteTM Mammalian Total RNA Miniprep Kit 
and RNA extraction was performed according to the 
manufacturer's protocol. The resulting RNA extracts 
were then digested with RQ1 RNase-free DNase. 
First strand synthesis was performed using AMV 
Reverse Transcription System and the resulting cDNA 
was amplified with Taq-platinum in an Eppendorff 
Mastercycler Gradient PCR machine with the follow-
ing program: (1) 94°C 5 min; (2) 94°C 30 sec; (3) X°C 
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FIGURE 1 A-F   Effects on the release of IL-6 (A,C,E) and cell viability (B,D,F) in cultures of the human microglial cell line CHME-3 
exposed to Aβ1-40 (A,B), IFN-γ (C,D) or 10 µM Aβ + IFN-γ (E,F). The amount of cytokine release and cell viability after treatment is 
expressed as % of vehicle, which is set to 100%. Vehicle (indicated by bars with thick stripes) = 0 µM Aβ1-40 (A,B), 0 µM IFN-γ (C,D), 
and 0 µM Aβ1-40 + 0 µM IFN-γ (E,F). Error bars represent standard deviation. Statistical significance is defined as p <0.05 as compared 
to vehicle (indicated by *). The non-parametric Kruskal-Wallis test and the Mann-Whitney test were used for statistical analyses. Aβ1-40 = 
β-amyloid; IFN-γ = interferon-γ; IL-6 = interleukin-6; MTT = 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyl tetrazolium bromide.
1 min; (4) 72°C 1 min (the (2) - (4) steps were repeated 
with X being 63°C for the first cycle and 58°C for 
the last cycle with decrements of 0.5°C in between); 
(5) 94°C 30 sec; (6) 58°C 1 min; (7) 72°C 1 min ((5) 
- (7) were repeated 25 times); (8) 72°C 7 min; (9) 4°C 
(infinity). The primer sequences used were the same 
as those previously reported by Böhm et al. (Böhm et 
al., 2002). The primers were used in a concentration of 
0.02 µM. 
   Positive controls (genomic DNA extracted from 
the human microglial cell line) and negative controls 
(DNase-digested RNA-extract not subjected to reverse 
transcription) were included in all reactions. The PCR-
products were analysed on a 1.5% agarose gel stained 
with 10 µg/ml ethidium bromide. The results were 
documented with a Fujifilm Diana 1 CCD-camera con-
nected to a computer with Diana 1.6 software.
Statistical Analysis
Data were analysed with the non-parametric Kruskal-
Wallis test. The Mann-Whitney test was used for the 
statistical comparisons between groups. The statistical 
significance was established at a level of p <0.05.
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FIGURE 2 A-F   Effects on the release of IL-6 (A,C,E) and cell viability (B,D,F) in cultures of the human microglial cell line CHME-3 
exposed to α-MSH (A,B), 10 µM Aβ1-40 + α-MSH (C,D) or 10 µM Aβ1-40 + 100 ng/ml IFN-γ + α-MSH (E,F). The amount of cytokine 
release and cell viability after treatment is expressed as % of vehicle, which is set to 100%. Vehicle (indicated by bars with thick stripes) = 
0 µM α-MSH (A,B), 0 µM Aβ1-40 + 0 µM α-MSH (C,D) and 0 µM Aβ1-40 + 0 µM IFN-γ (E,F). Error bars represent standard deviation. 
Statistical significance is defined as p <0.05 as compared to vehicle (indicated by *). The non-parametric Kruskal-Wallis test and the Mann-
Whitney test were used for statistical analyses. Aβ1-40 = β-amyloid1-40; α-MSH = α-melanocyte-stimulating hormone; IFN-γ = interferon- γ; 
IL-6 = interleukin-6; MTT = 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyl tetrazolium bromide.
RESULTS
The effects of α-MSH on the secretion of IL-6 and on 
cellular viability were assessed in a human microglial 
cell line, CHME3, both under basal conditions and in 
cells activated with Aβ1-40, and/or the inflammatory 
cytokine IFN-γ. In addition, the cellular expression of 
different receptors for α-MSH, MCRs, was analysed.
Cytokine Secretion
The time-response curve for Aβ1-40 showed a small 
increase in the secretion of IL-6 from the human 
microglia already after 5 h incubation with 20 or 40 
µM Aβ1-40, with a continuous increase up to 48 h (data 
not shown). Incubation of the cells with Aβ1-40 at 10, 
20, 40 or 60 µM or with vehicle, showed a very low, or 
non-detectable, secretion of TNF-α, IL-1α, IL-1β and 
caspase-1 (data not shown), and these proteins were not 
analysed further.
   Activation of the microglia with freshly dissolved 
Aβ1-40 (FIG. 1A) or the incubation with IFN-γ (FIG. 
1C), resulted in a dose-dependent increase in IL-6 
secretion as compared to basal secretion. 
The dose of 10 µM Aβ1-40 resulted in about 100% 
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FIGURE 3 A-F   Effects on the release of IL-6 (A,C,E) and cell viability (B,D,F) in cultures of the human microglial cell line CHME-3 
exposed to 20 µM α-MSH + agouti (A,B), agouti (C,D) or 20 µM α-MSH + H89 (E,F). The amount of cytokine release and cell viability 
after treatment is expressed as % of vehicle, which is set to 100%. Vehicle (indicated by bars with thick stripes) = 0 µM α-MSH + 0 µM 
agouti (A,B), 0 µM agouti (C,D) and 0 µM α-MSH + 0 µM H89 (E,F). Error bars represent standard deviation. Statistical significance is 
defined as p <0.05 as compared to vehicle (indicated by *), or to 20 µM α-MSH + 0 µM agouti (A, indicated by #) and 20 µM α-MSH + 0 
µM H89 (F, indicated by #), bars with thin stripes (A-B and E-F). The non-parametric Kruskal-Wallis test and the Mann-Whitney test were 
used for statistical analyses. α-MSH = α-melanocyte-stimulating hormone; H89 = protein kinase A (PKA) inhibitor; IL-6 = interleukin-6; 
MTT = 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyl tetrazolium bromide.
increase in IL-6 release, and 30-40% reduction in cell 
viability (FIGs. 1 and 2). This dose of Aβ (10 µM) was 
used in the co-stimulatory experiments, since higher 
doses of Aβ1-40 resulted in considerably larger reduction 
in cell viability.
   Co-stimulation of the microglia with Aβ1-40 (10 µM) 
and IFN-γ (1-100 ng/ml) did not result in a further 
increase in the IL-6 secretion, as compared to incuba-
tion with either Aβ1-40 or IFN-γ alone (see FIG. 1E). 
   α-MSH, at 0.001-100 µM concentration, did not 
affect the secretion of IL-6 from the human microglial 
cells in response to Aβ or Aβ + IFN-γ (see FIG. 2C 
and 2E, respectively), whereas a small reduction in the 
basal release of IL-6 was observed at low concentra-
tions (0.01 and 0.1 µM) of α-MSH (FIG. 2A). Higher 
concentrations of α-MSH (1 and 20 µM) resulted in a 
marked increase in the basal IL-6 secretion (FIG. 2A). 
Incubation with agouti resulted in a dose-dependent 
increase in the secretion of IL-6 induced by 20 µM 
α-MSH (FIG. 3A), as well as in the basal secretion of 
IL-6 (FIG. 3C). The PKA-inhibitor H89 (0.1-10 µM) 
had no effect on IL-6 release induced by 20 µM α-MSH 
(FIG. 3E).
Cell Viability
The time-response curve for Aβ1-40 showed a marked 
decrease in cell viability of the human microglia after 
24 h incubation at the concentration of 20 and 40 µM 
Aβ1-40, and was further decreased at 48 h (data not 
shown). Freshly dissolved Aβ1-40 (5-60 µM) resulted in 
a decreased viability of the human microglial cells in 
a dose-dependent manner (FIG. 1B). Incubation with 
IFN-γ alone (1-100 ng/ml) did not affect the cell viabil-
ity (FIG. 1D), neither did IFN-γ affect the reduction in 
cell viability induced by 10 µM Aβ1-40 (FIG. 1F).
   α-MSH at concentrations 0.001-100 µM did not 
affect basal cell viability (FIG. 2B), nor the reduced cell 
viability observed after incubation Aβ (FIG. 2D) or Aβ 
+ IFN-γ (FIG. 2F). Co-incubation with agouti (0.1-20 
µM) and α-MSH (20 µM) induced a small, although 
not significant, reduction in the cell viability (FIG. 3B). 
Incubation with α-MSH (20 µM) and H89 resulted in 
a small dose-dependent decrease in the cell viability, as 
compared to vehicle or incubation with 20 µM α-MSH 
alone (FIG. 3F).
Expression of MCR Subtypes
RT-PCR analysis of RNA extracted from cells of the 
human microglial CHME3 cell line showed expression 
of MCR1, MCR3, MCR4 and MCR5 mRNA (FIG. 
4). MCR4 mRNA was constitutively expressed in all 
of the 6 different passages analysed, whereas mRNA 
for MCR1 (4 of 6 experiments), MCR3 (1 of 6) and 
MCR5 (3 of 6) had varying expression. The size of the 
PCR products for each MCR subtype corresponded 
to the expected size, i.e., 416 bp for MCR1, 366 bp 
for MCR3, 566 bp for MCR4, and 357 bp for MCR5, 
and to the size of the positive controls consisting of 
genomic DNA from the same human microglial cell 
line (FIG. 4). No signal was observed in the negative 
controls treated with DNase (not shown).
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FIGURE 4 A-B   RT-PCR analysis of total RNA extracted from cells of the human microglial cell line CHME3 using primers specific for the 
melanocortin receptor (MCR) subtypes MCR1, MCR3, MCR4 and MCR5, respectively. (A) The size of the bands is indicated by the number 
of base pairs (bp). Lane 1 = base pair ladder; lanes 2, 4, 6 and 8 = PCR-product from genomic DNA for MCR1, 3, 4 and 5, respectively; 
lanes 3, 5, 7 and 9 = RT-PCR-product from extracted RNA-samples for MCR1, 3, 4 and 5, respectively. (B) The figure demonstrates the 
same experiment after longer exposure to visualise the weak band for MCR3 mRNA. PC = positive control, i.e., genomic DNA extracted 
from the CHME3 microglial cells; S = sample of RNA extracted from the CHME3 microglial cells.
DISCUSSION
The presence of activated microglia within and around 
senile plaques suggests that Aβ, the major component 
in plaques, is involved in the activation of microglial 
cells in AD. In vitro studies provide evidence that Aβ 
peptides induce cytokine synthesis and release from 
microglial cells (Araujo and Cotman, 1992; Meda et 
al., 1995; Murphy et al., 1998; Combs et al., 2001; 
Szczepanik et al., 2001; Lee et al., 2002; Takata et 
al., 2003; Lindberg et al., 2005). In the present study, 
we have investigated Aβ1-40-induced activation of the 
human CHME3 microglial cell line and the effects 
thereupon of α-MSH, a neuropeptide with anti-inflam-
matory properties (see Catania and Lipton, 1998), with 
regard to cytokine production and cell viability. Freshly 
dissolved Aβ1-40 stimulated the release of IL-6 from 
these cells in a dose-dependent manner, in accordance 
with studies using pre-aggregated Aβ1-42 on human pri-
mary microglia (Lue et al., 2001). 
   α-MSH did not affect the release of IL-6 from 
human microglial cells stimulated with Aβ1-40, or with 
Aβ1-40 and IFN-γ. In studies on the aggregated form of 
Aβ1-42, the major form in amyloid plaques in the AD 
brain, α-MSH had an inhibitory effect on the release of 
TNF-α and NO (Galimberti et al., 1999). Furthermore, 
α-MSH reduced the release of IL-6, TNF-α and NO, 
from murine microglia activated with LPS and IFN-γ 
(Delgado et al., 1998). A possible explanation for the 
different effects of α-MSH is a species difference. To 
our knowledge, studies on the effects of α-MSH on 
microglia have, so far, been performed exclusively 
on murine cells (Delgado et al., 1998; Galimberti et 
al., 1999). Furthermore, the effects of α-MSH on Aβ-
induced cytokine release may depend on the Aβ-form 
used. Indeed, previous studies on the effects of Aβ-pep-
tides on microglia from different species have shown 
differential effects on cytokine release, depending on 
the aggregational form, and on the use of either Aβ1-40 
or Aβ1-42 (Araujo and Cotman, 1992; Meda et al., 1995; 
Murphy et al., 1998; Combs et al., 2001; Szczepanik et 
al., 2001; Lee et al., 2002; Takata et al., 2003; Lindberg 
et al., 2005). Freshly dissolved Aβ1-40 was chosen for 
the present study since freshly dissolved Aβ-peptide 
was more potent than the fibrillar form and a further 
aggregated form, so called βamy balls (Westlind-
Danielsson and Arnerup, 2001), in stimulating the 
release of pro-inflammatory cytokines from primary rat 
microglial cultures (Lindberg et al., 2005). Aβ peptides 
are highly aggregational-prone, Aβ1-42 more so than 
Aβ1-40 (Jarrett et al., 1993). The preparation of freshly 
dissolved Aβ1-40 used in the present study was shown 
previously to contain mainly oligomeric forms, such as 
tetramers, hexamers, dodecamers and 24-mers, while 
the preparation of freshly dissolved Aβ1-42 was shown 
to contain a mixture of oligomers and fibrils during 
24h of incubation in culture medium (Lindberg et al., 
2005). Based on the findings that the oligomeric forms, 
i.e., so called Aβ-derived diffusible ligands (ADDLs), 
believed to represent the most neurotoxic forms 
(Aksenova et al., 1996; Hartley et al., 1999; Dahlgren 
et al., 2002; Selkoe, 2002; Hoshi et al., 2003), Aβ1-40, 
and not Aβ1-42, was chosen for the present study. The 
human microglial cell line responded to the preparation 
of freshly dissolved Aβ1-40 with a markedly reduced 
cell viability. This reduction in cell viability was not 
affected by IFN-γ or α-MSH. Interestingly, inhibition 
of PKA with H89, together with α-MSH, gave rise to a 
decrease in cell viability. PKA, a downstream mediator 
of MCR signalling, has been shown to activate murine 
microglial cells not previously activated (Min et al., 
2004). However, inhibition of PKA did not reduce 
the α-MSH-induced release of IL-6 from the human 
microglia. These findings indicate that PKA-signalling 
is involved in the reduction of cell viability, but not in 
mediating the release of IL-6. Although increased cAMP-
signalling upon α-MSH stimulation inhibits the activation 
of murine microglia (Konda et al., 1994; Delgado et al., 
1998), increased cAMP may have both stimulatory (Pyo 
et al., 1999; Marcus et al., 2003; Woo et al., 2004)  and 
inhibitory (Yoshimura et al., 1997; Si et al., 1998)  effects 
on the release of inflammatory factors.
   Monocytes have previously been shown to express 
the MCR1, 3 and 5 subtypes (Rajora et al., 1996; 
Ichiyama et al., 2000), and we now show the expres-
sion of mRNA for these receptors, as well as MCR4, 
in the human microglial cell line, suggesting that all 
of these receptors are possible candidates for mediat-
ing the effects of α-MSH on these cells. However, 
the endogenous antagonist of α-MSH-mediated activ-
ity, agouti, specific for MCR1 and MCR4 (Dinulescu 
and Cone, 2000), did not inhibit the α-MSH-induced 
release of IL-6. Instead, agouti further increased the 
α-MSH-induced release of IL-6. These findings would 
seem to indicate that α-MSH-induced secretion of IL-
6 was mediated by MCR3 and/or MCR5. Agouti has 
some affinity for both of these MCRs (Dinulescu and 
Cone, 2000), but further studies will be necessary to 
establish whether it is sufficient to affect the α-MSH-
induced stimulation of the human microglia.
   There is ample evidence for anti-inflammatory 
effects of α-MSH (see Catania and Lipton, 1998), and 
the present finding that α-MSH stimulates, rather than 
inhibits the release of IL-6, is intriguing. Many stud-
ies show neuroprotective and regenerative activities of 
α-MSH (see Gispen et al., 1994; Strand, 1999; Catania 
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et al., 2004) as well as of IL-6 (Maeda et al., 1994; 
Loddick et al., 1998; Streit et al., 2000; Poulsen et al., 
2005) in the nervous system. Recent studies have dem-
onstrated neuroprotective effects of α-MSH in models 
of cerebral ischemia (Huh et al., 1997; Hwang et al., 
2004; Forslin Aronsson et al., submitted). Thus, it may 
be hypothesised that α-MSH, through the release of 
IL-6 from microglial cells, can have beneficial effects 
on neurons.
   The microglial cell line, CHME3, used in the pres-
ent studies has previously been reported to express 
receptors for IFN-γ and to respond with increased 
production of major histocompatibility (MHC) class 
II molecules upon stimulation with IFN-γ (Janabi et 
al., 1995). The activation of these cells by IFN-γ was 
supported by our results showing a dose-dependent 
increase in the release of IL-6. However, unlike earlier 
studies on murine microglia (Gasic-Milenkovic et al., 
2003), there was no potentiating effect of IFN-γ on the 
Aβ1-40-induced secretion of IL-6. This could be due to 
the fact that IFN-γ and IL-6 share the same signalling 
pathway, i.e., the JAK/STAT pathway (Heinrich et 
al., 1998; Platanias and Fish, 1999; Kerr et al., 2003). 
Previous characterisation of the CHME3 cells has also 
demonstrated that they have the same repertoire of che-
mokine receptors as primary cultures of adult human 
microglia (Flynn et al., 2003), and that their responses 
to chemokines are similar to those of primary cultures 
of adult rat microglia (Cross and Woodroofe, 1999). 
This is interesting in view of the findings of increased 
chemokine levels in CSF samples from AD patients 
(Galimberti et al., 2003), and supports the relevance of 
using this cell line as a model for human microglia.
   The results from the present study support the hypoth-
esis that Aβ1-40 activates microglial cells to produce IL-
6 in the AD brain, which could further stimulate the 
production of Aβ1-40, via stimulation of APP synthesis 
and processing (Del Bo et al., 1995). This would pro-
mote chronic inflammation that is believed to be part 
of AD brain pathology. Unexpectedly, α-MSH was 
not found to inhibit the release of IL-6, but resulted 
in increased basal secretion from the microglial cells. 
Further studies will be required to clarify whether or 
not this effect is responsible for the neuroprotective 
activities of α-MSH.
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Abstract  
Glial activation and increased inflammation characterize neuropathology in Alzheimer’s 
disease (AD). The aim was to develop a model for studying phagocytosis of -amyloid (A) 
peptide by human microglia, and to test effects thereupon by immunomodulatory substances. 
Human CHME3 microglia showed intracellular A1-42 co-localized with lysosome-associated 
membrane protein-2, indicating phagocytosis. This was increased by interferon-, and to a 
lesser degree with Protollin, a proteosome-based adjuvant. Secretion of brain-derived 
neurotrophic factor (BDNF) was decreased by A1-42 and by interferon- and interleukin-1. 
These cytokines, but not A1-42, stimulated interleukin-6 release. Microglia which 
phagocytosed A1-42 exhibited a higher degree of expression of interleukin-1 receptor type I 
and inducible nitric oxide synthase. In conclusion, we show that human microglia are able to 
phagocytose A1-42 and that this is associated with expression of inflammatory markers. A1-
42 and interferon- decrease BDNF secretion suggesting a new neuropathological role for A1-
42 and the inflammation accompanying AD. 
 
 
Key words: Alzheimer, amyloid, BDNF, brain-derived neurotrophic factor, cytokine, 
interferon, interleukin, Protollin 
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Introduction 
Alzheimer’s disease (AD) is the most common cause of dementia. The major pathological 
hallmarks of AD besides neuronal loss are amyloid plaques and neurofibrillary tangles 
(NFTs). Both amyloid plaques and NFTs have been implicated in neuronal impairment and 
death in a large number of studies. Although a great deal of controversy exists about the 
relative importance of amyloid plaques contra NFT:s in AD [1], there is an overwhelming 
body of evidence showing that amyloid plaques and the peptides they are composed of are 
culprits in the neurodegenerative processes in AD [2]. The main component of amyloid 
plaques is the -amyloid (A) peptide, that is secreted by neurons and other cells through 
cleavage of the larger, membrane-bound, amyloid precursor protein (APP). APP can be 
processed by two major pathways: the amyloidogenic pathway that yields A, and the non-
amyloidogenic yielding fragments believed to be non-pathogenic. The A peptides are prone 
to self-aggregation and deposition into insoluble plaques. This is especially true for the 42 
amino acid form (A1-42), which is the predominant form in the dense core plaques [3]. A-
species also exist in the forms of soluble monomers and oligomers which similarly to the 
amyloid plaques are more abundant in the AD brain than in the non-AD brain [4]. Somehow, 
the balance between production and clearance/degradation of A is disturbed in AD.  
 
Damage to brain tissue induces an inflammation, a response which is present in many, if not 
all neurodegenerative conditions. In the central nervous system (CNS), glial cells, i.e. 
microglia and astrocytes, represent the main source of inflammatory reactions. In normal 
conditions, glia have supportive functions, including maintenance of ionic homeostasis, 
clearance of neurotransmitters and in the case of astrocytes, providing nutrients to the energy-
demanding work of the neurons [5]. Glial, particularly microglial, cell responses can also 
serve in the elimination of debris from damaged cells and to remove pathogens. Removal of 
pathogens is executed by the process of phagocytosis, a capability that glial cells share with 
peripheral immunocompetent cells including monocytes and macrophages. In the brain, 
phagocytosis is believed to be performed mainly by microglia, but astrocytes also have this 
capability [6]. 
Under stress, glial cells proliferate and become activated, which leads to production of 
neurotoxic molecules such as free radical species and proinflammatory cytokines [7,8]. In 
contrast to the potentially tissue-damaging responses, glia can also produce factors that 
promote neuroprotection and neuronal plasticity [9]. These protective and supportive 
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functions may be downregulated during stress. Therefore, inflammation in the brain may 
worsen the outcome of an already existing trauma or pathological condition. 
In the AD brain, activated microglia and astrocytes are present in the areas of 
neurodegeneration and amyloid plaques [10] and there is an increased production of 
proinflammatory cytokines such as interleukin (IL) -1 [11] and IL-6 [12]. In addition, 
elevated levels of IL-1 and IL-6 have been found in serum and cerebrospinal fluid (CSF) from 
AD patients [13,14]. In vitro studies have demonstrated that A peptides can indeed activate 
glial cells to produce inflammatory factors [15-18], which can contribute to the 
neurodegenerative process [19]. Evidence from studies on rat cortical microglia showed that 
the smaller aggregational forms of Asuch as oligomers are more potent in stimulating glial 
secretion of proinflammatory cytokines [18]. IL-1 increases the production of APP in human 
[20] glia, and the APP gene contains a binding site for the prime inflammatory transcription 
factor nuclear factor B (NFB) [21]. Furthermore, inflammation may shift processing of 
APP towards the amyloidogenic pathway [22]. A consequence of the interactions between 
inflammation and the APP/A-peptide may be a vicious circle [23], in which inflammation 
increases A levels through increased production and reduced clearance, which in turn results 
in neuronal cell death and a perpetuated and increased glial activation and release of 
proinflammatory factors, as well as neuronal cell death, and so forth. 
 
Removal of a disease-causing pathogen is probably the most effective way of treating a 
disease. To stimulate cellular uptake, phagocytosis, of A is a promising strategy. In studies 
on animal models of AD, active and passive immunizations have been shown to be effective 
in removing plaques and to improve cognitive performance [24]. Human clinical trials with 
active immunization have been started, but were aborted due to serious sideeffects in a few 
cases [25]. However, several clinical trials with modified protocols, including passive 
immunizations, are currently being carried out. Phagocytosis is an activity that is performed 
primarily by cells of the immune system, notably cells of the monocyte lineage. In the light of 
the studies on active and passive immunization we are presented with a strategy for treatment 
of AD, to activate the immune system into phagocytosis of A. Although inflammation 
generally is believed to stimulate phagocytic activities, there is also evidence indicating that 
inflammation may inhibit phagocytosis [26], whereas anti-inflammatory cytokines such as 
transforming growth factor- (TGF-) can stimulate phagocytosis [27]. Thus, it is of 
importance to search for compounds that can promote phagocytosis without starting the 
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damaging processes of inflammation. In short, directed and differential activation of immune 
cells residing in, or destined for, the CNS constitutes a potential therapeutic target. 
 
In the present study, the aim was to characterise the responses of human microglia to the 
exposure of A. In order to investigate the possibilities to increase glial uptake of A we have 
analysed the effects of different immunomodulatory substances. The effects of the adjuvant 
Protollin, as well as those of the archetypical proinflammatory cytokines, IL-1 and 
interferon-(IFN), were analysed in an in vitro model of human microglial cells with regard 
to A1-42 uptake, microglial phenotype, and the secretion of IL-6 and brain-derived 
neurotrophic factor (BDNF).  
 
IL-6 is a cytokine that is induced by IL-1 and tumour necrosis factor- (TNF) and can thus 
be considered a general measure of inflammation [28]. BDNF is a neurotrophic growth factor 
of importance in memory formation and neuroprotection [29,30]. Protollin is an adjuvant 
made of Shigella flexneri 2a lipopolysaccharides (LPS) associated non-covalently to 
meningococcal outer membrane proteins (proteosomes), that has been proven to be safe for 
use in humans [31]. While LPS activates Toll-like receptor type 4 (TLR4), cd11 and cd14, 
proteosomes activate TLR2 [32]. Activation of TLR2 has been associated with increased 
phagocytosis in mice with sciatic nerve lesions [33]. Furthermore, intranasal application of 
Protollin was shown to prevent accumulation of A in young transgenic mice expressing the 
human APP with the Swedish mutation, and also to stimulate clearance of A from the brain 
of aged mice of the same transgenic strain [34]. A correlation was found between the removal 
of Aand the level of microglial activation, as demonstrated by increased expression of the 
activation marker CD11b in conjunction with the removal of A in animals treated with 
Protollin [34]. To investigate the effects of Protollin on cellular inflammatory markers, and 
the association of these markers with uptake of A1-42 by the human microglial cells, the 
expression of inducible nitric oxide synthase (iNOS), IL-1 and the signalling type I receptor 
for IL-1 (IL-1RI) was analyzed in cells showing uptake of A1-42. iNOS is induced in 
inflammation and shown to be harmful for neurons due to the production of radical nitrogen 
species [35]. It has been shown to be associated with neurodegenerative disorders such as AD 
[36].  
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Materials and Methods 
Chemicals 
Protollin was provided by Glaxo-Smith Kline Biologicals, Laval, Quebec, Canada. A1-42 
conjugated with HiLyteFluor488 or biotin was obtained from Anaspec (Fremont, USA). 
Dimethylsulfoxide (DMSO), Triton-X100, bovine serum albumin (BSA), 4',6-diamidino-2-
phenylindole (DAPI) and (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), were purchased from Sigma, Stockholm, Sweden. Normal donkey and goat serum, 
and fluorescence mounting medium (DakoPatts, Stockholm, Sweden). Streptavidin-7-amino-
4-methyl-3-coumarinylacetic acid (AMCA) (Jackson ImmunoResearch Europe Ltd, Suffolk, 
UK). Lactate deydrogenase (LDH)-assay (Roche, Stockholm, Sweden). ELISA-kits for IL-6 
and BDNF (R&D systems, Abingdon, United Kingdom). IFN (Bachem, Weil am Rhein, 
Germany). Cell culture medium, phosphate-buffered saline (PBS), GlutaMaxII, foetal calf 
serum (FCS) and PBS-based enzyme-free cell dissociation buffer (Invitrogen, Stockholm, 
Sweden). Cell culture bottles and multi-well plates (BD Biosciences, Stockholm, Sweden). 
 
Cell cultures 
Human microglial cells (CHME3) were obtained as a kind gift from Prof. M Tardieu 
(Neurologie pédiatrique, Hôpital Bicêtre, Assistance publique, Hôpitaux de Paris, Paris, 
France). CHME3 cells were cultured in T75 or T175 bottles in culture medium (DMEM/high 
glucose w/o sodium pyruvate supplemented with 2 mM L-glutamine or GlutaMaxII and 10% 
heat-inactivated FCS). The cells were subcultured at confluence using enzyme-free cell 
dissociation buffer after washing once with PBS without Mg
2+
 and Ca
2+
. 
 
Experimental procedures 
The CHME3 microglial cells were seeded in 48-well plates for analysis of cell viability 
(MTT) and cytotoxicity (LDH) (see Supplementary material), in 6-well plates for flow-
cytometry and analysis of substances released to the medium, or on glass coverslips in 24- or 
48-well plates for immunocytochemistry. All experiments were performed at a confluence of 
~60%. A1-42 was dissolved in DMSO and stored in darkness at +4
o
C until use at a final 
concentration of 1 g/ml for all experiments except for a dose-response curve. In higher doses 
we observed aggregate-like precipitates of fluorescent A1-42 which were unwanted in this 
study. Before the addition of A1-42 or vehicle (DMSO), the cells were pre-stimulated for 24 h 
with either Protollin (0.001, 0.01 and 0.1 g/ml in serum-free culture medium) or cytokines 
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(50 ng/ml IL-1, 50 ng/ml IFN, or IL-1 + IFN). At 0, 24, 48, 72 and 96 h after addition of 
A1-42 the cultures were analyzed for uptake of A1-42, expression of cellular markers and 
secretory products. Uptake of fluorescent A1-42 by living cells was analysed in a Nikon 
TE600 inverted fluorescence microscope. Cell viability and cell death were also analysed (see 
Supplementary material). 
 
Quantification of A1-42 phagocytosis and cellular markers by flow-cytometry 
After the experimental treatment, the CHME3 microglial cells were dissociated with PBS-
based enzyme-free dissociation buffer as described above, and centrifuged at 1500 x g for 10 
min. The cells were then resuspended and fixed in 1% para-formaldehyde (PF) in PBS, for 40 
min at room temperature, after which the fixative was diluted 20X by addition of PBS and the 
cells were centrifuged at 1500 x g for 10 min. Fixation with PF renders cells permeable to PI 
and therefore all fixed cells will be stained with PI, allowing the distinction of cells from cell 
debris. Analysis was performed in a FACScalibur (BD) flow-cytometer. A detected event was 
defined as a cell if it was gated through the front-scatter (FSC) and side-scatter (SSC) plot 
gate in addition to being positive for PI. A cell positive for phagocytosis of A1-42(A1-42+) 
was defined as a PI-positive cell that was also being positive for the fluorophore conjugated to 
A1-42 (HyliteFluor488). Negative controls were utilized to establish the limits of detection 
for positive signals.  
To investigate the phenotype of the cells with regard to the presence of inflammatory 
markers, and the degree of co-localization of each marker with phagocytosed A1-42, the cells 
were stained with antibodies directed against human IL-1 (1:400; gift from Dr. Stefan 
Svensson, Statens Bakteriologiska Laboratorium, Stockholm, Sweden), IL-1RI (1:200; 
Amgen (Immunex Corporation) Thousand Oaks, USA) and iNOS (1:600; R&D systems, 
London, England). The cells were harvested and fixed as described above and subsequently 
an aliquot of the cell suspension was incubated with the primary antibodies, diluted in PBS 
containing 5% normal donkey serum and 0.1% Triton-X100. Omission of primary antibodies 
served as negative control to establish the limits of detection for positive signals. After 
incubation with primary antibodies overnight at +4
o
C, the cell suspension was washed by 
addition of PBS followed by centrifugation at 2500 x g for 20 min. The cells were 
resuspended in PBS and incubated with donkey anti-goat IgG-NL637 antibodies (1:500; R&D 
systems, London, England) and PI for 1 h at room temperature. After incubation, the cell 
suspension was diluted with PBS and analyzed by flow-cytometry. A cell displaying 
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immunoreactivity for an antibody was defined as a cell showing a stronger signal in this 
channel than the negative control. A cell displaying uptake of A1-42 (A1-42+) was defined as 
described above. The results were analysed from a scatter plot with fluorescence from the 
secondary antibody on the y-axis and fluorescence from HyliteFluor488 on the X-axis, 
divided into quadrants with borders based on the negative controls as described. The cells 
were thus being viewed in a two-way binary fashion with a cell being present in a certain 
quadrant thus indicating: a) positive for immunoreactivity to IL-1 IL-1+), IL-1RI (IL-
1RI+) or iNOS (iNOS+) and for A1-42-uptake (A1-42+), b) positive for immunoreactivity to 
one of these markers and negative for A1-42-uptake c) negative for immunoreactivity to the 
markers and positive for A1-42-uptake, or d) negative for immunoreactivity to the markers 
and for A1-42-uptake. The parameters extracted from the data were a) total proportion of the 
cells showing immunoreactivity to a marker, b) immunoreactivity of cells negative for A1-42-
uptake and c) immunoreactivity of cells positive for A1-42-uptake.  
 
Immunocytochemistry and staining of fixed and living cells for microscopy 
To analyse the microglial cell expression of certain inflammatory markers and the localization 
of phagocytosed A1-42 by microscopy the culture medium was removed and the coverslips 
dried at 37
o
C for ~2 h. The cells were fixed with 4% PF for 20 min at room temperature, 
washed in PBS and incubated overnight at 4
o
C with antibodies against IL-1 (1:400), IL-1RI 
(1:200) and iNOS (1:600), respectively. The antibodies were diluted in PBS containing 5% 
normal donkey serum and 0.1% Triton-X100. After rinsing in PBS, the coverslips were 
incubated for 1 h at room temperature with goat anti-rabbit-IgG conjugated with Cy2 (1:200), 
diluted in PBS containing 5% normal goat serum, 0.1% Triton-X100 and 1 g/ml PI. For 
visualization of biotinylated A1-42, streptavidin-AMCA was included in the secondary 
antibody solution (2 µg/ml). The coverslips were then washed with PBS, mounted with 
fluorescence mounting medium, and inspected in a Nikon E800 microscope. To investigate 
the targeting of A1-42 toward degradation, cells were incubated with HyliteFluor488-
conjugated A1-42 and then fixed and incubated overnight at 4
o
C with mouse antibodies 
against human lysosome-associated membrane protein-2 (lamp-2, Millipore). After washing, 
the cells were incubated with donkey anti-mouse antibodies conjugated with Cy3 and with the 
nuclear stain DAPI, and then mounted and inspected as described above. 
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Enzyme-linked immunosorbent assay (ELISA) 
The levels of IL-6 and BDNF in the cell culture medium were analyzed with commercially 
available ELISA-kits according to the manufacturer’s instructions. Analysis of optical density 
(OD) was performed in a TECAN Safire2 plate reader. 
 
Cell viability – MTT assay 
To analyse cell viability the culture medium was removed and after washing with serum- and 
phenol-free DMEM/high glucose with GlutaMaxII, MTT (0.3 mg/ml) was added and the cells 
incubated at 37
o
C for 1 h. The crystals formed by the reaction were dissolved in DMSO and 
the OD was measured with a TECAN Safire2 plate reader (Tecan, Mölndal, Stockholm) at 
592 nm with 620 nm as a reference wavelength. 
 
Cell death – LDH assay 
To analyse cell death the culture medium was removed and added to a 96-well plate, and then 
incubated with LDH-reagent according to the manufacturer’s instructions. The OD was 
measured at 492 nm with 620 nm as reference wavelength. 
 
Statistics 
The data were normalized to vehicle (MTT-assay, ELISA), A1-42 (flow-cytometry, for 
uptake) or positive control (LDH-assayu), or not normalized (flow-cytometry, for association 
of cellular markers with the uptake of A1-42, correlation between variables). The results were 
analysed with Kruskal-Wallis non-parametric analysis of variance (ANOVA) and the data 
were then compared pair-wise using the non-parametric Mann-Whitney U test with Bonferoni 
correction. Pair-wise comparison of variable within experimental groups was performed with 
the Wilcoxon Matched Pairs Test. Correlation between variables were performed with the 
Spearman Rank Order Correlations test. All statistical analyses were performed in Statistica 
v8 (Statsoft). 
 
Results 
Human CHME3 microglial cells exposed to immunomodulatory substances were studied with 
regard to phagocytosis of A1-42 and expression of cellular markers (IL-1, IL-1RI and 
iNOS). As an indicator of an inflammatory response we analysed the secretion of IL-6 in the 
culture medium. To assess beneficial and neuroprotective activities the secretion of BDNF 
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was determined. The levels of BDNF released into the medium varied between 8 and 300 
pg/ml and the levels of IL-6 varied between 20 and 950 pg/ml under basal conditions (vehicle 
group at 24 h). Cell death and viability were also analysed (see Supplementary material).  
 
The ability of CHME3 microglia to take up A1-42 was confirmed by inspection of living cells 
using phase contrast/fluorescence microscopy (Fig. 1A), and fluorescence microscopy on the 
fixed cell suspension used for flow-cytometry (Fig. 1B), and by confocal microscopy on fixed 
and living cells (Fig. 2). The first signs of uptake (visible in inverted fluorescence 
microscope) by the microglial cells were observed approximately 4 h after the addition of 
A1-42. Analysis of the intracellular content of A1-42 was performed by flow-cytometry at 24 
and 96 h after addition of different concentrations of A1-42 (Fig. 3A). The uptake increased 
with increasing concentrations of A1-42. A 50-fold increase in the concentration of A1-42 
from 0.1 to 5 g/ml resulted in a 10-fold increase in the fraction of cells taking up A1-42 (p < 
0.05). 
 
Effects of A1-42 on secretion of BDNF and IL-6 
In dose-response experiments with 0.1, 0.5, 1 and 5 µg/ml of A1-42, we found that 5 µg/ml 
reduced the levels of BDNF in the culture medium by 50% compared to vehicle (p < 0.01, 
Fig. 3B). A similar degree of decrease was seen for 5 µg/ml A1-42 when compared with the 
other concentrations of A1-42 (p < 0.01). At 96 h, the concentrations of 0.1 and 0.5 µg/ml 
A1-42 slightly increased the secretion of BDNF (p < 0.05). No effect was seen on the 
secretion of IL-6 with the concentrations of A1-42 tested. 
 
Effects of IL-1 and IFNon uptake of A1-42 
To evaluate the potential of stimulating CHME3 microglia into phagocytosis by 
inflammation, the cells were incubated with the proinflammatory cytokines IL-1 and IFN. 
Pretreatment with IFN resulted in an increase in the proportion of cells showing A1-42 
uptake (A1-42+ cells) with a median increase of 50% at 72 h (p < 0.01, Fig. 4, grey boxes), 
and the combined stimulation with IL-1 and IFN lead to a median increase of 66% at 72 h 
(p <0.01) as compared to controls (with A1-42 alone), and a 62% increase compared to IL-1 
(p = 0.05). IL-1 alone had no significant effect on the A1-42 uptake. The observed effects 
appeared to linger at 96 h although the differences were not significant. 
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Effects of IL-1 and IFN on secretion of BDNF and IL-6 
The levels of secreted BDNF were markedly reduced by the incubation with the 
proinflammatory cytokines IL-1 and IFN (Fig. 5A, white boxes). Thus, IFN decreased the 
median secretion of BDNF as compared to vehicle with 41% at 72 h and with 44% at 96 h (p 
< 0.05 at both time points). There was no effect of IL-1 alone, but the combination of IL-1 
and IFN resulted in a significant, almost 50%, decrease in BDNF secretion at 72 and 96 h (p 
< 0.05 at both time points) (Fig. 5A, white boxes). 
Treatment of the cells with proinflammatory cytokines resulted in a marked inflammatory 
response evidenced by a dramatic increase in IL-6 secretion (Fig. 5B, white boxes). At 0 h 
(i.e. 24 h after addition of the cytokines and at the time point of addition of A1-42, or in this 
case, vehicle), IL-1 and IL-1  stimulated the IL-6 secretion, producing levels that 
were 50 and 90 times higher than control (vehicle), respectively (p < 0.05 in both cases (Fig. 
5B, white boxes). At 24 h (i.e. after 48 h incubation with the cytokines), IL-1 and IL-
1  induced a 200- and 140-fold increase in IL-6 secretion, respectively, and the 
combination of IFN and IL-1 resulted in a 25X higher induction than that by IFN alone (p 
< 0.05). The incubation with IL-1 N was still effective at 96 h in increasing secreted the 
levels of IL-6 (p = 0.0108). At this time point, IL-1  alone significantly 
increased the levels of IL-6 several-fold (p < 0.05 in both cases).  
 
Effects of IL-1 and IFN in combination with A1-42 on secretion of BDNF and IL-6 
Similarly to the effect seen for cytokines, the combined incubation of cytokines and A1-42 
resulted in reduced secretion of BDNF (Fig. 5A, black boxes). There was no effect of A1-42 
alone on secretion of BDNF in this series of experiments. At 24 h, pretreatment with IFN 
resulted in a median reduction to 77% in BDNF secretion compared to vehicle (100%) (p = 
0.0086). At 72 h, the median reduction was 25% (p < 0.01) and at 96 h it was 45% (p < 0.01) 
(Fig. 5A, black boxes). The combination of A1-42 with IFN pretreatment resulted in 
significantly lower secretion of BDNF than that observed after treatment with A1-42 alone at 
72 h (p < 0.01). Pretreatment with IL-1 decreased the median BDNF level to 88% of vehicle 
at 96 h (p < 0.01). At 72 h, pretreatment with IL-1+IFN resulted in a significant decrease in 
BDNF level to 64% of vehicle levels (p < 0.01) which was also lower than the levels induced 
by A1-42 alone at this time point (97% of vehicle, p < 0.01). This effect was still present at 96 
h when pretreatment with IL-1+IFN resulted in a decrease in BDNF level to 43% of vehicle 
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(p < 0.01), which also at this time point was lower than the level induced by A1-42 alone 
(88% of vehicle, p = 0.017). The pretreatment with IL-1+IFN also reduced the levels of 
BDNF compared with IL-1 at 72 h (p < 0.05). 
 
Treatment of the cells with cytokines before addition of A1-42 (Fig. 5B, black boxes) resulted 
in a marked increase in IL-6 secretion that paralleled the increase observed in the absence of 
A1-42 (Fig. 5B, white boxes). In this series of experiments there were no effects of A1-42 
alone at any time point on the levels of IL-6. The pretreatment of the CHME3 microglial cells 
with IL-1 or IL-1+IFN had a strong stimulatory effect on the secretion of IL-6 as 
compared to vehicle and to A1-42 alone (Fig. 5B, black boxes). At 24 h, IL-1 increased the 
median levels of IL-6 25-fold compared with vehicle and A1-42 alone (p < 0.01 in both 
cases). A significant stimulatory effect of IL-1 pretreatment was present at 48 h with levels 
35-fold those of vehicle and A1-42 alone (p < 0.01 in both cases). At 48 h, a stimulatory 
effect of IFN became apparent, with median levels of IL-6 that were 5-fold compared with 
vehicle and A1-42 alone (p < 0.01 in both cases). Compared with vehicle and A1-42 alone, 
the combined pretreatment with IL-1+IFN induced a 35-fold increase at 24 h (p < 0.01 in 
both cases), a 28-fold increase at 48 h (p < 0.01 in both cases) and a 5-fold increase at 96 h 
compared with vehicle (p < 0.01). Also, the combined stimulation with IFN and IL-1 prior 
to A1-42 resulted in an increase of almost 6 times in the mean secretion of IL-6 at 48 h as 
compared to IFN alone (p <  0.005), but not compared to IL-1. A significant increase was 
still seen at 96 h upon pretreatment with the combination of IL-1 and IFN, i.e. almost 5 
times the secretion of IL-6 seen after incubation with vehicle (p < 0.005), but no difference in 
comparison to A1-42 alone. Also, at 48 h, the secreted levels of IL-6 following pretreatment 
with IL-1+IFN were 6 times higher than those seen after pretreatment with IFN alone (p < 
0.01). 
 
Effects of Protollin on uptake of A1-42 
Pretreatment of the microglial cells with Protollin at 0.001 µg/ml was found to increase the 
median proportion of cells showing uptake of A1-42 to 115% (p < 0.05) as compared to 
control (A1-42 alone, 100%, Fig. 4). This effect was seen at 96 h, but no significant changes 
in any direction could be detected at the earlier time points. 
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Effects of Protollin, with and without A1-42, on secretion of BDNF and IL-6 
Treatment with Protollin alone i.e. prior to addition of vehicle, did not affect the levels of 
BDNF (data not shown). The incubation with A1-42 alone resulted in a decrease in the levels 
of BDNF in this series of experiments, i.e. a reduction to 82% of vehicle at 24 h (p < 
0.0000001), to 77% of vehicle at 48 h (p < 0.005) and to 95% of vehicle at 96 h (p < 0.05). 
In cultures pretreated with the lowest concentration of Protollin (0.001 µg/ml) followed by 
incubation with A1-42 there was a 22% reduction at the 24 h time point as compared to 
vehicle (p = 0.05), whereas at the higher concentrations of Protollin and at later time points 
there was no significant differences in the secretion of BDNF in comparison with control 
conditions (no Protollin and no A1-42). 
Pretreatment with Protollin followed by A1-42 or vehicle did not induce any significant 
effects on the levels of IL-6 in culture supernatants (data not shown).  
 
Cellular markers and relation to phagocytosis of A1-42 
The uptake of A1-42 in cells expressing the inflammatory markers IL-1, IL-1RI and iNOS in 
the cultures treated with A1-42 following pretreatment with Protollin was demonstrated by 
immunocytochemistry (Fig. 6). The proportion of cells positive for these markers was 
analysed by flow-cytometry, both after incubation with A1-42 alone, and after pretreatment 
with Protollin, in order to assess the phenotype of the cells taking up A1-42 (A1-42+) (Fig. 7). 
 
IL-1 immunoreactive cells 
In untreated (vehicle) cultures, the proportion of CHME3 microglial cells with 
immunoreactivity to IL-1 had a median of 2.9% at 24 h. Incubation of the cells with 1 µg/ml 
A1-42 did not significantly affect the number of IL-1 immunoreactive cells compared with 
vehicle at any time point. 
The expression of IL-1 in A1-42+ cells was not significantly different from that in A1-42- 
cells according to the Wilcoxon Matched Pairs test, except at 72 h when the population of 
A1-42+/IL-1+ cells was larger than the A1-42-/IL-1+ cell population (Fig. 7A). 
Pretreatment with Protollin increased the number of IL-1+ cells displaying A1-42 uptake 
(Fig 7A). Significant differences were observed between A1-42+/IL-1+ cells and A1-42-/IL-
1+ cells treated with Protollin at 24 h in concentrations of 0.001 µg/ml (p < 0.05), 0.1 µg/ml 
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(p < 0.05) and 1 µg/ml (p < 0.05), at 48 h in concentrations of 0.1 µg/ml (p < 0.05) and 1 
µg/ml (p < 0.05), and at 72 h in a concentration of 0.1 µg/ml (p < 0.05).  
 
IL-1RI immunoreactive cells 
In untreated (vehicle) cultures the proportion of CHME3 microglial cells with 
immunoreactivity for IL-1RI (IL-1RI+) had a median value of 12.5% at 24 h. Incubation with 
1 µg/ml A1-42, with or without pretreatment with Protollin, did not significantly affect the 
number of IL-1RI immunoreactive cells at any time point (Fig 7B).  
When incubated with A1-42 alone, the population of A1-42+/IL-1RI+ cells was significantly 
larger than the A1-42-/IL-1RI+ population at 24, 48 and 72 h (p < 0.05, Fig 7B). When 
pretreated with Protollin, there was a significantly larger proportion of A1-42+ cells that were 
immunoreactive to IL-1RI (A1-42+/IL-1RI+) at 24 h in concentrations of 0.001 µg/ml (p < 
0.05), 0.1 µg/ml (p < 0.05) and 1 µg/ml (p < 0.05), at 48 h in concentrations of 0.1 µg/ml (p < 
0.05) and 1 µg/ml (p < 0.05) and at 72 h in a concentration of 0.1 µg/ml (p < 0.05).  
 
iNOS immunoreactive cells 
In untreated (vehicle) cultures the median proportion of CHME3 microglial cells with 
immunoreactivity to iNOS (iNOS+) had a median of 16% at 24 h under basal (vehicle) 
conditions. None of the treatments affected the total number of cells immunoreactive for 
iNOS. 
When incubated with A1-42 alone, the population of A1-42+/iNOS+ cells was significantly 
larger than the population of A1-42-/iNOS+ cells at all time points (p = 0.0173 at 24 h, p = 
0.0172 at 48 h, p = 0.0117 at 72 h and p = 0.05 at 96 h, Fig 7C).  Also when cells were 
pretreated with Protollin, the A1-42+/iNOS+ population was significantly larger than the A1-
42-/iNOS+ population, at all concentrations tested (0.001 µg/ml: p = 0.0117 at 24 h, p = 
0.0357 at 48 h and p = 0.025 at 72 h; 0.01 µg/ml: p = 0.0117 at 24 h and p = 0.0117 at 48 h; 
0.1 µg/ml: p = 0.0117 at 24 h, p = 0.05 at 48 h and p = 0.0251 at 72 h:  and p = 0.025 at 72 h: 
0.1 µg/ml: p = 0.0117 at 24 h, Fig 7C). 
 
Correlation between secretion of BDNF and uptake of A1-42 
We found a significant negative correlation (p < 0.05) between the levels of BDNF in culture 
supernatant and the proportion of A1-42+ cells at all the time points in the experiments (Fig. 
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8). The data were analysed by correlating the BDNF-levels with the proportion of A1-42+ 
cells in all the treatments at one time point, and in one treatment at one time point, using the 
Spearman Rank Order Correlation test. There was a significant negative correlation in all 
analyses performed, except at 48 h, when the treatment with 0.001 mg/ml Protollin was void 
of a significant correlation. 
 
Cell death and viability 
The effects of A1-42 and the immunomodulatory substances on cell death and viability were 
analysed by the LDH and MTT assays, respectively. Neither A1-42 nor Protollin, nor their 
combination, produced any significant effects on cell viability (data not shown). 
The incubation with IFN or IL-1+IFN decreased the signal from the MTT assay 
significantly to almost 50% of vehicle starting at 48 h (p < 0.05), and at 72 (p < 0.005) and 96 
h (p < 0.005) (Fig. 9). This effect was seen both when the microglia were stimulated with the 
cytokines alone and when they were added before A1-42. 
There were no significant differences in the LDH-activity in the medium from any of the 
treatments (not shown). Inspection with microscope, however, showed signs of cell death in 
treatments associated with a significant decrease in MTT signal. 
 
Discussion 
In this study, a human microglial cell line was used to model phagocytosis of A and to 
evaluate the effects of different substances. The ability to analyse the effects of different 
substances with a human microglial cell line, which can be cultured in significant quantities, 
and the cellular reactions to pathological factors, such as A, is a valuable tool in studies of 
human CNS-pathologies. The CHME3 cell line was established by Prof. M. Tardieu [37]. 
This cell line responds to stimulation with LPS by increased secretion of IL-6 [38], a cytokine 
also secreted under basal conditions. We have found that CHME3 microglial cells also secrete 
low, but detectable, levels of IL-1 and TNF as well as other cytokines (unpublished 
observations). 
Phagocytosis of A1-42 was established using fluorophore-labelled A1-42.  The uptake was 
first detectable at 4 h after the addition as seen by microscopical analysis of living cells. 
Phagocytosis of A1-42 was differentiated from unspecific adherence to cell membranes by 
confocal microscopy which confirmed the lysosomal location of A1-42. In terms of 
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inflammatory response, the incubation with A1-42 at the concentration used (1 µg/ml) did not 
affect the basal secretion of IL-6, in accordance with studies on primary human embryonic 
microglia in which A1-42 failed to increase transcription of the IL-6 gene and A25-35 had no 
effect on IL-6 secretion [39]. Similarly, the secretion of IL-6 from rat microglial cells was not 
altered upon incubation with 75 µM A1-42, a concentration 150-fold the concentration used 
in this study [18]. In contrast, primary mouse microglia have been shown to respond with 
markedly increased IL-6 secretion upon stimulation with A1-42 in a concentration similar to 
that in the present study [40], indicating a species difference. In our previous studies on the 
CHME3 microglia a marked increase in the secreted levels of IL-6 could be seen upon 
incubation with A1-40 [38], suggesting a difference in the immune-activating properties of 
the two forms of A.  
We show here that the human microglial cell line produces and secretes BDNF, in agreement 
with studies on human post mortem tissue [41]. Studies in different injury models in animals 
have shown the induction of BDNF production in microglia [42], supporting a view of BDNF 
as a glial response to neuronal injury serving to help neurons to recover. In this context it is 
remarkable that the incubation with A1-42 reduced the secretion of BDNF, which to our 
knowledge is the first time A1-42 has been shown to exert this effect on any cell type. This 
adds to the negative effects of A1-42 and indicates a further reason for limiting the 
amyloidosis in AD. Evidence for detrimental interference by A1-42 on BDNF signalling in 
neurons has been provided previously [43]. A reduced secretion and an impaired signalling of 
BDNF may contribute to the cell death and impaired neuronal function in AD. In fact, 
decreased levels of BDNF have been observed in the CSF of AD patients, and at later stages 
of the disease this reduction correlated with the severity of impairment [44]. 
Interestingly, a marked decrease in basal BDNF secretion was observed also upon incubation 
of the microglial cells with IFN, an effect that was also observed upon co-incubation with 
IL-1 In contrast, studies on rodent microglia showed an increase in the levels of BDNF in 
association with induction of inflammation [42], again suggesting species differences in 
microglial responses. Furthermore, studies on rat astrocytes indicated a stimulating effect on 
BDNF production by TNF mediated by NFB [45]. In this study IL-1, which is also 
known to activate NFB [46], caused a mild inhibitory effect on BDNF secretion at 96 h. 
To analyse the possibility to stimulate the phagocytosis of A1-42, we analysed the effects of 
different immunomodulatory substances. Pretreatment of the human microglial cells with 
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IFN, alone or together with IL-1, resulted in a significant increase in the proportion of cells 
with an uptake of A1-42. This was accompanied by a pronounced reduction in BDNF 
secretion, as well as decreased cell viability. The results indicate that pro-inflammatory 
factors may be able to stimulate A1-42 phagocytosis. However, the stimulation by IFN was 
seen in the later time points and it may be speculated that the acute inflammation at the start 
of the experiment had expired at this stage with presumably only low levels of the added 
cytokines still present in the medium. The effects observed may thus be due to factors 
induced by, and secondary to IFN. The effect of long-term, chronic exposure to 
inflammatory stimulation may be different. The influence of inflammation on A1-42 
phagocytosis and clearance is a complex matter, where factors such as age and species may be 
pivotal. Even more complexity is added by the effects of A1-42 itself on inflammation, 
including the findings that the 40 and 42 amino acid peptides, and the aggregational form of 
A1-42 (monomers, oligomers, protofibrils, etc), induces different inflammatory responses as 
seen in studies on rat microglia [18]. Furthermore, the shorter and longer species of A1-42 
have not been characterized with regard to their influence on glia. In the present study we 
prepared A1-42 by dissolving the lyophilized peptide in pure DMSO, and therefore it is 
reasonable to assume that soluble monomers or oligomers dominate at the start of the 
experiments. Interestingly, we could not detect any significant difference in the proportion of 
A1-42+ cells with time (data not shown). Factors influencing this proportion may be the rate 
of phagocytosis, degradation of the peptide, or changes in cell number. Our data show an 
ongoing cell proliferation continuing to the end of the experiment. This fact, taken together 
with a stable A1-42+ cell proportion with time suggest that phagocytosis is continuous. An 
exception was seen upon treatment with IFN in which the A1-42+ proportion increased 
significantly simultaneous with a reduction in cell viability.  
 
Protollin, a proteosome-based adjuvant with immunomodulatory activities, was found to 
modestly increase A1-42 uptake by the human CHME3 microglia at 96 h after addition of 
A1-42, but not at the earlier time points and only at the lowest concentration tested (0.001 
µg/ml). This potentially stimulatory effect of Protollin on A1-42 uptake is concordant with 
results from in vivo studies on Protollin in an AD mouse model [34], showing clearance of 
amyloid plaques and improved cognitive performance upon intranasal administration of 
Protollin. The limited effect of Protollin in the present in vitro experiments as compared to the 
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in vivo studies may have several explanations. In the mouse in vivo model, the stimulatory 
effect of Protollin on A-uptake appears to be mediated via activation of monocytes in the 
periphery that migrate to the brain and phagocytose Arather than direct activation of 
microglial cells resident in the brain [34]. Also, there was no evidence from the in vivo studies 
that Protollin translocates to the brain following nasal administration [34].  The modest 
stimulatory effect of Protollin on A1-42 uptake by microglial cells in the present study may 
reflect the absence of accessory cells in the in vitro cultures, i.e. cells that Protollin directly 
activates in the periphery in vivo. Alternatively, considering that the effect of Protollin did not 
become apparent until the later part of the experiment, it may also be speculated that 
activation of microglial cell precursors by Protollin in the periphery results in the secretion of 
factors in a para/autocrine fashion, that with time build up to concentrations that stimulate 
phagocytosis. Species differences should also be considered. The response repertoire of glial 
cells appear to be different in human as compared with murine cells [47] [48].  
Interestingly, the pretreatment with Protollin appeared to ameliorate the A1-42-induced 
decrease in BDNF secretion. This highlights a therapeutic target: stimulation of glial cells for 
the production of beneficial and neuroprotective molecules. As indicated above, beneficial 
effects of Protollin in the context of immunotherapy may be elicited through stimulation of 
peripheral monocytes [34], directly, or indirectly through interaction with other 
immunocompetent cells. The present data, e.g. on BDNF, suggest that Protollin or similarly 
acting substances may also stimulate beneficial effects on glial cells within the brain. 
To our knowledge, no studies on human cells have until now investigated the effects of TLR2 
activation on BDNF secretion.  
Analysis with flow-cytometry showed that cells displaying phagocytosis of A1-42 had a 
significantly higher degree of expression of IL-1RI and iNOS, indicating that phagocytosis of 
A1-42 was associated with an inflammatory phenotype. Similarly, in a mouse AD-model, the 
expression of CD11b, a microglial activation marker that has been used as an indicator of 
harmful inflammation in several studies, was associated with removal of A [34]. 
 
We also observed a strong negative correlation between the A1-42+ cell proportion and the 
levels of BDNF. This result can be due to a negative effect on phagocytosis by BDNF or a 
decrease in BDNF secretion by cells performing phagocytosis. In a previous study BDNF was 
found to stimulate phagocytosis [49]. Although the experiments were performed on mouse 
19 
 
peritoneal macrophages the results support the latter explanation for the negative correlation 
between BDNF levels and phagocytosis. 
Protollin appeared to decrease the proportion of iNOS+ cells displaying phagocytosis of A1-
42, although the total number of iNOS+ cells remained unchanged. This proportion was 
significantly higher at all time points when incubated with A1-42 alone. At 96 h, the pre-
treatment with Protollin abolished this difference. A reduction in the levels of iNOS is 
beneficial due to the contribution of this enzyme to oxidative stress, supporting beneficial 
effects of Protollin. 
The decrease in cell viability accompanying the induction of A phagocytosis by IFN and 
IL-1 suggests microglial cell death. This was confirmed by microscopical inspection of the 
cultures. In spite of this, there was no detectable increase in the LDH-activity. However, a 
decrease in cell number as indicated by the MTT-assay could mask an increase in cell death 
as measured by the LDH-assay since fewer cells are available to release LDH into the 
medium. IFN has been shown to induce cell death in murine microglia, concomittant with an 
upregulation of the expression of Fas and FasL [50]. In addition, IL-1 and IFN are known 
to be involved in the expression and activation of iNOS [51,52], which in turn may lead to 
oxidative stress. 
 
In conclusion, we provide a model suitable for testing candidates for stimulating the 
phagocytosis of A1-42 by human microglial cells. The capacity to withstand serum-
withdrawal for long periods of time and the high rate of proliferation makes the human 
CHME3 cell line suitable for this type of studies. Expanding primary cultures of microglia for 
large experimental series is not trivial. The data presented indicate differences between 
human microglial cells and murine glia, as described in other studies. In the present study, we 
show that the immunomodulatory substance Protollin affects the proportion of cells 
phagocytosing A and their expression of inflammatory markers. Pretreatment with IFN had 
a robust stimulatory effect on phagocytosis of A1-42 at later time points, suggesting influence 
of secondary factors induced by this cytokine. In addition, we present data suggesting a 
neuropathological role for IFN by decreasing BDNF levels. Importantly, we show a strong 
negative effect of A1-42 on BDNF secretion. The presumed decrease in secretion of BDNF 
from phagocytic cells, indicated by the negative correlation between phagocytosis and BDNF, 
suggests an interesting parameter for future evaluation of potential drugs. The results present 
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a scenario in which inflammation increases phagocytosis of A1-42, induces microglial cell 
death and reduces secretion of BDNF. This reduction is unwanted, since it deprives the brain 
of an important neuroprotective and plasticity-promoting factor. Considering the presence of 
inflammation in AD, it may be suggested that the combined effect of A, IL-1 and IFN on 
the secretion of BDNF from microglia may contribute to the neuronal pathology in AD. We 
hope that this and future studies can help develop directed and controlled activation of 
differential pro- and anti-inflammatory responses for therapeutic use. 
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Figure Legends 
 
Fig. 1 A – B. Uptake of A1-42 in human microglial cells. The micrographs in A show living 
human CHME3 microglial cells in culture after incubation with A1-42, seen by phase contrast 
and fluorescence microscopy, and after merging of these. The micrographs in B show fixed 
CHME3 microglial cells in suspension after incubation with A1-42, seen by fluorescence 
microscopy with filters for propidium iodide (PI) staining and HiLyte488-conjugated A1-42, 
respctively, and the micrographs are merged in the 3
rd
 micrograph. Magnifications 10X (A) 
and 40X (B).  
 
Fig. 2. Uptake of A1-42 in human microglial cells. The confocal micrograph (63X) shows 
fixed CHME3 microglial cells demonstrating intracellular lysosomal location of HiLyte488-
conjugated A1-42 (green filter). Lysosomes were visualized by staining with an antibody 
against lysosome-associated membrane protein-2 (lamp-2) and Cy3-conjugated secondary 
antibodies (red filter). Yellow colour thus indicates colocalization of lamp-2 and HiLyte488-
conjugated A1-42. 
 
Fig. 3A - B. Uptake of A1-42 (A) and the concurrent secretion of interleukin-6 (IL-6) and 
brain-derived neurotrophic factor (BDNF) (B) by human CHME3 microglial cells at 24 and 
96 h. The cells were incubated with concentrations of A1-42, ranging between 0.1 and 5 
µg/ml, or vehicle. The cells were harvested and the medium collected at 24 and 96 h. In A, 
the data are expressed as the proportion of cells with intracellular A1-42. n = 4. In B, the data 
are expressed as % of control (vehicle) set at 100% and shown as median ± percentiles (25% - 
75% and 10% - 90%). There was a significant effect of the treatment on the uptake of A1-42 
at 24 h (p = 0.0045) and at 96 h (p = 0.0375). The secretion of BDNF was also significantly 
altered by the treatment at 24 h (p = 0.0102) and at 96 h (p = 0.0375). Statistical difference 
from A1-42, 5 g/ml, is indicated by ¤¤ (p < 0.01), statistical difference from vehicle is 
indicated by ** (p < 0.01). 
 
Fig. 4. Effects of Protollin (white boxes) and, interleukin-1 (IL-1) and interferon- (IFN) 
(grey boxes) on the uptake of A1-42 in human CHME3 microglial cells. The cells were 
incubated with 1 µg/ml A1-42 following pre-stimulation for 24 h with  Protollin at 0.001 – 1 
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µg/ml, or  50 ng/ml IL-1 and 50 ng/ml IFN. The cells were harvested at 24, 48, 72 and 96 h 
after addition of A1-42. The data are expressed as % uptake of control A1-42 set at 100%, and 
shown as median ± percentiles (25% - 75% and 10% - 90%). n = 19 (Protollin) or n = 4 
(cytokines) for 24 and 48 h, n = 17 (Protollin) of n = 6 (cytokines) for 72 and 96 h. A 
statistically significant effect of treatment was found by Kruskal-Wallis ANOVA at 96 h 
when incubating microglia with Protollin (p = 0.0157) and at 72 h when incubating with IL-
1 and/or IFN(p = 0.0022). Statistical difference from control is indicated by # (p < 0.05), 
## (p < 0.01) and ### (p < 0.005). † indicates statistical difference (p < 0.01) between IL-1 
and IL-1+IFN. 
 
Fig. 5A - B. Effects of incubation with interleukin-1 (IL-1) and interferon- (IFN), added 
24 h before incubation with 1 µg/ml A1-42 (black boxes) HiLyte488-conjugated A1-42 or 
vehicle (white boxes), on secreted levels of IL-6 (A) and BDNF (B) from CHME3 microglial 
cells. The cells were incubated with 1 µg/ml HiLyte488-conjugated A1-42 following pre-
stimulation for 24 h with  50 ng/ml IL-1 and 50 ng/ml IFN. The cells were harvested at 24, 
48, 72 and 96 h after addition of A1-42. The data are expressed as % uptake of control vehicle 
set at 100%, and shown as median ± percentiles (25% - 75% and 10% - 90%). n = 4 for 24 h 
and 48 h and n = 6 for 72 and 96 h. A statistically significant effect of treatment was found by 
Kruskal-Wallis ANOVA at 24 h (p = 0.0087), at 72 h (p = 0.004) and at 96 h (p = 0.004). 
Statistical difference from control is indicated by ** (p < 0.01), difference from A1-42 # is 
indicated by (p < 0.05) and ## (p < 0.01). † indicates statistical difference (p < 0.05) between 
IL-1 and IL-1+IFN. 
 
Fig. 6. Uptake of A1-42 and expression of cellular markers in human microglial cells. The 
micrographs show human CHME3 microglial cells after incubation in culture with 
biotinylated A1-42, after which they were fixed and stained with antibodies against 
interleukin-1 (IL-1), IL-1 receptor type I (IL-1RI) and inducible nitric oxide synthase 
(iNOS), and subsequent incubation with Cy2-conjugated secondary antibodies. Cell nuclei 
were stained with propidium iodide (PI) and the biotinylated A1-42 was visualized with 
AMCA-conjugated streptavidin. All micrographs are in 20X magnification. 
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Fig. 7A - C. Differential phenotype of human CHME3 microglia, in the populations of cells 
displaying (A1-42+, grey boxes) or not displaying (A1-42-, white boxes) phagocytosis of A1-
42, with regard to immunoreactivity for interleukin-1 (IL-1), inducible nitric oxide synthase 
(iNOS) and IL-1 receptor type I (IL-1RI), following pretreatment with Protollin (0.001 – 1 
µg/ml). After 24 – 96 h of exposure to A1-42, the cells were subjected to 
immunocytochemistry and analysed by flow-cytometry. The population of cells with 
immunoreactivity to the different markers within the A1-42+ cell population was compared 
with the corresponding population in the A1-42- cell population in each treatment group, 
using the Wilcoxon Matched Pairs Test. The data are shown as median ± percentiles (25% - 
75% and 10% - 90%), n =7. Statistical differences between the A1-42+ and A1-42- cells with 
regard to each marker are indicated by * (p < 0.05). 
 
Fig. 8. Correlation between the level of BDNF and the proportion of A1-42+ cells. The levels 
of BDNF (pg/ml) and the proportion of A1-42+ cells in the Protollin series of experiments 
were analysed at each time point using the Spearmen Rank Order Correlations test. A 
significant negative correlation was found at all time points. A statistical significant 
correlation is indicated by * (p < 0.05). 
 
Fig. 9. . Effects of interleukin-1 (IL-1) and interferon- (IFN) on cell viability in human 
CHME3 microglial cells treated with A1-42 (grey boxes) or vehicle (white boxes). The cells 
were pre-incubated with 50 ng/ml IL-1 and 50 ng/ml IFN for 24 h prior to addition of A1-
42 (1 µg/ml). At 24, 48, 72 and 96 h after addition of A1-42 the viability of the cultures were 
assessed with the MTT assay. The data are expressed as % of control (vehicle) set at 100%, 
and shown as median ± percentiles (25% - 75% and 10% - 90%). n = 4 (24, 48 h), n = 6 (72, 
96 h). Statistical difference from vehicle is indicated by * (p < 0.05), and *** (p < 0.005), and 
statistical difference from A1-42 is indicated by # (p < 0.05) and ## (p < 0.01). łł (p < 0.01) 
indicates statistical difference between IFN and IL-1+IFN, and † (p < 0.05) and ††† (p < 
0.05) indicate differences between IL-1 and IL-1+IFN. 
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inflammatory markers in plasma, nor was there any relation 
with  APOE . A significant correlation was observed at baseline 
between sIL-1RII and A  1–42 levels in CSF.  Conclusions: Treat-
ment of AD patients with   -3 FAs for 6 months did not influ-
ence inflammatory or biomarkers in CSF or plasma. The cor-
relation between sIL-1RII and A  1–42 may reflect the reciprocal 
interactions between IL-1 and A  peptides.  
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Abundant evidence indicates that inflammatory pro-
cesses are active in Alzheimer’s disease (AD). Epidemio-
logical surveys suggest a lower prevalence of AD in sub-
jects treated with non-steroidal anti-inflammatory drugs 
(NSAIDs), but clinical trials have yielded limited effects 
 [1, 2] . A central event in AD is the activation of microglia 
by different factors, including   -amyloid (A  ) and pro-
inflammatory cytokines  [3, 4] . Microglia release cyto-
kines, e.g. interleukin (IL)-1  , IL-6, and tumour necrosis 
factor-  (TNF-  ), which may lead to neuronal dysfunc-
tion  [5, 6] . Previous studies of inflammatory biomarkers 
in peripheral blood of AD patients have yielded inconclu-
sive results. Serum as well as cerebrospinal fluid (CSF) 
 Key Words 
 Alzheimer’s disease   Inflammation   Cerebrospinal fluid   
  -3 fatty acids   Cytokines 
 Abstract 
 Background:   -3 fatty acids (  -3 FAs) found in dietary fish or 
fish oils are anti-inflammatory agents that may influence
Alzheimer’s disease (AD).  Objective: To study the effects of 
dietary   -3 FA supplementation on inflammatory markers in 
cerebrospinal fluid (CSF) and plasma from patients with mild 
to moderate AD.  Methods: Thirty-five patients (70.3  8 8.2 
years) were randomized to a daily intake of 2.3 g   -3 FAs or 
placebo for 6 months. The inflammatory markers interleukin 
(IL)-6, tumour necrosis factor-  and soluble interleukin-1 re-
ceptor type II (sIL-1RII) were analysed in CSF and plasma at 
baseline and at 6 months. The AD markers tau-protein, hyper-
phosphorylated tau-protein and   -amyloid (A  1–42 ) were as-
sessed in CSF. High-sensitivity C-reactive protein was assessed 
in plasma. A possible relation to the  APOE  genotype was in-
vestigated.  Results: There was no significant treatment effect 
of   -3 FAs on inflammatory and AD biomarkers in CSF or on 
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levels of soluble IL-6 receptor and TNF-  have been re-
ported to be decreased, unchanged or increased  [7, 8] . In 
patients with elevated TNF-   levels, cytokine-inactivat-
ing therapies are ongoing  [9] .
 Neuronal cell membranes and synapses are enriched 
with polyunsaturated fatty acids such as the   -3 fatty acid 
(  -3 FA) docosahexaenoic acid (DHA). Synapse loss cor-
relates with cognitive decline in AD, and synaptic func-
tion is affected by A   [10] . Fatty fish is the major dietary 
source of DHA. Epidemiological data imply that in-
creased intake of fish or DHA can reduce the risk of de-
veloping AD  [11, 12] . Animal data are also in line with 
these findings  [13] . Interestingly, the DHA levels in se-
rum and brain have been found to be lower in AD patients 
than in controls  [14, 15] . DHA and eicosapentaenoic acid 
(EPA) are FAs found in the brain, incorporated as struc-
tural components of neural membrane glycerophospho-
lipids, and are substrates for generating lipid mediators. 
The incorporation and proportions of   -3 and   -6 FAs 
markedly influence neural membrane properties such as 
fluidity and permeability, and gene expression. Oxygen-
ation of   -6 FAs generates pro-inflammatory mediators 
whereas actions of 15-lipoxygenase-like enzymes on 
DHA generate anti-inflammatory mediators.
 These second messengers, the docosanoids, are potent 
endogenous anti-inflammatory and pro-resolving chem-
ical lipid mediators  [16] . Thus, growing evidence suggests 
that the generation of   -3 FA metabolites may be an in-
ternal anti-inflammatory protective mechanism for pre-
venting brain damage in neurodegenerative diseases  [17–
20] . DHA and EPA reduce chronic inflammation by at-
tenuating NF-  B, in turn modulating the expression of 
pro-inflammatory cytokines including TNF-  and IL-
1  and   . The intake of DHA and EPA reduces the syn-
thesis of eicosanoids. How DHA and EPA decrease the 
activation of NF-  B is not clear at present. However, these 
FAs may decrease the phosphorylation of I  B, thereby 
modulating the availability of NF-  B. This process can 
modulate the expression of the pro-inflammatory genes 
for COX-2, intracellular adhesion molecule-1, vascular 
adhesion molecule-1, E-selectin, TNF-  , IL-  , IL-6, ni-
tric oxide synthetase, and matrix metalloproteinases  [21] . 
Collective evidence suggests that   -3 FAs are associated 
with cognitive development, memory-related learning, 
neural membrane plasticity, synaptogenesis, and synap-
tic transmission, and suppress the production of pro-in-
flammatory cytokines such as TNF-  , IL-1, IL-2, and IL-
6  [20] .
 This provides us with an opportunity to use DHA as 
a nutraceutical or pharmaceutical tool in brain disorders 
such as AD  [22] . The majority of the published epidemio-
logical studies are consistent with a positive association 
between reported high DHA consumption or high DHA 
blood levels and a lower risk of developing AD later in life 
 [15] . Such observations have prompted analysis of the ef-
fects of DHA in transgenic animal models of AD, show-
ing that DHA exerts a beneficial effect against A  accu-
mulation, cognitive impairment, synaptic marker loss, 
and hyperphosphorylation of tau  [13] . Multiple mecha-
nisms of action can be associated with the neuroprotec-
tive effects of DHA and include antioxidant properties 
and activation of distinct cell-signalling pathways  [18] . 
Inflammation is a component of a range of acute and 
chronic human diseases, and is characterized by the pro-
duction of inflammatory cytokines, arachidonic-acid-
derived eicosanoids, other inflammatory mediators (e.g. 
platelet-activating factor) and adhesion molecules.   -3 
polyunsaturated FAs  decrease the production of inflam-
matory mediators and the expression of adhesion mole-
cules. They act both directly (e.g. by replacing arachidon-
ic acid as an eicosanoid substrate and inhibiting arachi-
donic acid metabolism) and indirectly (e.g. by altering
the expression of inflammatory genes through effects on 
transcription factor activation). Thus,   -3 FAs could be 
potent anti-inflammatory agents. As such, they have been 
proposed as therapeutic agents for AD  [22, 23] .
 In a recently performed randomized placebo-con-
trolled trial, the OmegAD Trial, 174 patients with mild to 
moderate AD received either treatment with the   -3 FA 
preparation or placebo for 6 months, followed by 6 months 
with   -3 FA treatment in both groups. The trial was pow-
er calculated to detect statistical differences on cognition 
using the cognitive portion of the Alzheimer Disease As-
sessment Scale (ADAS-Cog)  [24] and the Mini Mental 
Test Examination (MMSE)  [25] . Administration of 2.3 g 
  -3 FAs (1.7 g DHA and 0.6 g EPA) did not delay the rate 
of cognitive decline according to the MMSE or the ADAS-
Cog  [26] , nor was there any effect on neuropsychiatric 
symptoms  [27] . However, in a small group (n = 32) of pa-
tients with very mild AD (MMSE  1 27), the cognitive de-
cline was postponed  [26] .
 In the present report of the OmegAD Trial, we have 
studied whether supplementation of AD patients with   -
3 FAs affects the levels of inflammatory markers in CSF 
and plasma. The possible relation to  APOE  genotype was 
also investigated. Since high concentrations of high-sen-
sitivity C-reactive protein (hs-CRP) have been proposed 
as a predictor of cognitive decline and dementia  [28] , we 
also analysed the plasma levels of this inflammatory 
marker.
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 Material and Methods 
 Subjects and Study Design 
 This study was part of a larger randomized, double-blind pla-
cebo-controlled trial conducted between December 13, 2000, and 
March 25, 2004, in which 204 patients were enrolled  [26, 27] . The 
Ethical Committee at Karolinska University Hospital approved 
the study protocol. Before entering the study, both the patients 
and knowledgeable informants (most often caregiver) signed an 
informed consent. The inclusion criteria required that the pa-
tients had a diagnosis of AD according to the DSM-IV criteria 
 [29] , had an MMSE  [25] score between 15 and 30, were living in 
their own home, and had been treated with a stable dose of ace-
tylcholine esterase inhibitors (AChEIs) for at least 3 months be-
fore the study start. Patients were excluded if treated with NSAIDs 
(low-dose acetylsalicylic acid was accepted),   -3 FA preparations, 
anticoagulation agents, or if they abused alcohol, suffered from a 
concomitant serious disease, or did not have a caregiver. The pa-
tients were randomized in blocks of four in sealed envelopes to 
receive four 1-gram capsules daily, each containing either 430 mg 
DHA (22: 6   -3 FA) and 150 mg EPA (20: 5   -3 FA), i.e. EPAX
1050TG (Pronova Biocare A/S, Lysaker, Norway), or an isocaloric 
placebo oil (containing 1 g of corn oil, including 0.6 g of linoleic 
acid, here denoted placebo) for 6 months. EPAX1050TG is a 60% 
  -3 FA concentrate in triglyceride form produced according to 
Good Manufacturing Practice. Four milligrams of vitamin E (to-
coferol) was added to each capsule. The reason for choosing a 
DHA-enriched compound was that a significant reduction in to-
tal A  by 70% compared to control chow diets was found in ani-
mal studies  [13] , and that patients with AD have lower levels of 
DHA in their brains  [14] .
 Patients in the OmegAD Trial underwent the following evalu-
ations: routine blood and urine sampling, assessment of blood 
pressure, body mass index (BMI), and cognitive function using 
the MMSE and the modified ADAS-Cog  [24] , neuropsychiatric 
evaluation using the Neuropsychiatric Inventory (NPI)  [30] and 
evaluation of depression using the Montgomery and Asberg De-
pression Rating Scale  [31] . Due to ethical considerations, approv-
al for 40 patients to undergo lumbar puncture (LP) was given by 
the ethical committee. According to the study protocol, the first 
consecutive 40 patients enrolled in the study were asked to un-
dergo LP at baseline and after 6 months. Two patients (from the 
  -3 FA group) did not want to perform LP and 2 patients (from 
the placebo group) dropped out within the first 12 weeks due to 
stomach pain and headache ( fig. 1 ). Data from 1 patient were ex-
cluded due to extreme values and thus the final analysis was based 
on 35 patients.
 Blood samples for analysis of serum FA levels were obtained 
to assess compliance with the   -3 FA therapy. The data on   -3
FA levels all included 204 patients and were presented by Freund-
Levi et al.  [26] .
 The primary efficacy variables for the OmegAD Trial were 
cognitive functions assessed by MMSE and ADAS-Cog. Second-
ary outcomes were safety and tolerability assessed by the Clinical 
Dementia Rating Scale global and summary of boxes  [26] .
Assessed for eligibility (n = 361)
204 AD patients randomized
to -3 FAs or placebo
103 randomized to -3 FAs 101 randomized to placebo
20 randomized to -3 FAs,
planned for LP at baseline
20 randomized to placebo,
planned for LP at baseline
18 randomized to -3 FAs,
had LP at baseline
20 randomized to placebo,
had LP at baseline
18 treated with -3 FAs,
had LP after 6 months
18 treated with placebo,
had LP after 6 months
Excluded (n = 157) – not meeting
inclusion criteria for AD
2 dropouts
2 refused LP
at baseline
 Fig. 1. Patient flow chart. 
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 This paper is based on CSF and plasma data from 35 patients 
at baseline and after 6 months treatment with   -3 FAs or placebo 
( fig. 1 ).
 Sample Collection and Analysis of CSF and Plasma 
 Blood, plasma and CSF samples from the 35 patients were col-
lected at baseline and at 6 months. The LP was performed in a 
standardized manner with all patients in a sitting position be-
tween 11 a.m. and 1 p.m.; the tap was performed with a non-trau-
matic cannula placed in the intervertebral space L3/L4 or L4/L5. 
Five millilitres of CSF were collected in sterile polypropylene 
tubes and put on ice and centrifuged according to standard rou-
tine at 3,000 rpm for 10 min at 4 ° C. The supernatants were ali-
quoted and stored at –70 ° C until analysis.
 Plasma samples were obtained by venous puncture and col-
lected in 1.25-ml Na-heparin tubes and centrifuged according to 
the standard procedure at 3,000 rpm for 10 min at 4 ° C and the 
supernatants were aliquoted and kept at –70 ° C until analysis.
 The levels of IL-6, TNF-  , and soluble interleukin-1 receptor 
type II (sIL-1RII) were analysed in CSF and plasma samples by 
enzyme-linked immunosorbent assay (ELISA) using commer-
cially available kits (R&D Systems, Abingdon, UK). The detection 
range was 0.16–10 pg/ml for IL-6 and 31.3–2,000 pg/ml for sIL-
1RII in both plasma and CSF. For TNF-  , the lowest detectable 
range was 0.038–0.191 pg/ml in CSF samples and 15.6–1,000 pg/
ml in plasma samples. The levels of hs-CRP in plasma were anal-
ysed using a commercially available kit from LX 20 (Beckman AB, 
Bromma, Sweden) and performed at the Department of Clinical 
Chemistry, Karolinska University Hospital. A near-infrared im-
munoassay rate method based on the binding of an anti-CRP an-
tibody-coated particle that binds to CRP in the presence of a pa-
tient sample was used. The detection range was 0.2–380 mg/l.
 Frozen CSF samples were sent on dry ice to the Clinical Neu-
rochemistry Laboratory, Mölndals Lasarett, Gothenburg, Swe-
den, for analysis of A  1–42 , and tau protein (T-tau). The total lev-
els of CSF T-tau were determined using a sandwich ELISA con-
structed to detect both normal and hyperphosphorylated tau 
(P-tau)  [32] . CSF P-tau levels were determined using a sandwich 
ELISA, constructed to specifically detect tau phosphorylated at 
Thr181  [33] . The levels of A  1–42 were analyzed in CSF samples 
using a sandwich ELISA, constructed to specifically measure 
A  1–42  [34] .
 Serum samples for assessment of serum FA levels were anal-
ysed by gas chromatography (TR-Fame column, 30 m ! 0.32 mm 
ID  ! 0.25   m film gas chromatography column; Thermo Elec-
tron Corp., Waltham, Mass., USA). For details of the analysis and 
the full results, see Freund-Levi et al.  [26]  and Boberg et al. [35] .
 Patient DNA samples for  APOE  genotype analysis were ex-
tracted from peripheral white blood cells using standard methods 
 [36] and the  APOE  genotype was determined by a microsequenc-
ing method on microtiter plates (AffiGene ApoE; Sangtec Medi-
cal, Bromma, Sweden).
 Statistical Analysis 
 Data are presented as mean and 95% confidence interval (CI) 
or standard deviation (SD). Between- and within-group analyses 
of skewed variables were performed by the Mann-Whitney U test. 
Due to missing data at baseline or after 6 months, the effects of 
  -3 FA and time on the levels of IL-6, sIL-1RII, TNF-  , P-tau, T-
tau and A  1–42, were analysed using linear mixed-effect models. 
In all models, gender, age,  APOE , NPI, ADAS-Cog, BMI, treat-
ment group, time and the interaction between treatment and time 
were controlled for. The outcome variables, IL-6, sIL-1RII, TNF-
  , and T-tau, were positively skewed, or expressed heterogeneous 
variance and therefore a logarithmic scale was used. In  table 2 , the 
results from the analysis of the skewed variables have been back-
transformed. In this case, the data are expressed in relative values 
rather than absolute values; hence the results from these analyses 
are presented in percentages (i.e. the ratio between   -3 FA treat-
ment and placebo at 6 months).
 A backward selection was performed to evaluate which vari-
ables to include in the final models. An exclusion criterion of p  1 
0.05 was used. Cook’s distance was used to reveal observations 
with a substantial influence on the results. One such observation 
was found in the analysis of IL-6, P-tau, T-tau and A  1–42 , and was 
excluded from the analysis.
 The statistical analysis was carried out with SPSS (SPSS for 
Windows, Rel. 16.02; SPSS Inc., Chicago, Ill., USA) or the Statis-
tica  7.0 software package (Stat soft, Tulsa, Okla., USA).
 Results 
 Demographic, clinical and cognitive data from the 35 
patients are shown in  table 1 . There was a significant dif-
ference at baseline between the   -3 FA and the placebo 
groups in the ADAS-Cog scores (p = 0.02) and BMI (p = 
0.03). After 6 months of treatment, these differences be-
Table 1. Demographic data at baseline 
-3 FAs
(n = 18)
Placebo
(n = 17)
p
value
Age, years 72.288.8 68.387.3 0.1
Females, n 8 (44%) 6 (30%) 1.0
APOE4, n
0
1
2
4 (22%)
9 (50%)
5 (28%)
2 (12%)
9 (53%)
6 (35%)
Acetyl salicylic acid, n 4 (22%) 2 (10%) 0.3
Systolic blood pressure, mm Hg 143820 134810 0.9
Diastolic blood pressure, mm Hg 7886 7786 0.3
BMI 25.982.2 23.782.9 0.031
MMSE score 24.383.8 23.984.0 0.8
ADAS-Cog score 22.8810.9 29.287.1 0.021
MADRS score 1.782.3 2.283.2 0.9
NPI score 12.388.5 17.7814.3 0.3
MMSE, 0–30 points; ADAS-Cog, 0–85 points; MADRS = Mont-
gomery Åsberg Depression Rating Scale, 0–30 points; NPI, 0–144 
points.
1 Significance of differences between groups using the Mann-
Whitney U test.
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tween the groups did not remain (p = 0.3 for ADAS-Cog 
scores and p = 0.2 for BMI, data not shown). There was 
no significant interaction between age, gender,  APOE , 
MMSE, NPI, ADAS-Cog, treatment or levels of IL-6, 
TNF-  , sIL-1RII or A  1–42 over time (0–6 months) ( ta-
ble 2 ). The plasma levels of EPA, DHA and linoleic oil at 
baseline or 6 months did not affect the levels of IL-6, 
TNF-  , sIL-1RII, A  1–42 , T-tau or P-tau (data not pre-
sented).
 Inflammatory and Dementia Biomarkers in CSF 
 IL-6, TNF-  , and sIL-1RII. The levels of sIL-1RII were 
positively correlated to A  1–42 levels at baseline (r = 0.56; 
p = 0.001,  fig. 2 ) but not after 6 months of treatment. 
 There was no significant difference at baseline or at 6 
months between the   -3 FA and the placebo group with 
regard to CSF levels of IL-6, TNF-  ,  or sIL-1RII ( table 3 ), 
nor was there any significant effect of treatment over time 
between groups ( table 3 ), or within each group, except for 
levels of TNF-  , which significantly decreased in both 
groups over time (p  ! 0.001 within each group).The levels 
of IL-6 were (8%) higher in the   -3 FA group than in the 
placebo group at the 6-month time point although the 
differences did not reach statistical significance.
 A  1–42 , T-tau and P-tau . Strong correlations were 
found between the levels of T-tau and P-tau at baseline
(r = 0.95, p  ! 0.001) and at 6 months (r = 0.96, p  ! 0.001). 
There was no significant difference in A  1–42 , T-tau and 
Table 2. Parameter estimates of log-and non-transformed outcome 
variables using linear mixed effect models. In all models, gender, 
age, APOE, NPI, ADAS-cog, BMI, treatment group, time and the 
interaction between treatment and time were controlled for
Comparison Estimate: 
ratio1 or 
difference2
SE p
value
95% CI
lower
limit
upper
limit
IL-6 plasma1
-3 FA: time 6 vs. 0 26% NA 0.07 –3% 46%
Placebo: time 6 vs. 0 30% NA 0.03 5% 49%
Time 0: -3 vs. placebo 21% NA 0.34 –18% 68%
Time 6: -3 vs. placebo 13% NA 0.54 –24% 31%
IL-6 CSF1
-3 FA: time 6 vs. 0 –2 NA 0.76 –13 9
Placebo: time 6 vs. 0 –11 NA 0.06 –24 0
Time 0: -3 vs. placebo 11 NA 0.37 –13 41
Time 6: -3 vs. placebo 22 NA 0.1 –4 54
sIL-1RII CSF1
-3 FA: time 6 vs. 0 –2 NA 0.79 –15 11
Placebo: time 6 vs. 0 –4 NA 0.53 –11 13
Time 0: -3 vs. placebo –16 NA 0.17 –35 9
Time 6: -3 vs. placebo –14 NA 0.23 –33 49
sIL-1RII plasma1
-3 FA: time 6 vs. 0 3 NA 0.77 –20 22
Placebo: time 6 vs. 0 –3 NA 0.79 –26 16
Time 0: -3 vs. placebo –4 NA 0.76 –15 20
Time 6: -3 vs. placebo 2 NA 0.85 –20 20
TNF- CSF1
Time 0: Placebo vs. -3 –1 NA 0.97 –53 106
Time 6: Placebo vs. -3 –28 NA 0.41 –38 209
-3 FA: time 6 vs. 0 –89 NA    < 0.001 –94.8 –77
Placebo: time 6 vs. 0 –85 NA    < 0.001 –93.1 –67
TNF- Plasma1
Time 0: Placebo vs. -3 –17 NA 0.85 –88 495
Time 6: Placebo vs. -3 27 NA 0.81 –82 805
-3 FA: time 6 vs. 0 14 NA 0.54 –43 35
Placebo: time 6 vs. 0 73 NA 0.02 8 179
T-tau CSF1
-3 FA: time 6 vs. 0 –2.4 NA 0.37 –8.1 3
Placebo: time 6 vs. 0 –5 NA 0.05 –11 1
Time 0: -3 vs. placebo 0 NA 0.99 –27 37
Time 6: -3 vs. placebo 3 NA 0.85 –25 40
APOE 0 vs. 1-2 67 NA 0.02 10 154
P-tau CSF2
-3 FA: time 6 vs. 0 –5.85 3.20 0.08 –12.39 0.70
Placebo: time 6 vs. 0 –7.28 3.06 0.02 –13.52 1.05
Time 0: -3 vs. placebo –1.31 8.40 0.88 –18.3 15.68
Time 6: -3 vs. placebo 0.13 8.31 0.99 –16.70 16.95
APOE 0 vs. 1-2 27.73 11.13 0.02 5.09 50.37
A 1–42  CSF2
-3 FA: time 6 vs. 0 –3.33 14.55 0.82 –41.91 35.24
Placebo: time 6 vs. 0 –2.02 15.29 0.9 –42.45 38.41
Time 0: -3 vs. placebo –37.39 32.40 0.26 –121.77 47.00
Time 6: -3 vs. placebo –36.07 32.06 0.27 –119.68 47.54
1 Ratio between means expressed as percentage. log-transformed out-
come variable. 2 Mean difference between groups. Non-transformed out-
come variable. Time 0 = At baseline; time 6 = at 6 months.
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 Fig. 2. Positive linear relationship between sIL-1RII and A  1–42 in 
CSF at baseline in AD patients (r = 0.56, p = 0.001, n = 33). 
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Table 3. Analysis of inflammatory and dementia biomarkers in CSF in -3 FA and placebo groups at baseline 
and after 6 months follow-up1
Variables Baseline 6 months 0–6 months
p valuemean level p value mean level p value
IL-6, pg/ml
-3 FAs 3.2 (2.6–3.8) 1.0 3.3 (2.7–4.0) 0.3 0.3
Placebo 3.7 (2.3–5.0) 2.7 (2.3–3.1)
sIL-1RII, pg/ml
-3 FAs 80.2 (65.6–94.9) 0.6 79.6 (64.5–94.7) 1.0 1.0
Placebo 85.6 (70.1–101.2) 84.7 (63.0–106.3)
TNF-, pg/ml
-3 FAs 0.98 (0.7–1.2) 1.0 0.25 (0.1–0.4) 0.9 0.7
Placebo 0.96 (0.8–1.2) 0.18 (0.1–0.3)
A1–42, ng/l
-3 FAs 345.7 (289.1–402.3) 0.4 349.0 (307.8–390.2) 0.4 0.8
Placebo 371.1 (327.1–415.1) 365.3 (325.6–405.1)
T-tau, ng/l
-3 FAs 596.2 (454.1–738.3) 0.5 597.0 (460.6–733.5) 0.9 0.8
Placebo 720.8 (540.9–900.8) 616.9 (532.7–701.1)
P-tau, ng/l
-3 FAs 79.1 (63.2–95.0) 0.4 76.9 (62.5–91.3) 0.9 0.9
Placebo 91.5 (72.4–110.5) 78.3 (68.0–88.7)
95% CIs are shown in parentheses.
1 Significance of difference between the -3 FA and placebo groups and change over time using the Mann-
Whitney U-test.
Table 4. Analysis of plasma biomarkers in -3 FA and placebo groups at baseline and after 6 months follow-
up1
Variables Baseline 6 months 0–6 months
p valuemean level p value mean level p value
IL-6, pg/ml
-3 FAs 1.4 (0.7–2.0) 0.2 1.5 (1.0–1.9) 0.3 0.8
Placebo 0.7 (0.5–1.0) 1.1 (0.7–1.5)
sIL-1RII, pg/ml
-3 FAs 1,591 (1,264–1,917) 0.8 1,771 (1,381–2,163) 0.8 0.3
Placebo 1,624 (1,287–1,961) 1,556 (1,291–1,821)
TNF-, pg/ml
-3 FAs 105.8 (–4.0 to 216) 0.6 110 (–19 to 238) 0.6 1.0
Placebo 103.3 (15.5–191.0) 104.0 (23.5–184.6)
hs-CRP, mg/l
-3 FAs 1.5 (0.5–2.5) 0.6 1.7(0.5–2.9) 0.4 0.4
Placebo 0.9 (0.5–1.2) 1.5 (0.2–2.7)
95% CIs are shown in parentheses.
1 Significance of difference between the -3 FA and placebo groups and change over time using the Mann-
Whitney U-test.
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P-tau levels between the   -3 FA and the placebo group at 
baseline or at 6 months, nor was there any effect of treat-
ment over time ( table 3 ). The T-tau levels at baseline were 
almost twice as high in  APOE  4 carriers (711.1 pg/ml,
n = 29) as compared to non- APOE  4 carriers (394.2 pg/
ml, n = 6, p = 0.03). At baseline, there were also signifi-
cantly higher P-tau levels in  APOE  4 carriers (91.3 pg/ml, 
n = 29) as compared to non- APOE  4 carriers (55.3 pg/ml, 
n = 6, p = 0.03). As there were only 2 non- APOE  4 carri-
ers in the placebo group, it was not possible to evaluate 
interaction with   -3 FA and placebo treatment.
 Inflammatory Biomarkers in Plasma 
 Plasma levels of IL-6, TNF-  , sIL-1RII and hs-CRP 
did not differ significantly either at baseline or after 6 
months between the   -3 FA and placebo group, nor was 
there any significant effect of treatment over time ( ta-
ble 4 ).
 Discussion 
 In the present study, we have analysed CSF and plasma 
levels of IL-6, TNF-  and sIL-1RII as well as the levels of 
T-tau, P-tau and A  1–42 in CSF in patients with mild to 
moderate AD, upon treatment with   -3 FAs for 6 months. 
In addition, the possible relation to  APOE genotype was 
investigated since  APOE  4  is a major risk factor for de-
veloping AD  [37] . Treatment with   -3 FAs resulted in 
null effects on the inflammatory markers in CSF and in 
plasma. Nor was there any effect of treatment on the lev-
els of dementia biomarkers as compared to placebo. In 
cell cultures and animal studies as well as in epidemio-
logical surveys, agents known to decrease inflammation, 
such as vitamins, anti-oxidants,  Gingko biloba and long-
term NSAIDs, have shown protective effects against AD 
pathology or reduced risk for dementia  [38, 39] . Random-
ized controlled clinical trials using these anti-inflamma-
tory agents have, however, failed to show clear positive 
treatment benefits  [1] . Some of the difficulties to perform 
clinical trials on whether anti-inflammatory drugs can 
delay or prevent adverse health events in the field of AD 
can be due to the length of time needed to demonstrate a 
difference with treatment. This has been discussed using 
the Alzheimer’s Disease Anti-inflammatory Prevention 
Trial as an example. Similarly to other treatment trials, 
those targeting AD dementia balance these benefits 
against the risks of treatment. In contrast, the benefit 
seen in prevention trials, if any, will be found only in the 
absence or delay in disease onset, often after years of con-
tinuous treatment. Other difficulties relate to the length 
of prevention trials and dosages  [2] .
 Low intake of   -3 FAs has been found to be a risk fac-
tor for developing dementia  [12] and dietary DHA has 
been shown to reduce amyloid burden in transgenic mice 
 [13] . From animal studies it is also known that   -3 FAs 
exert anti-inflammatory actions such as decreasing ara-
chidonic-acid-derived eicosanoids with pro-inflamma-
tory properties, increasing EPA-derived eicosanoids with 
less pro-inflammatory effects, and increasing the genera-
tion of EPA- and DHA-derived anti-inflammatory re-
solvins. In a mouse model of rheumatoid arthritis, the lev-
els of the inflammatory cytokines TNF-  , IL-1  , IL-6 and 
IL-8 were reduced in response to   -3 FA treatment  [40] .
 Some studies on cytokine levels in clinical samples 
have shown elevated CSF levels of sIL-1RII in mild to 
moderate AD  [41] , and elevated levels of TNF-  in CSF 
and plasma of AD patients  [42, 43] . The CSF levels of sIL-
1RII and IL-6 in the present study confirm our earlier 
findings  [41] and those of Jia et al.  [42] , respectively. The 
range of plasma levels of IL-6 are similar to those found 
by Zuliani et al.  [43] . Recently, plasma levels of IL-1 and 
TNF-  were indicated as strong predictors for develop-
ment of AD  [44] .
 The present data from the OmegAD study did not 
show any effects of   -3 FA treatment on inflammatory 
markers in CSF (sIL-1RII, IL-6, TNF-  ) and plasma (sIL-
1RII, IL-6, TNF-  , hs-CRP). This may be explained by 
the limited number of CSF samples or that there is no 
drug effect. The results can also be due to a factual null 
effect. Similarly, the pretreatment differences concerning 
the scores of ADAS-Cog and BMI can be based on the low 
number of patients selected for LP. Furthermore, the 
treatment with   -3 FA could affect other biomarkers 
than the ones analysed in the present study. However, our 
data are consistent with the lack of effect on cognition 
and neuropsychiatric symptoms previously reported in 
these patients although some positive effects were found 
in subsets of patients  [26, 27] . Thus, the   -3 FA treatment 
was found to postpone cognitive decline in patients with 
very mild AD  [26] . Whether or not the inflammatory 
markers were affected in this subgroup of patients awaits 
further studies, since only very few of these patients were 
among those selected for LP.
 TNF-  levels in CSF were significantly reduced in 
both groups over time, suggesting a methodological in-
fluence rather than a biological effect.
 The significant difference between ADAS-Cog scores 
as well as BMI of the two groups at baseline is cumber-
some since they were strictly randomized in blocks of 
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four. In the OmegADtrial on 174 patients previously re-
ported, the treatment and the placebo groups did no dif-
fer at baseline  [26] . The explanation for this discrepancy 
may be that the significances at baseline reported in this 
paper are due to a chance significance because of the 
smaller sample number.
 All patients in the present study were on standard 
treatment with AChEIs, therefore representing a relevant 
clinical sample of patients with AD. AChEIs have been 
linked to anti-inflammatory properties both in animal 
and human studies, and were shown to reduce the levels 
of cytokines such as IL-6  [45, 46] . In view of this, the con-
comitant treatment with AChEIs in the present study 
may have masked a smaller anti-inflammatory effect of 
the   -3 FAs, and may be one of several explanations for 
the lack of effect on the inflammatory markers observed 
in our AD patients.
 Another explanation may be the dose of   -3 FAs
(2.3 g; 1.7 g DHA + 0.6 g EPA/day) used: a higher dose 
may be needed to attenuate the inflammation. To our 
knowledge, there are two short-term clinical trials of   -3 
FAs in AD patients using doses of 240 mg/day of DHA 
and arachidonic acid  [47] or 0.25 ml   -linoleic acid  [48] , 
and showing improvement in cognition  [47] and quality 
of life  [48] , but these studies did not investigate inflam-
matory markers. Other studies with DHA in the field of 
AD are ongoing  [49] .
 The proportion of DHA and EPA in the   -3 FA sup-
plementation may be of significance since EPA and DHA 
display partly different modes of action. Thus, DHA 
binds to the RXR receptor, enhances membrane fluidity 
and exerts neuroprotection  [17, 21] . Furthermore, the 
brain is rich in DHA, but contains virtually no EPA, sug-
gesting that a higher proportion of DHA as compared to 
EPA may be beneficial in trials on AD patients, even if 
EPA and DHA to some extent can be metabolized to each 
other. Although many studies have studied the effects of 
mainly EPA-rich fish oils on inflammatory reactions, few 
have investigated the effects of mainly DHA-rich fish oils. 
Effects of   -3 FA treatment on the levels of A  1–42 , T-tau 
and P-tau in CSF from AD patients have so far not been 
studied. A 6-month   -3 FA treatment with the doses used 
here did not affect these dementia biomarkers. The stabil-
ity of the biomarkers over time is not fully clear although 
several studies have shown unchanged levels for at least 1 
year in patients with AD  [50] while in patients with mild 
cognitive impairment who convert to AD, P-tau has been 
found to increase over time  [51] . Since the treatment du-
ration here was only 6 months, the AD biomarkers in the 
placebo group did not, as expected, change.
 Analyses of the inflammatory markers and dementia 
biomarkers in relation to the  APOE  genotype did not re-
veal a significant association, but the treatment and pla-
cebo groups as well as the number of non- APOE 4 carri-
ers may have been too small to detect such correlations.
 Correlation analysis between inflammatory markers 
and the AD biomarkers showed a positive correlation at 
baseline between sIL-1RII and A  1–42 in the CSF. A re-
lated finding was seen in transgenic mice, in which a 
strong correlation was observed between the brain levels 
of A  1–42 and the cytokines IL-1  and IL-1   [52] . Such a 
correlation was also seen with regard to the levels of
IL-1  , IL-6 and TNF-  in normal mouse brains  [52] . The 
levels of  sIL-1RII in CSF were shown to be elevated in a 
group of patients with mild to moderate AD  [41] , whereas 
no significant difference was seen in patients with mild 
cognitive impairment, nor at later stages of the disease 
 [53] . Since sIL-1RII binds to IL-1  and acts as a ‘sink’ for 
IL-1  , the increase in sIL-1RII shedding may be an at-
tempt to limit negative effects of IL-1  expression and ac-
tivity in the brain  [54] . Interestingly, after 6 months
of treatment with   -3 FAs or placebo, the sIL-1RII and 
A  1–42 correlation found at baseline had disappeared. 
However, a higher number of patients in each group may 
be required to see a differential effect between   -3 FAs 
and placebo. Further research is needed to clarify the pos-
sible link between sIL-1RII and amyloid in CSF in AD.
 For future research, long-term randomized placebo-
controlled studies of different dosages of DHA in patients 
with mild cognitive impairment and pre-AD including 
analyses of inflammatory markers in CSF and plasma are 
warranted.
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Abstract 
Omega-3 fatty acids have been suggested to have beneficial effects on patients suffering from 
Alzheimer’s disease (AD). With the aim to better understand the effects of the omega-3 fatty 
acid docosahexanoic acid (DHA) on neuroinflammation related to AD, human CHME3 
microglia were incubated with DHA, alone or together with A 1-42 or latex beads. The 
influence of inflammation induced by IL-1  was also investigated. It was found that DHA 
could stimulate phagocytosis of A 1-42 but not latex beads. Furthemore, DHA was shown to 
decrease the secretion of several TH1 and TH2 cytokines. DHA at high concentrations also 
reduced the levels of brain-derived neurotrophic factor (BDNF). High concentrations of DHA 
also reduced microglial viability. Analysis of phagocytic cells suggested that phagocytosis of 
latex beads and A 1-42 are performed by different mechanisms or by microglia of different 
phenotypes. 
 
Key words: Alzheimer, amyloid, BDNF, brain-derived neurotrophic factor, cytokine, 
docosahexanoic acid, interleukin, omega-3 
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Introduction 
Omega-3 fatty acids (O3:s) constitute a popular food supplement that has been ascribed 
several health benefits. Among the health conditions that O3:s are described as having a 
positive effect on are rheumatoid arthritis [1,2], cancer [3,4] and cardiovascular diseases [5,6]. 
In addition, there is increasing evidence indicating a positive effect of O3:s on disorders of the 
central nervous system (CNS) [7-10]. One of the most common neurodegenerative disorders 
is Alzheimer’s disease (AD). AD is a progressive neurodegenerative disorder that is 
characterized by the impairment and death of neurons, increased levels of the amyloid-  (A ) 
peptide [11], increased presence of intracellular tangles composed of a hyperphosphorylated 
form of the microtubule protein tau [12], and inflammation [13-15]. Although there is still 
controversy regarding the importance of A  and hyperphosphorylated tau for the inititation 
and progression of AD [16] it is believed that increased levels of A  are one of the culprits for 
the disease. A  is produced by intramembraneus cleavage of the amyloid precursor protein 
(APP), yielding a peptide which usually is 40 or 42 amino acids long, although both longer 
and shorter variants exist [17,18]. A 1-42, and to a lesser degree A 1-40, are prone to 
aggregation thus forming oligomers, fibrils and plaques [19]. The monomers and the different 
aggregational forms have been implicated in neurotoxicity and impairment in a plethora of 
studies [20]. Recently, the toxicity of dimers and trimers of A  has been considered [21,22], 
and it may be hypothesized that these forms are responsible for the neurotoxic effects and that 
the plaques may be relatively inert, or even beneficial, as they bind A  molecules, thereby 
preventing them from attaining neurotoxic configurations. On a clinical level, AD is 
characterized by cognitive deficits that initially affect learning and memory, but later in the 
disease are manifested by a global cognitive decline. The clinical symptoms mirror the 
pathological changes in the brain where the neuronal loss and plaque/tangle pathology begin 
in the memory-related areas (entorhinal cortex, hippocampus) and then spread to other parts 
of the cortex [23,24].  
Docosahexanoic acid (DHA) is the O3 that has received most attention for its beneficial 
effects on factors related to AD [25-27]. To our knowledge, there is only one completed 
intervention study in which AD-patients have been treated with O3-supplements [28]. There 
was no effect on cognition, except in a subgroup of patients with very mild symptoms of AD, 
suggesting the importance of early intervention. The disorders in which O3:s have been 
reported as being beneficial have in common a component of inflammation. Inflammation is 
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prominent in AD as evidenced by activated microglia and astrocytes [29] and increased levels 
of pro-inflammatory cytokines in the AD brain [14,15]. It is unclear if inflammation is an 
original driving force in the pathogenesis of AD or a consequence of the disease. 
Inflammation has likely evolved for the body to effectively remove pathogens in the acute 
stage and after this is accomplished, promote tissue healing and repair in the resolving phase. 
However, in the case of chronic inflammatory states, such as in AD, the detrimental and 
tissue-damaging activities of inflammation are dominating [30]. Other evidence for the 
detrimental involvement of inflammation in AD is that patients under treatment with non-
steroidal anti-inflammatory drugs (NSAID:s) have been shown to be protected against 
developing AD [31]. On a mechanistic level, A  has been shown to induce inflammation [32-
35] and inflammation has been shown to increase the production of A  [36,37]. It has not 
been proven whether this reciprocal relationship is relevant for the progression of the disease, 
but a scenario with a self-reinforcing vicious circle is apparent.  
There are also positive effects of inflammation that can help in healing the tissue. Secretion of 
neurotrophic growth factors from activated microglia is one activity related to inflammation 
that can protect and improve the function of neurons [38-41]. Another important activity of 
microglia is the ability to remove, phagocytose, pathogens and debris from the tissue. 
Phagocytosis of A  by monocytes and microglia has been shown in several studies [42-45]. 
To induce phagocytosis of A , i.e. removal of a presumed pathogen without evoking the 
damaging activities of inflammation would be a promising therapy for AD. Ideally, beneficial 
activities such as microglial secretion of growth factors should also be increased, or at least 
not be decreased by such a therapy. DHA has been shown to downregulate inflammatory 
proteins in vitro [46,47] and in vivo [48]. DHA is also the precursor for the neurotrophic fatty 
acid neuroprotectin D1 [25] and is also an important cell membrane component. It is not 
known which of these activities are responsible for the proposed neuroprotective properties of 
DHA. Considering the widespread use of DHA-containing supplements and the urgent need 
for therapies to AD, it is of importance to investigate the effects of DHA not only on the 
traditional inflammatory markers but also on phagocytic activity and growth factor secretion 
to help characterize the effects of DHA on AD pathology. This may lead to better treatment 
and prevention strategies for AD, a disease which takes a heavy toll on society in terms of 
human suffering and care costs. To help realize this goal, we performed a series of 
experiments on a human microglia cell line (CHME3), in which the effects of DHA were 
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analysed with regard to phagocytosis of A 1-42, expression of cellular markers, secretory 
products and cell viability.  
 
Materials and methods 
Chemicals 
Docosohexanoic acid was purchased from Nucheckprep (Elysian, USA). A 1-42 conjugated 
with HiLyteFluor488 or biotin was obtained from Anaspec (Fremont, USA). Latex beads 
conjugated with Texas Red were bought from Sigma, Stockholm, Sweden. Dimethylsulfoxide 
(DMSO), Triton-X100, bovine serum albumin (BSA), and (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), were also purchased from Sigma, Stockholm, Sweden. 
Normal donkey and goat serum, and fluorescence mounting medium (DakoPatts, Stockholm, 
Sweden). Streptavidin-7-amino-4-methyl-3-coumarinylacetic acid (AMCA) (Jackson 
ImmunoResearch Europe Ltd, Suffolk, UK). Lactate deydrogenase (LDH)-assay (Roche, 
Stockholm, Sweden). ELISA-kits for interleukin (IL) -6 and brain-derived neurotrophic factor 
(BDNF) (R&D systems, Abingdon, United Kingdom). 10-plex Th1/Th2 cytokine assay 
(Meso Scale Diagnostics, Gaithersburg, USA). Cell culture medium, phosphate-buffered 
saline (PBS), GlutaMaxII, foetal calf serum (FCS) and PBS-based enzyme-free cell 
dissociation buffer (Invitrogen, Stockholm, Sweden). Cell culture bottles and multi-well 
plates (BD Biosciences, Stockholm, Sweden). 
 
Cell cultures 
Human microglial cells (CHME3) were obtained as a kind gift from Prof. M Tardieu, 
Neurologie pédiatrique, Hôpital Bicêtre, Assistance publique, Hôpitaux de Paris, Paris, 
France. CHME3 cells were cultured in T75 or T175 bottles in culture medium (DMEM/high 
glucose w/o sodium pyruvate supplemented with GlutaMaxII and 10% heat-inactivated FCS). 
The cells were subcultured at confluence using enzyme-free cell dissociation buffer after 
washing once with phosphate buffered saline (PBS) without Mg
2+
 and Ca
2+
. 
 
Experimental procedures 
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The CHME3 microglial cells were seeded in 48-well plates for analysis of cell viability 
(MTT) and cytotoxicity (LDH) (see Supplementary material) and in 6-well plates for flow-
cytometry and analysis of secretory products. For the experiments on latex beads 10 cm petri 
dishes were used. All experiments were performed at a confluence of ~60-70%. A 1-42 was 
dissolved in DMSO to a concentration of 5 mg/ml and stored in darkness at +4
o
C until use at 
a final concentration of 1 g/ml for all experiments. DHA was diluted in 95% EtOH to a 
concentration of 200 mM and stored in a nitrogen atmosphere. For experiments, the cells were 
washed with serum-free medium and then treated with A 1-42 or vehicle (DMSO) together 
with DHA or vehicle (95% EtOH), also in serum-free medium. For analyzing phagocytosis of 
latex beads the cells were washed with serum-free medium and latex beads were added in a 
1:4000 dilution together with vehicle, 0.05 M DHA, 50 ng/ml IL-1  or 0.05 M DHA 
together with 50 ng/ml IL-1  in serum-free medium  After 6, 24, and 48 h of incubation, the 
cultures were analyzed for uptake of A 1-42, expression of cellular markers and secretory 
products. Analysis of cultures incubated with latex beads were performed at 48 h. Cell 
viability and cell death were analysed at 24 h. 
 
 
Quantification of A 1-42/latex bead phagocytosis and cellular markers by flow-cytometry 
At 6, 24 and 48 h after starting the experiment, the CHME3 microglial cells were dissociated 
with PBS-based enzyme-free dissociation buffer, and centrifuged at 1500 x g for 10 min. The 
cells were then resuspended and fixed in 300 l of 1% para-formaldehyde (PF) in PBS, for 40 
min at room temperature in a 12 ml tube. The cells were then washed by addition of 10 ml 
PBS followed by centrifugation at 1500 x g for 10 min, removal of supernatant, resuspension 
in 300 ml of PBS and then stored at +4° C in darkness. 
For analysis of cellular uptake of A 1-42 and the expression of cellular markers, a volume of 
cell suspension was added to the same volume of a 2X PBS solution with a primary antibody 
to human IL-1  made in rabbit (1:200; gift from Dr. Stefan Svensson, Statens Bakteriologiska 
Laboratorium, Stockholm, Sweden), 10% normal donkey serum and 0.2% Triton X-100 
(Sigma, Sweden) in a 1.5 ml tube. The cells were incubated as such overnight after which 
they were washed with 1 ml PBS followed by centrifugation at 2500 x g for 20 min. A 
volume of the resulting cell suspension was then incubated for 1 h RT with the same volume 
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of a 2X PBS solution with a NL637-conjugated donkey-anti-rabbit secondary antibody 
(1:500; R&D systems, London, England), 1 g/ml propidium iodide (PI) and 20 % bovine 
serum albumin (Sigma, Sweden). Negative control for unstained cells (unstained control) was 
a cell suspension from the vehicle group incubated with solutions without primary and 
secondary antibodies. Negative control for the primary antibody (primary antibody control) 
was a cell suspension from the vehicle groups incubated with a solution without primary 
antibody followed by incubation with the secondary antibody. The cells were analysed 
immediately after incubation while the tubes not in use were kept at +4° C and in darkness. 
PI was used in conjunction with gating through the front-scatter (FSC) and side-scatter (SSC) 
plot to differentiate cells from debris. Fixation with PF renders cells permeable to PI and 
therefore the nuclei of all fixed cells will be stained with PI while debris will remain 
unstained. The background signal in the PI-wavelength was established by analyzing the 
unstained control and setting the limit of detection according to this signal. Events thus 
detected and gated by the flow-cytometer was further analysed in a quadrant plot for the 
presence of A 1-42 and IL-1 . A cell positive for phagocytosis of A 1-42 (A 1-42+) was defined 
as a cell that produced a signal in the HyliteFluor488-wavelength that was higher than the 
signal from the cells not incubated with A 1-42. Positive signal for IL-1  (IL-1 +) was defined 
as a cell producing a signal higher than the signal produced by the primary antibody control. 
By setting up the quadrant border in this way it is possible to determine if a cell is negative 
for both A 1-42 and IL-1  (A 1-42-/IL-1 -), negative for A 1-42 and positive for IL-1  (A 1-42-
/IL-1 +), positive for A 1-42 and negative for IL-1  (A 1-42+/IL-1 -) or positive for both A 1-
42 and IL-1  (A 1-42+/IL-1 +). Analysis of phagocytosis of latex beads were performed in a 
similar way, except for the use of acridine orange (AO) as a nuclear stain. 
 
Enzyme-linked immunosorbent assay (ELISA) and multiplex Th1/Th2 cytokine assay 
The levels of IL-6 and BDNF in the cell culture medium were analyzed with commercially 
available ELISA-kits according to the manufacturer’s instructions. Analysis of optical density 
(OD) was performed in a TECAN Safire2 plate reader. The levels of interferon-  (IFN- ),  IL-
10, IL-12p70, IL-13, IL-1 , IL-2, IL-4, IL-5, IL-8 and tumour necrosis factor-  (TNF- ), 
were analysed with a multiplex Th1/Th2 human cytokine kit according to the manufacturer’s 
instructions in a Meso Scale Diagnostics Model 1200 plate reader. 
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Results 
Cell viability and cell death 
To investigate the cytotoxic potential of DHA on CHME3 human microglia, the cells were 
incubated with 1 and 10 M DHA for 48 h. Microscopical inspection of the cultures indicated 
severe cellular stress (rounded-up and detached cells) in the cultures treated with 10 M 
DHA. Analysis with MTT and LDH assays indicated decreased cell viability and increased 
cell death in the cultures treated with this dose (Fig. 1). The results were not statistically 
significant which may be due to the low number of experiments (n=4) in these analyses. 
However, the microscopical observations and the fact that the results were at least suggestive 
of cell death or stress cautioned for using concentrations of 10 M. 
 
Effects of DHA on uptake of A 1-42 
Analysis by flow-cytometry of the uptake of A 1-42 by the CHME3 microglia revealed a 
significant stimulatory effect of DHA at 6 h. The concentration of 0.05 M DHA resulted in a 
23% (p < 0.05) increase in the uptake as compared with control (A 1-42 alone), and with 0.5 
M there was an increase of 18% (p < 0.05) (Fig. 2). The stimulatory effect appeared to linger 
at 24 h although the results were void of significance, while at 48 h the degree of uptake was 
similar in all treatments. 
 
Effects of DHA on uptake of latex beads 
There was no significant effect on the uptake of latex beads by any treatment as analyzed with 
flow-cytometry. 
 
Immunoreactivity to IL-1  and iNOS and the relation to phagocytosis of A 1-42 
The phenotype of microglial cells with and without uptake of A 1-42 was analysed by flow-
cytometry with regard to immunoreactivity to IL-1  and iNOS (Fig. 3A-B) in the different 
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treatment groups. Incubation with 0.5 or 2.5 M DHA for 24 h resulted in an increase in the 
number of IL-1 + microglia (Fig. 3A). At 0.5 M the increase was 60% (p < 0.01) as 
compared with vehicle, while 2.5 M increased IL-1  immunoreactivity by 21% (p < 0.05). 
At 48 h, the immunoreactivity to IL-1  was similar in all groups.  
The immunoreactivity to iNOS appeared to increase after 48 h of incubation with DHA 
although the only significant increase was observed with 0.05 M DHA (Fig. 4). There were 
no significant changes in immunoreactivity to IL-1  or iNOS seen upon incubation of the 
microglia with A 1-42 alone, or with A 1-42 together with DHA. 
To investigate the phenotype of the microglia displaying phagocytosis of A 1-42, the 
phagocytic and non-phagocytic populations of microglia in each treatment were compared 
with regard to the proportion of cells with immunoreactivity to IL-1  (Fig. 4A) and iNOS 
(Fig. 4B). Analysis of treatment with A 1-42 alone showed that a significantly larger 
proportion of phagocytic cells were immunoreactive to IL-1  at 6 h (p < 0.00005) and at 48 h 
(p < 0.05). Microglia treated with DHA together with A 1-42 showed the same pattern, i.e. 
significantly more phagocytic cells were immunoreactive to IL-1  at 6, 24 and 48 h in all 
concentrations tested.  
Analysis of the differential immunoreactivity to iNOS at 24 and 48 h showed that there were 
significantly more cells displaying immunoreactivity to iNOS in the phagocytic population at 
48 h. However, when DHA was added together with A 1-42, the difference was abolished 
(Fig. 4B). At 24 h the treatment with 0.05 DHA together with A 1-42 induced a phagocytic 
population with significantly higher expression of iNOS. 
 
Secretion of BDNF and IL-6 from microglial cultures incubated with A 1-42 
The secreted levels of BDNF and IL-6 were analysed with ELISA (Fig. 5). The incubation 
with A 1-42 alone did not affect the levels of BDNF and IL-6 as compared with vehicle. There 
were no significant differences in the secreted levels of IL-6 upon treatment with DHA. 
Incubation with 0.01 M DHA together with A 1-42 decreased the levels of BDNF in the 
medium with 53% of vehicle at 24 h (p < 0.001), and incubation with 2.5 M DHA at 48 h 
decreased the levels of BDNF in the medium to 74% of vehicle (p < 0.001).  
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Secretion of Th1 and Th2 cytokines from microglial cultures incubated with latex beads
The secretion of a set of Th1/Th2 cytokines (IFN , IL-10, IL-12p70, IL-13, IL-1 , IL-2, IL-4, 
IL-5, IL-8 and TNF ) at 48 h of incubation was analyzed with Meso Scale Diagnostics 
multiplex technology (Fig. 6). All cytokines were present at detectable levels in the 
conditioned medium. The incubation with 0.05 M DHA decreased the levels of IL-12p70 to 
51% of vehicle (p < 0.05). The same treatment also decreased the levels of IL-13 (58% of 
vehicle), IL-1  (50% of vehicle) and IL-8 (75% of vehicle) (p < 0.05 in all cases). Treatment 
with 0.05 M DHA together with 50 ng/ml IL-1  reduced the levels of TNF  to 48% of 
vehicle (p < 0.05), and the levels of IL-1  itself to 5% of vehicle (p < 0.05). 
 
Secretion of BDNF and IL-6 from microglial cultures incubated with latex beads 
The levels of secreted BDNF and IL-6 were measured with ELISA (Fig. 7). We found that 50 
ng/ml IL-1  increased the secretion of BDNF by 38% compared to vehicle (p < 0.01). IL-1  
increased the secreted levels of IL-6 with more than 20-fold (p < 0.05). Co-incubation with 
0.05 M DHA and 50 ng/ml IL-1  increased the secreted levels of IL-6 15-fold as compared 
to vehicle (p < 0.05), and to DHA alone (p < 0.05). 
 
Immunoreactivity to IL-1 , IL-1RI, TNF , IL-4R, iNOS and IL-6 and the relation to 
phagocytosis of latex beads 
There were no significant differences in immunoreactivity between the treatment groups when 
analyzing the microglia by flow-cytometry with regard to the expression of IL-1 , IL-1RI, 
TNF , IL-4R, iNOS and IL-6 at 48 h incubation with latex beads. When analyzing the 
differential expression of cellular markers we found that the cells showing phagocytosis of 
latex beads had a significantly lower expression of iNOS in all treatment groups (p < 0.05 in 
all cases) (Fig. 8). Treatment with 0.05 M DHA slightly decreased the number of phagocytic 
cells displaying immunoreactivity to TNF . Treatment with 0.05 M DHA together with 50 
ng/ml IL-1  increased the number of phagocytic cells displaying immunoreactivity to IL-6 
with (p < 0.05). 
 11 
Discussion 
In the present study, we provide data that both support and contradict the hypothesis that 
DHA can protect neurons in a setting of AD-like pathology. DHA was found to have 
stimulatory effects on phagocytosis of A 1-42 and to exert inhibitory effects on the secretion of 
pro-inflammatory cytokines and chemokines that have been suggested to be a part of, or 
worsen, the pathological changes in the AD-afflicted brain. On the other hand, high 
concentrations of DHA were found to decrease the secretion of the neuroprotective growth 
factor BDNF. DHA also decreased the levels of anti-inflammatory cytokines. Anti-
inflammatory cytokines, such as IL-4, have been suggested to be neuroprotective [49,50] and 
stimulatory on phagocytosis [51-53]. There was no effect on phagocytosis of latex beads by 
DHA or IL-1 , or by their combination. In a previous study we could not detect any effect on 
phagocytosis of A 1-42 by IL-1  [54].  
Little is known about the effects of DHA on human microglia. To our knowledge, the present 
study is the first to examine the effects of DHA, or any O3, on phagocytosis by microglia, 
derived from any species. A few studies have been performed to investigate the effects by 
DHA on phagocytosis by monocytes, which have a similar repertoire of responses as 
microglia. Monocytes are believed to enter the CNS and then differentiate to resident 
microglia [55] and the comparison is therefore relevant. It has been suggested that 
phagocytosis of A 1-42 is mainly performed by monocytes newly entered into the CNS and 
that phagocytosis by resident microglia is secondary to the action of the migrated monocytes 
[56].   
A study by Halvorsen et al showed that diet supplementation of highly purified DHA did not 
affect phagocytosis of E. Coli by human monocytes collected and isolated from the 
participants in the study [57]. In contrast, a study by Gorjão et al showed an increase in the 
phagocytosis of Zymosan A particles by monocytes isolated from blood collected from 
human subjects treated with fish-oil capsules [58]. Since the capsules contained 
eicosapentaenoic acid (EPA) in addition to DHA, and also other constituents not mentioned in 
the study, a comparison with the present study is difficult, except for the conclusion that DHA 
by itself may not be optimal for stimulating phagocytosis. As the data from this study also 
suggest, the nature of the object being phagocytosed, may also modulate the profile of 
induced activation. It should also be mentioned that in the study by Gorjão et al, there was 
evidence of pro-inflammatory activation of the monocytes including a large increase in the 
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production of reactive oxygen species, IFN  and TNF , and decreased IL-2 and IL-4 
production. This activation contradicts the results obtained by others, where O3-
supplementation produced an anti-inflammatory effect [59,60]. 
We have observed a negative effect of A 1-42 on the microglial secretion of BDNF in previous 
studies [54]. In the present study, the reduction in the secretion of BDNF in microglial 
cultures treated with A 1-42 was just void of significance at 24 h. However, when A 1-42 was 
added together with 0.01 mM DHA, there was a significant reduction in BDNF at 24 h. In 
cultures treated without A 1-42 the impression was that DHA stimulated the secretion of 
BDNF, although the results were not statistically significant. At 48 h after adding the 
substances, the highest concentration of DHA 2.5 ( M) reduced the secretion of BDNF 
significantly to 60% of the levels observed upon treatment with vehicle. 
One mechanism that has been suggested to mediate the effects of DHA is the production of 
anti-inflammatory and neuroprotective fatty acids: neuroprotectins and maresins, for which 
DHA is the precursor [25,61]. Maresins are suggested to be involved in the resolving phase of 
inflammation, when phagocytosis is abundant and an anti-inflammatory state is dominating in 
the tissue (for example, [62]). Interestingly, maresin R1 has been shown to increase 
phagocytosis of Zymosan A particles by human monocytes [61]. The stimulatory effect on 
phagocytosis of A 1-42 by DHA was observed after 6 h of incubation and appeared to 
dissipate with time. Fatty acids easily become oxidized and DHA and its downstream 
effectors could disappear from the culture in this way at an early time point, having a limited 
effect with time. It can also be hypothesized that other cell types in the brain, apart from 
microgli, are the main responsible for converting DHA into active substances such as 
maresins, due to a higher expression of the biosynthetic enzymes. Other factors such as the 
impact of cell membrane composition and fluidity have also been suggested as mediators of 
the effects of DHA regarding AD-related impairment in cognition [63], and may also play a 
role in modulating the responses of immune cells. 
In this study, we observed signs of inflammatory activation of human microglia after 
treatment with DHA in the form of an increase in the number of IL-1 + cells and a slight 
increase in IL-6 secretion. However, when the CHME3 microglia were incubated with IL-1  
there was a lower number of cells that displayed uptake of A 1-42 compared to the vehicle 
group at 48 h. At this time point the levels of IL-6 in the cultures were 20-fold higher upon 
treatment with IL-1 , indicating an inflammatory activation by IL-1 . This may indicate that 
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cells secreting IL-1  decrease their cellular levels of this cytokine, which makes sense under 
the assumption that the process of secretion is working at a faster pace than the translatory 
machinery. Adding to the credibility of this explanation is the relatively low cellular level of 
IL-6 in cultures treated with IL-1 . The overall impression is that DHA decreased microglial 
activation as shown by a reduction in the secreted levels of both pro- and anti-inflammatory 
cytokines. Another indication of an anti-inflammatory effect of DHA is that the increase in 
the number of iNOS+/A 1-42+ cells in the cultures treated with A 1-42 alone, was abolished 
when DHA was added together with A 1-42. Interestingly, this effect was not seen when DHA 
was added to cells incubated with latex beads where the pattern was reversed; cells displaying 
phagocytosis of latex beads were significantly less prone to express iNOS. This discrepancy 
hints at different pathways of uptake for latex beads and A 1-42. We conclude that DHA would 
not cause deleterious effects and that it may even reduce the pathology by alleviating the 
inflammation and increasing the phagocytosis of the pathogenic A 1-42 peptide. It should be 
kept in mind, however, that the downstream effects of DHA are dependent on the expression 
of enzymes and of the receptors for the DHA-derived products, which is a new field in 
medicine. Further studies on these aspects are necessary to produce data that can be translated 
into therapies for AD. 
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Figure legends 
Fig. 1 Effects of docosahexanoic acid (DHA) on cell viability and cell death of human 
CHME3 microglial cells. The cells were incubated with DHA at 1 and 10 M for 48 h after 
which they were analysed with MTT and LDH assays. The data from the MTT-assay are 
expressed as % of control (vehicle) set at 100%, while the data from the LDH-assay are 
expressed as % of positive control (vehicle-treated cells lysed with Triton-X100) and shown 
as median ± percentiles (25% - 75% and 10% - 90%). 
 
Fig. 2. Effects of docosahexanoic acid (DHA) on the uptake of A 1-42 in human CHME3 
microglial cells. The cells were incubated with 1 µg/ml A 1-42, alone or together with 0.01 – 
2.5 M DHA for 6, 24 and 48 h, after which they were harvested and fixed. The cells were 
then analysed by flow-cytometry for the uptake of A 1-42. The data are expressed as % uptake 
of A 1-42 set at 100%, and shown as median ± percentiles (25% - 75% and 10% - 90%). 
Statistical difference from control is indicated by * (p < 0.05). 
 
Fig 3A-B. Effects of docosahexanoic acid (DHA), alone or together with A 1-42, on 
immunoreactivity to interleukin (IL)-1  and inducible nitric oxide synthase (iNOS) in human 
CHME3 microglial cells. The cells were incubated with 1 µg/ml A 1-42, alone or together with 
0.01 – 2.5 M DHA for 6, 24 and 48 h, after which they were harvested, fixed and subjected 
to indirect immunocytochemistry for IL-1  (A) and iNOS (B). The data are expressed as % 
immunoreactivity upon incubation with A 1-42 alone set at 100%, and shown as median ± 
percentiles (25% - 75% and 10% - 90%). Statistical difference from control is indicated by * 
(p < 0.05) and ** (p < 0.01). 
 
Fig. 4A-B. Differential expression of interleukin (IL)-1  and inducible nitric oxide synthase 
(iNOS) by human CHME3 microglia in the populations of cells displaying (A 1-42+) or not 
displaying (A 1-42-) phagocytosis of A 1-42 after treatment with docosahexanoic acid (DHA) 
(0.01 – 2.5 µM) together with 1 µg/ml A 1-42. After 6, 24 and 48 h of exposure to A 1-42, the 
cells were fixed, subjected to immunocytochemistry, and analysed by flow-cytometry. The 
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number of IL-1 + (A) or iNOS+ (B) cells in the A 1-42+ population was compared with the 
corresponding proportion in the A 1-42- population of cells. The comparison was performed in 
each treatment group, using the Wilcoxon Matched Pairs Test. The data are shown as median 
± percentiles (25% - 75% and 10% - 90%), n = 7. Statistical difference in immunoreactivity 
between A 1-42-negative/positive cells is indicated by * (p < 0.05), ** (p < 0.01) and *** (p < 
0.001). 
 
Fig 5. Effects of docosahexanoic acid (DHA), alone or together with A 1-42, on the secretion 
of brain-derived neurotrophic factor (BDNF) from human CHME3 microglia. The cells were 
incubated with 1 µg/ml A 1-42, alone or together with 0.01 – 2.5 M DHA for 24 and 48 h. 
The data are expressed as % of control vehicle set at 100%, and shown as median ± 
percentiles (25% - 75% and 10% - 90%). Statistical difference from control is indicated by 
*** (p < 0.001). 
 
Fig 6. Effects of docosahexanoic acid (DHA), alone or together with interleukin (IL)-1 , on 
the secretion of IL-12p70, IL-13, IL-1 , IL-8 and tumour necrosis factor-  (TNF- ) from 
human CHME3 microglia. The cells were incubated with 0.05 M DHA and 50 ng/ml IL-1 , 
alone or in combination, for 48 h after which the medium was collected and analysed with 
Meso Scale Diagnostics multiplex technology for the levels of a set of Th1/Th2 cytokines. 
The data are expressed as % of control vehicle set at 100%, and shown as median ± 
percentiles (25% - 75% and 10% - 90%). Statistical difference from control is indicated by * 
(p < 0.05). 
 
Fig 7. Effects of docosahexanoic acid (DHA) and interleukin (IL)-1  incubated with latex 
beads on the secretion of IL-6 and brain-derived neurotrophic factor (BDNF) from human 
CHME3 microglia. The cells were incubated with latex beads together with vehicle, 
docosahexanoic acid (DHA) (0.05 µM), IL-1  (50 ng/ml), or DHA (0.05 µM) together with 
IL-1  (50 ng/ml).  After 48 h of treatment, the culture medium was collected and analysed 
with ELISA for the levels of IL-6 and BDNF. The data are expressed as % of control vehicle 
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set at 100%, and shown as median ± percentiles (25% - 75% and 10% - 90%). Statistical 
difference from control is indicated by * (p < 0.05). 
 
Fig 8A-B. Differential expression of interleukin (IL)-  and inducible nitric oxide synthase 
(iNOS) by human CHME3 microglia in the populations of cells displaying or not displaying 
phagocytosis of latex beads after treatment with vehicle, docosahexanoic acid (DHA) (0.05 
µM), IL-1  (50 ng/ml), or DHA (0.05 µM) together with IL-1  (50 ng/ml).  After 48 h of 
exposure the cells were fixed, subjected to immunocytochemistry, and analysed by flow-
cytometry. The proportion of cells positive to IL-6 (A) or iNOS (B) in the population of cells 
displaying phagocytosis of latex beads was compared with the corresponding proportion in 
the non-phagocytic population. The comparison was performed in each treatment group, 
using the Wilcoxon Matched Pairs Test. The data are shown as median ± percentiles (25% - 
75% and 10% - 90%), n = 7. Statistical difference in immunoreactivity between A 1-42-
negative/positive cells is indicated by * (p < 0.05). 
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